10003586|t|Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.
10003586	30	38	abacavir	drug	Drug_0
10003586	129	139	lamivudine	drug	Drug_1
10003586	144	154	zidovudine	drug	Drug_2

10003587|t|No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir.
10003587	37	47	lamivudine	drug	Drug_0
10003587	51	61	zidovudine	drug	Drug_1
10003587	133	141	abacavir	drug	Drug_2

10003588|t|Abacavir has no effect on the pharmacokinetic properties of ethanol.
10003588	0	8	Abacavir	drug	Drug_0
10003588	60	67	ethanol	drug	Drug_1

10003589|t|Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.
10003589	0	7	Ethanol	drug	Drug_0
10003589	188	196	abacavir	drug	Drug_1
10003589	104	113	methadone	drug	Drug_2
10003589	mechanism	Drug_0	Drug_1

10003590|t|In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
10003590	182	191	methadone	drug	Drug_0
10003590	118	124	ZIAGEN	brand	Drug_1
10003590	mechanism	Drug_0	Drug_1

10003591|t|Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%.
10003591	28	42	cholestyramine	drug	Drug_0
10003591	90	99	ezetimibe	drug	Drug_1
10003591	mechanism	Drug_0	Drug_1

10003592|t|The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
10003592	46	55	ezetimibe	drug	Drug_0
10003592	59	73	cholestyramine	drug	Drug_1
10003592	effect	Drug_0	Drug_1

10003593|t|Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established.
10003593	70	78	fibrates	group	Drug_0
10003593	42	51	ezetimibe	drug	Drug_1

10003594|t|Co-administration of ZETIA with fibrates is not recommended until use in patients is studied.
10003594	21	26	ZETIA	brand	Drug_0
10003594	32	40	fibrates	group	Drug_1
10003594	advise	Drug_0	Drug_1

10003595|t|Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.
10003595	53	64	fenofibrate	drug	Drug_0
10003595	96	105	ezetimibe	drug	Drug_1
10003595	mechanism	Drug_0	Drug_1

10003596|t|Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold.
10003596	53	64	gemfibrozil	drug	Drug_0
10003596	96	105	ezetimibe	drug	Drug_1

10003597|t|HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.
10003597	0	28	HMG-CoA reductase inhibitors	group	Drug_0
10003597	100	109	ezetimibe	drug	Drug_1
10003597	135	147	atorvastatin	drug	Drug_2
10003597	149	160	simvastatin	drug	Drug_3
10003597	162	173	pravastatin	drug	Drug_4
10003597	175	185	lovastatin	drug	Drug_5
10003597	190	201	fluvastatin	drug	Drug_6

10003598|t|Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.
10003598	132	144	cyclosporine	drug	Drug_0
10003598	24	33	ezetimibe	drug	Drug_1
10003598	mechanism	Drug_1	Drug_0

10003599|t|Patients who take both ezetimibe and cyclosporine should be carefully monitored.
10003599	23	32	ezetimibe	drug	Drug_0
10003599	37	49	cyclosporine	drug	Drug_1
10003599	advise	Drug_0	Drug_1

10003600|t|Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
10003600	158	167	ezetimibe	drug	Drug_0
10003600	61	89	HMG-CoA reductase inhibitors	group	Drug_1
10003600	91	98	statins	group	Drug_2

10003601|t|When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor.
10003601	5	10	ZETIA	brand	Drug_0
10003601	162	189	HMG-CoA reductase inhibitor	drug	Drug_1

10003602|t|These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
10003602	240	253	hypoglycemics	group	Drug_0
10003602	66	94	Coumarin-type anticoagulants	group	Drug_1
10003602	96	105	Phenytoin	drug	Drug_2
10003602	107	119	Cyclosporine	drug	Drug_3
10003602	121	129	Rifampin	drug	Drug_4
10003602	131	143	Theophylline	drug	Drug_5
10003602	145	156	Terfenadine	drug	Drug_6
10003602	158	167	Cisapride	drug	Drug_7
10003602	169	179	Astemizole	drug	Drug_8
10003602	181	190	Rifabutin	drug	Drug_9
10003602	192	202	Tacrolimus	drug	Drug_10
10003602	204	232	Short-acting benzodiazepines	group	Drug_11
10003602	325	333	DIFLUCAN	brand	Drug_12
10003602	344	363	hypoglycemic agents	group	Drug_13
10003602	effect	Drug_12	Drug_13

10003603|t|one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use.
10003603	78	86	DIFLUCAN	brand	Drug_0
10003603	91	100	glyburide	drug	Drug_1
10003603	effect	Drug_0	Drug_1

10003604|t|DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
10003604	0	8	DIFLUCAN	brand	Drug_0
10003604	35	46	tolbutamide	drug	Drug_1
10003604	48	57	glyburide	drug	Drug_2
10003604	63	72	glipizide	drug	Drug_3
10003604	mechanism	Drug_0	Drug_3
10003604	mechanism	Drug_0	Drug_1
10003604	mechanism	Drug_0	Drug_2

10003605|t|When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
10003605	5	13	DIFLUCAN	brand	Drug_0
10003605	56	93	sulfonylurea oral hypoglycemic agents	group	Drug_1
10003605	174	186	sulfonylurea	group	Drug_2
10003605	advise	Drug_0	Drug_1

10003606|t|Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.
10003606	111	139	coumarin-type anticoagulants	group	Drug_0
10003606	98	106	DIFLUCAN	brand	Drug_1
10003606	effect	Drug_1	Drug_0

10003607|t|In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.
10003607	44	61	azole antifungals	group	Drug_0
10003607	242	253	fluconazole	drug	Drug_1
10003607	272	280	warfarin	drug	Drug_2
10003607	effect	Drug_1	Drug_2

10003608|t|Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.
10003608	61	69	DIFLUCAN	brand	Drug_0
10003608	74	102	coumarin-type anticoagulants	group	Drug_1
10003608	advise	Drug_0	Drug_1

10003609|t|Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.
10003609	59	68	phenytoin	drug	Drug_0
10003609	11	19	DIFLUCAN	brand	Drug_1
10003609	mechanism	Drug_1	Drug_0

10003610|t|Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended.
10003610	82	91	phenytoin	drug	Drug_0
10003610	69	77	DIFLUCAN	brand	Drug_1
10003610	advise	Drug_1	Drug_0

10003611|t|Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.
10003611	50	62	cyclosporine	drug	Drug_0
10003611	14	22	DIFLUCAN	brand	Drug_1
10003611	mechanism	Drug_1	Drug_0

10003612|t|Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine.
10003612	121	133	cyclosporine	drug	Drug_0
10003612	108	116	DIFLUCAN	brand	Drug_1
10003612	advise	Drug_1	Drug_0

10003613|t|Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN.
10003613	10	18	Rifampin	drug	Drug_0
10003613	72	80	DIFLUCAN	brand	Drug_1
10003613	mechanism	Drug_0	Drug_1

10003614|t|Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.
10003614	93	101	DIFLUCAN	brand	Drug_0
10003614	131	139	rifampin	drug	Drug_1
10003614	advise	Drug_0	Drug_1

10003615|t|Theophylline: DIFLUCAN increases the serum concentrations of theophylline.
10003615	61	73	theophylline	drug	Drug_0
10003615	14	22	DIFLUCAN	brand	Drug_1
10003615	mechanism	Drug_1	Drug_0

10003616|t|Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.
10003616	91	103	theophylline	drug	Drug_0
10003616	78	86	DIFLUCAN	brand	Drug_1
10003616	advise	Drug_1	Drug_0

10003617|t|Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.
10003617	177	188	terfenadine	drug	Drug_0
10003617	139	156	azole antifungals	group	Drug_1
10003617	effect	Drug_1	Drug_0

10003618|t|Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.
10003618	51	62	fluconazole	drug	Drug_0
10003618	81	89	DIFLUCAN	brand	Drug_1
10003618	175	186	terfenadine	drug	Drug_2
10003618	mechanism	Drug_1	Drug_2

10003619|t|The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.
10003619	20	31	fluconazole	drug	Drug_0
10003619	67	78	terfenadine	drug	Drug_1
10003619	advise	Drug_0	Drug_1

10003620|t|The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.
10003620	24	35	fluconazole	drug	Drug_0
10003620	72	83	terfenadine	drug	Drug_1
10003620	advise	Drug_0	Drug_1

10003621|t|Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.
10003621	119	128	cisapride	drug	Drug_0
10003621	103	114	fluconazole	drug	Drug_1
10003621	effect	Drug_1	Drug_0

10003622|t|A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
10003622	42	53	fluconazole	drug	Drug_0
10003622	143	152	cisapride	drug	Drug_1
10003622	mechanism	Drug_0	Drug_1

10003623|t|The combined use of fluconazole with cisapride is contraindicated.
10003623	20	31	fluconazole	drug	Drug_0
10003623	37	46	cisapride	drug	Drug_1
10003623	advise	Drug_0	Drug_1

10003624|t|Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
10003624	67	77	astemizole	drug	Drug_0
10003624	23	34	fluconazole	drug	Drug_1
10003624	mechanism	Drug_1	Drug_0

10003625|t|Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.
10003625	82	91	rifabutin	drug	Drug_0
10003625	66	77	fluconazole	drug	Drug_1
10003625	effect	Drug_1	Drug_0

10003626|t|Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.
10003626	19	28	rifabutin	drug	Drug_0
10003626	33	44	fluconazole	drug	Drug_1
10003626	advise	Drug_0	Drug_1

10003627|t|Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.
10003627	90	100	tacrolimus	drug	Drug_0
10003627	74	85	fluconazole	drug	Drug_1
10003627	effect	Drug_1	Drug_0

10003628|t|Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.
10003628	19	29	tacrolimus	drug	Drug_0
10003628	34	45	fluconazole	drug	Drug_1
10003628	advise	Drug_0	Drug_1

10003629|t|Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.
10003629	0	28	Short-acting Benzodiazepines	group	Drug_0
10003629	123	132	midazolam	drug	Drug_1
10003629	74	85	fluconazole	drug	Drug_2
10003629	mechanism	Drug_1	Drug_2

10003630|t|This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.
10003630	15	24	midazolam	drug	Drug_0
10003630	110	121	fluconazole	drug	Drug_1
10003630	effect	Drug_0	Drug_1

10003631|t|If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
10003631	3	31	short-acting benzodiazepines	group	Drug_0
10003631	122	133	fluconazole	drug	Drug_1
10003631	183	197	benzodiazepine	group	Drug_2
10003631	advise	Drug_0	Drug_1

10003632|t|Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
10003632	0	11	Fluconazole	drug	Drug_0
10003632	146	163	ethinyl estradiol	drug	Drug_1
10003632	168	182	levonorgestrel	drug	Drug_2
10003632	94	108	contraceptives	group	Drug_3
10003632	mechanism	Drug_0	Drug_2
10003632	mechanism	Drug_0	Drug_1

10003633|t|however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels.
10003633	68	85	ethinyl estradiol	drug	Drug_0
10003633	90	104	levonorgestrel	drug	Drug_1

10003634|t|The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation.
10003634	76	93	ethinyl estradiol	drug	Drug_0
10003634	98	112	levonorgestrel	drug	Drug_1
10003634	129	140	fluconazole	drug	Drug_2

10003635|t|While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
10003635	135	146	fluconazole	drug	Drug_0
10003635	167	184	ethinyl estradiol	drug	Drug_1
10003635	188	202	levonorgestrel	drug	Drug_2
10003635	mechanism	Drug_0	Drug_2
10003635	mechanism	Drug_0	Drug_1

10003636|t|You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
10003636	16	24	mazindol	drug	Drug_0
10003636	45	72	monoamine oxidase inhibitor	group	Drug_1
10003636	74	78	MAOI	group	Drug_2
10003636	88	101	isocarboxazid	drug	Drug_3
10003636	103	110	Marplan	brand	Drug_4
10003636	113	128	tranylcypromine	drug	Drug_5
10003636	130	137	Parnate	brand	Drug_6
10003636	143	153	phenelzine	drug	Drug_7
10003636	155	161	Nardil	brand	Drug_8
10003636	advise	Drug_0	Drug_5
10003636	advise	Drug_0	Drug_2
10003636	advise	Drug_0	Drug_6
10003636	advise	Drug_0	Drug_3
10003636	advise	Drug_0	Drug_1
10003636	advise	Drug_0	Drug_8
10003636	advise	Drug_0	Drug_4
10003636	advise	Drug_0	Drug_7

10003637|t|Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.
10003637	11	18	insulin	drug	Drug_0
10003637	92	100	mazindol	drug	Drug_1
10003637	advise	Drug_0	Drug_1

10003638|t|Mazindol may reduce the effects of guanethidine (Ismelin).
10003638	0	8	Mazindol	drug	Drug_0
10003638	35	47	guanethidine	drug	Drug_1
10003638	49	56	Ismelin	brand	Drug_2
10003638	effect	Drug_0	Drug_2
10003638	effect	Drug_0	Drug_1

10003639|t|Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
10003639	68	92	tricyclic antidepressant	group	Drug_0
10003639	101	114	amitriptyline	drug	Drug_1
10003639	116	122	Elavil	brand	Drug_2
10003639	125	134	amoxapine	drug	Drug_3
10003639	136	143	Asendin	brand	Drug_4
10003639	146	153	doxepin	drug	Drug_5
10003639	155	163	Sinequan	brand	Drug_6
10003639	166	179	nortriptyline	drug	Drug_7
10003639	181	188	Pamelor	brand	Drug_8
10003639	191	201	imipramine	drug	Drug_9
10003639	203	211	Tofranil	brand	Drug_10
10003639	214	226	clomipramine	drug	Drug_11
10003639	228	237	Anafranil	brand	Drug_12
10003639	240	253	protriptyline	drug	Drug_13
10003639	255	263	Vivactil	brand	Drug_14
10003639	269	280	desipramine	drug	Drug_15
10003639	282	291	Norpramin	brand	Drug_16

10003640|t|Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.
10003640	35	45	cimetidine	drug	Drug_0
10003640	136	147	mebendazole	drug	Drug_1
10003640	mechanism	Drug_0	Drug_1

10003641|t|Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.
10003641	19	30	antibiotics	group	Drug_0
10003641	35	47	sulfonamides	group	Drug_1
10003641	85	102	ganglion blockers	group	Drug_2
10003641	advise	Drug_1	Drug_2
10003641	advise	Drug_0	Drug_2

10003642|t|The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.
10003642	14	26	Mecamylamine	drug	Drug_0
10003642	67	89	antihypertensive drugs	group	Drug_1
10003642	94	101	alcohol	drug	Drug_2
10003642	effect	Drug_0	Drug_2
10003642	effect	Drug_0	Drug_1

10003643|t|Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.
10003643	0	17	Aminoglutethimide	drug	Drug_0
10003643	50	71	depo-subQ provera 104	brand	Drug_1
10003643	127	130	MPA	drug	Drug_2
10003643	mechanism	Drug_0	Drug_1

10003644|t|Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs.
10003644	104	114	zidovudine	drug	Drug_0
10003644	118	127	rifabutin	drug	Drug_1
10003644	162	179	megestrol acetate	drug	Drug_2

10003645|t|A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.
10003645	62	79	megestrol acetate	drug	Drug_0
10003645	198	207	indinavir	drug	Drug_1
10003645	mechanism	Drug_0	Drug_1

10003646|t|Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.
10003646	35	44	indinavir	drug	Drug_0
10003646	92	109	megestrol acetate	drug	Drug_1
10003646	advise	Drug_0	Drug_1

10003647|t|The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
10003647	15	24	indinavir	drug	Drug_0
10003647	26	36	zidovudine	drug	Drug_1
10003647	40	49	rifabutin	drug	Drug_2
10003647	77	94	megestrol acetate	drug	Drug_3

10003648|t|Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
10003648	558	567	melatonin	drug	Drug_0
10003648	49	56	aspirin	brand	Drug_1
10003648	67	73	NSAIDs	group	Drug_2
10003648	104	115	fluvoxamine	drug	Drug_3
10003648	188	201	beta blockers	group	Drug_4
10003648	235	245	fluoxetine	drug	Drug_5
10003648	345	354	progestin	group	Drug_6
10003648	395	410	benzodiazepenes	group	Drug_7
10003648	627	642	corticosteroids	group	Drug_8
10003648	int	Drug_0	Drug_6
10003648	int	Drug_0	Drug_2
10003648	int	Drug_0	Drug_7
10003648	int	Drug_0	Drug_5
10003648	int	Drug_0	Drug_8
10003648	effect	Drug_0	Drug_8
10003648	int	Drug_0	Drug_1
10003648	int	Drug_0	Drug_4
10003648	effect	Drug_0	Drug_6
10003648	int	Drug_0	Drug_3

10003649|t|ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.
10003649	0	14	ACE inhibitors	group	Drug_0
10003649	36	42	NSAIDs	group	Drug_1
10003649	87	133	angiotensin-converting enzyme (ACE) inhibitors	group	Drug_2
10003649	effect	Drug_1	Drug_2

10003650|t|This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
10003650	66	72	NSAIDs	group	Drug_0
10003650	92	106	ACE inhibitors	group	Drug_1
10003650	advise	Drug_0	Drug_1

10003651|t|Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.
10003651	39	46	aspirin	brand	Drug_0
10003651	134	143	meloxicam	drug	Drug_1
10003651	mechanism	Drug_0	Drug_1

10003652|t|however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.
10003652	23	29	NSAIDs	group	Drug_0
10003652	61	70	meloxicam	drug	Drug_1
10003652	75	82	aspirin	brand	Drug_2
10003652	advise	Drug_1	Drug_2
10003652	advise	Drug_0	Drug_2

10003653|t|Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.
10003653	39	46	aspirin	brand	Drug_0
10003653	150	155	MOBIC	brand	Drug_1
10003653	effect	Drug_0	Drug_1

10003654|t|MOBIC is not a substitute for aspirin for cardiovascular prophylaxis.
10003654	0	5	MOBIC	brand	Drug_0
10003654	30	37	aspirin	brand	Drug_1

10003655|t|Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.
10003655	48	62	cholestyramine	drug	Drug_0
10003655	104	113	meloxicam	drug	Drug_1
10003655	mechanism	Drug_0	Drug_1

10003656|t|Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.
10003656	49	59	cimetidine	drug	Drug_0
10003656	120	129	meloxicam	drug	Drug_1

10003657|t|Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.
10003657	97	104	digoxin	drug	Drug_0
10003657	9	18	Meloxicam	drug	Drug_1

10003658|t|In vitro testing found no protein binding drug interaction between digoxin and meloxicam.
10003658	67	74	digoxin	drug	Drug_0
10003658	79	88	meloxicam	drug	Drug_1

10003659|t|Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.
10003659	130	140	furosemide	drug	Drug_0
10003659	86	92	NSAIDs	group	Drug_1
10003659	145	163	thiazide diuretics	group	Drug_2
10003659	effect	Drug_1	Drug_0
10003659	effect	Drug_1	Drug_2

10003660|t|Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect.
10003660	13	23	furosemide	drug	Drug_0
10003660	35	44	meloxicam	drug	Drug_1

10003661|t|Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam.
10003661	0	10	Furosemide	drug	Drug_0
10003661	113	122	meloxicam	drug	Drug_1

10003662|t|Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
10003662	46	56	furosemide	drug	Drug_0
10003662	61	66	MOBIC	brand	Drug_1
10003662	advise	Drug_0	Drug_1

10003663|t|Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
10003663	113	120	lithium	drug	Drug_0
10003663	29	35	NSAIDs	group	Drug_1
10003663	mechanism	Drug_1	Drug_0

10003664|t|In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.
10003664	234	241	lithium	drug	Drug_0
10003664	181	190	meloxicam	drug	Drug_1
10003664	mechanism	Drug_0	Drug_1

10003665|t|Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn.
10003665	12	19	lithium	drug	Drug_0
10003665	63	68	MOBIC	brand	Drug_1
10003665	advise	Drug_0	Drug_1

10003666|t|Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly.
10003666	143	155	methotrexate	drug	Drug_0
10003666	106	115	meloxicam	drug	Drug_1

10003667|t|Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate.
10003667	0	9	Meloxicam	drug	Drug_0
10003667	87	99	methotrexate	drug	Drug_1

10003668|t|In vitro, methotrexate did not displace meloxicam from its human serum binding sites.
10003668	10	22	methotrexate	drug	Drug_0
10003668	40	49	meloxicam	drug	Drug_1

10003669|t|Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.
10003669	154	162	warfarin	drug	Drug_0
10003669	118	123	MOBIC	brand	Drug_1
10003669	advise	Drug_1	Drug_0

10003670|t|The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8.
10003670	14	23	meloxicam	drug	Drug_0
10003670	132	140	warfarin	drug	Drug_1

10003671|t|In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.
10003671	19	28	meloxicam	drug	Drug_0
10003671	109	117	warfarin	drug	Drug_1

10003672|t|Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
10003672	42	47	MOBIC	brand	Drug_0
10003672	80	88	warfarin	drug	Drug_1
10003672	advise	Drug_0	Drug_1

10003673|t|DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
10003673	71	78	ALKERAN	brand	Drug_0
10003673	98	120	live organism vaccines	group	Drug_1
10003673	175	189	Nalidixic acid	drug	Drug_2
10003673	226	235	melphalan	drug	Drug_3
10003673	effect	Drug_2	Drug_3

10003674|t|Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease
10003674	126	135	melphalan	drug	Drug_0
10003674	166	177	cyclosporin	drug	Drug_1
10003674	effect	Drug_0	Drug_1

10003675|t|The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
10003675	69	90	anticholinergic drugs	group	Drug_0
10003675	92	102	amantadine	drug	Drug_1
10003675	104	136	antiarrhythmic agents of class I	group	Drug_2
10003675	144	153	quinidine	drug	Drug_3
10003675	156	170	antihistamines	group	Drug_4
10003675	172	192	antipsychotic agents	group	Drug_5
10003675	200	214	phenothiazines	group	Drug_6
10003675	217	232	benzodiazepines	group	Drug_7
10003675	234	248	MAO inhibitors	group	Drug_8
10003675	250	269	narcotic analgesics	group	Drug_9
10003675	277	287	meperidine	drug	Drug_10
10003675	290	298	nitrates	group	Drug_11
10003675	303	311	nitrites	group	Drug_12
10003675	313	335	sympathomimetic agents	group	Drug_13
10003675	337	362	tricyclic antidepressants	group	Drug_14
10003675	effect	Drug_0	Drug_7
10003675	effect	Drug_0	Drug_14
10003675	effect	Drug_0	Drug_2
10003675	effect	Drug_0	Drug_1
10003675	effect	Drug_0	Drug_12
10003675	effect	Drug_0	Drug_3
10003675	effect	Drug_0	Drug_10
10003675	effect	Drug_0	Drug_8
10003675	effect	Drug_0	Drug_5
10003675	effect	Drug_0	Drug_13
10003675	effect	Drug_0	Drug_6
10003675	effect	Drug_0	Drug_11
10003675	effect	Drug_0	Drug_4
10003675	effect	Drug_0	Drug_9

10003676|t|Anticholinergics antagonize the effects of antiglaucoma agents.
10003676	0	16	Anticholinergics	group	Drug_0
10003676	43	62	antiglaucoma agents	group	Drug_1
10003676	effect	Drug_0	Drug_1

10003677|t|Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.
10003677	0	21	Anticholinergic drugs	group	Drug_0
10003677	133	148	corticosteroids	group	Drug_1
10003677	effect	Drug_0	Drug_1

10003678|t|Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
10003678	0	22	Anticholinergic agents	group	Drug_0
10003678	122	129	digoxin	drug	Drug_1
10003678	mechanism	Drug_0	Drug_1

10003679|t|Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.
10003679	0	21	Anticholinergic drugs	group	Drug_0
10003679	104	118	metoclopramide	drug	Drug_1
10003679	effect	Drug_0	Drug_1

10003680|t|Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
10003680	8	16	antacids	group	Drug_0
10003680	54	76	anticholinergic agents	group	Drug_1
10003680	mechanism	Drug_0	Drug_1

10003681|t|Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
10003681	23	57	Central Nervous System Depressants	group	Drug_0
10003681	59	69	MEPERIDINE	drug	Drug_1
10003681	175	194	NARCOTIC ANALGESICS	group	Drug_2
10003681	204	215	ANESTHETICS	group	Drug_3
10003681	217	231	PHENOTHIAZINES	group	Drug_4
10003681	239	252	TRANQUILIZERS	group	Drug_5
10003681	254	272	SEDATIVE-HYPNOTICS	group	Drug_6
10003681	284	296	BARBITURATES	group	Drug_7
10003681	299	324	TRICYCLIC ANTIDEPRESSANTS	group	Drug_8
10003681	335	350	CNS DEPRESSANTS	group	Drug_9
10003681	362	369	ALCOHOL	drug	Drug_10
10003681	advise	Drug_1	Drug_5
10003681	advise	Drug_1	Drug_9
10003681	advise	Drug_1	Drug_6
10003681	advise	Drug_1	Drug_4
10003681	advise	Drug_1	Drug_2
10003681	advise	Drug_1	Drug_8
10003681	advise	Drug_1	Drug_7
10003681	advise	Drug_1	Drug_3
10003681	advise	Drug_1	Drug_10

10003682|t|Some anticonvulsants may interact with Mephenytoin.
10003682	5	20	anticonvulsants	group	Drug_0
10003682	39	50	Mephenytoin	drug	Drug_1
10003682	int	Drug_0	Drug_1

10003683|t|Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.
10003683	6	21	anticonvulsants	group	Drug_0
10003683	30	47	divalproex sodium	drug	Drug_1
10003683	49	62	valproic acid	drug	Drug_2
10003683	68	81	phenobarbital	drug	Drug_3

10003684|t|Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
10003684	223	234	Mephenytoin	drug	Drug_0
10003684	75	94	steroid medications	group	Drug_1
10003684	96	104	warfarin	drug	Drug_2
10003684	152	176	anti-infective medicines	group	Drug_3
10003684	178	188	furosemide	drug	Drug_4
10003684	193	205	theophylline	drug	Drug_5
10003684	effect	Drug_0	Drug_1
10003684	effect	Drug_0	Drug_5
10003684	effect	Drug_0	Drug_4
10003684	effect	Drug_0	Drug_2
10003684	effect	Drug_0	Drug_3

10003685|t|Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
10003685	0	11	Mequitazine	drug	Drug_0
10003685	30	44	CNS depressant	group	Drug_1
10003685	46	62	antichlolinergic	group	Drug_2
10003685	64	67	TCA	group	Drug_3
10003685	69	74	MAOIs	group	Drug_4
10003685	80	87	alcohol	drug	Drug_5
10003685	int	Drug_0	Drug_4
10003685	int	Drug_0	Drug_3
10003685	int	Drug_0	Drug_1
10003685	int	Drug_0	Drug_5
10003685	int	Drug_0	Drug_2

10003686|t|Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.
10003686	0	10	Probenecid	drug	Drug_0
10003686	105	114	meropenem	drug	Drug_1
10003686	mechanism	Drug_0	Drug_1

10003687|t|Therefore, the coadministration of probenecid with meropenem is not recommended.
10003687	35	45	probenecid	drug	Drug_0
10003687	51	60	meropenem	drug	Drug_1
10003687	advise	Drug_0	Drug_1

10003688|t|There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
10003688	23	32	meropenem	drug	Drug_0
10003688	60	73	valproic acid	drug	Drug_1
10003688	159	168	valproate	drug	Drug_2
10003688	mechanism	Drug_0	Drug_1

10003689|t|ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.
10003689	0	7	ARAMINE	brand	Drug_0
10003689	86	95	digitalis	group	Drug_1
10003689	100	122	sympathomimetic amines	group	Drug_2
10003689	effect	Drug_1	Drug_2

10003690|t|Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.
10003690	0	28	Monoamine oxidase inhibitors	group	Drug_0
10003690	32	57	tricyclic antidepressants	group	Drug_1
10003690	87	109	sympathomimetic amines	group	Drug_2
10003690	effect	Drug_1	Drug_2
10003690	effect	Drug_0	Drug_2

10003691|t|SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
10003691	0	8	SKELAXIN	brand	Drug_0
10003691	36	43	alcohol	drug	Drug_1
10003691	45	57	barbiturates	group	Drug_2
10003691	68	83	CNS depressants	group	Drug_3
10003691	effect	Drug_0	Drug_1
10003691	effect	Drug_0	Drug_3
10003691	effect	Drug_0	Drug_2

10003692|t|Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
10003692	195	202	aspirin	brand	Drug_0
10003692	64	77	methazolamide	drug	Drug_1
10003692	207	236	carbonic anhydrase inhibitors	group	Drug_2
10003692	effect	Drug_0	Drug_2
10003692	advise	Drug_0	Drug_1

10003693|t|Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.
10003693	44	58	anticoagulants	group	Drug_0
10003693	119	130	methimazole	drug	Drug_1
10003693	effect	Drug_0	Drug_1

10003694|t|Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid;
10003694	0	20	Digitalis glycosides	group	Drug_0
10003694	101	120	digitalis glycoside	group	Drug_1

10003695|t|Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.
10003695	165	172	opioids	group	Drug_0
10003695	95	110	levomepromazine	drug	Drug_1
10003695	effect	Drug_1	Drug_0
10003695	effect	Drug_0	Drug_1

10003696|t|Combination with tramadol (Ultram) is associated with increased risk of seizures.
10003696	17	25	tramadol	drug	Drug_0
10003696	27	33	Ultram	brand	Drug_1

10003697|t|Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.
10003697	63	78	levomepromazine	drug	Drug_0
10003697	93	108	benzodiazepines	group	Drug_1
10003697	112	124	barbiturates	group	Drug_2
10003697	effect	Drug_0	Drug_2
10003697	effect	Drug_0	Drug_1

10003698|t|Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
10003698	38	53	levomepromazine	drug	Drug_0
10003698	65	86	anticholinergic drugs	group	Drug_1
10003698	88	113	tricyclic antidepressants	group	Drug_2
10003698	118	141	antiparkinsonian-agents	group	Drug_3
10003698	advise	Drug_0	Drug_2
10003698	advise	Drug_0	Drug_3
10003698	advise	Drug_0	Drug_1

10003699|t|Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.
10003699	0	8	Caffeine	drug	Drug_0
10003699	35	44	ephedrine	drug	Drug_1
10003699	45	56	amphetamine	drug	Drug_2
10003699	101	116	levomepromazine	drug	Drug_3
10003699	effect	Drug_1	Drug_3
10003699	effect	Drug_2	Drug_3
10003699	effect	Drug_0	Drug_3

10003700|t|Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
10003700	6	14	Celontin	brand	Drug_0
10003700	167	179	methsuximide	drug	Drug_1
10003700	74	93	antiepileptic drugs	group	Drug_2
10003700	222	231	phenytoin	drug	Drug_3
10003700	236	249	phenobarbital	drug	Drug_4
10003700	advise	Drug_0	Drug_2
10003700	mechanism	Drug_1	Drug_4
10003700	mechanism	Drug_1	Drug_3
10003700	advise	Drug_1	Drug_2

10003701|t|Hypokalemia may develop during concomitant use of steroids or ACTH.
10003701	50	58	steroids	group	Drug_0
10003701	62	66	ACTH	drug	Drug_1

10003702|t|Thiazides may decrease arterial responsiveness to norepinephrine.
10003702	0	9	Thiazides	group	Drug_0
10003702	50	64	norepinephrine	drug	Drug_1
10003702	effect	Drug_0	Drug_1

10003703|t|Thiazide drugs may increase the responsiveness of tubocurarine.
10003703	0	14	Thiazide drugs	group	Drug_0
10003703	50	62	tubocurarine	drug	Drug_1
10003703	effect	Drug_0	Drug_1

10003704|t|Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.
10003704	72	79	lithium	drug	Drug_0
10003704	38	47	thiazides	group	Drug_1
10003704	mechanism	Drug_0	Drug_1

10003705|t|Thiazides may add to or potentiate the action of other antihypertensive drugs.
10003705	0	9	Thiazides	group	Drug_0
10003705	55	77	antihypertensive drugs	group	Drug_1
10003705	effect	Drug_0	Drug_1

10003706|t|Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
10003706	25	75	ganglionic adrenergic blocking drugs	group	Drug_0
10003706	39	75	peripheral adrenergic blocking drugs	group	Drug_1

10003707|t|When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.
10003707	5	15	methyldopa	drug	Drug_0
10003707	35	57	antihypertensive drugs	group	Drug_1
10003707	effect	Drug_0	Drug_1

10003708|t|Patients may require reduced doses of anesthetics when on methyldopa.
10003708	38	49	anesthetics	group	Drug_0
10003708	58	68	methyldopa	drug	Drug_1
10003708	advise	Drug_0	Drug_1

10003709|t|When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
10003709	5	15	methyldopa	drug	Drug_0
10003709	110	117	lithium	drug	Drug_1
10003709	advise	Drug_0	Drug_1

10003710|t|Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.
10003710	65	75	methyldopa	drug	Drug_0
10003710	101	116	ferrous sulfate	drug	Drug_1
10003710	120	137	ferrous gluconate	drug	Drug_2
10003710	mechanism	Drug_0	Drug_1
10003710	mechanism	Drug_0	Drug_2

10003711|t|Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.
10003711	20	30	methyldopa	drug	Drug_0
10003711	36	51	ferrous sulfate	drug	Drug_1
10003711	55	72	ferrous gluconate	drug	Drug_2
10003711	advise	Drug_0	Drug_2
10003711	advise	Drug_0	Drug_1

10003712|t|Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin.
10003712	0	10	Methyldopa	drug	Drug_0
10003712	139	142	VMA	drug_n	Drug_1
10003712	55	76	vanillylmandelic acid	drug_n	Drug_2
10003712	146	154	vanillin	drug_n	Drug_3

10003713|t|CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
10003713	25	46	Macrolide Antibiotics	group	Drug_0
10003713	51	70	Protease Inhibitors	group	Drug_1
10003713	178	198	ergot alkaloid drugs	group	Drug_2
10003713	205	222	dihydroergotamine	drug	Drug_3
10003713	227	237	ergotamine	drug	Drug_4

10003714|t|Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
10003714	63	84	macrolide antibiotics	group	Drug_0
10003714	92	104	erythromycin	drug	Drug_1
10003714	106	120	troleandomycin	drug	Drug_2
10003714	122	136	clarithromycin	drug	Drug_3
10003714	139	187	HIV protease inhibitors	group	Drug_4
10003714	155	187	reverse transcriptase inhibitors	group	Drug_5
10003714	195	204	ritonavir	drug	Drug_6
10003714	206	215	indinavir	drug	Drug_7
10003714	217	227	nelfinavir	drug	Drug_8
10003714	229	240	delavirdine	drug	Drug_9
10003714	245	262	azole antifungals	group	Drug_10
10003714	270	282	ketoconazole	drug	Drug_11
10003714	284	296	itraconazole	drug	Drug_12
10003714	298	310	voriconazole	drug	Drug_13

10003715|t|Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
10003715	31	41	saquinavir	drug	Drug_0
10003715	43	53	nefazodone	drug	Drug_1
10003715	55	66	fluconazole	drug	Drug_2
10003715	86	96	fluoxetine	drug	Drug_3
10003715	98	109	fluvoxamine	drug	Drug_4
10003715	111	119	zileuton	drug	Drug_5
10003715	125	137	clotrimazole	drug	Drug_6

10003716|t|Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
10003716	33	43	Methergine	brand	Drug_0
10003716	48	72	methylergonovine maleate	drug	Drug_1
10003716	106	122	vasoconstrictors	group	Drug_2
10003716	126	141	ergot alkaloids	group	Drug_3
10003716	advise	Drug_1	Drug_2
10003716	advise	Drug_0	Drug_2
10003716	advise	Drug_0	Drug_3

10003717|t|Ritalin may decrease the hypotensive effect of guanethidine.
10003717	0	7	Ritalin	brand	Drug_0
10003717	47	59	guanethidine	drug	Drug_1
10003717	effect	Drug_0	Drug_1

10003718|t|Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
10003718	44	51	Ritalin	brand	Drug_0
10003718	82	105	coumarin anticoagulants	group	Drug_1
10003718	107	122	anticonvulsants	group	Drug_2
10003718	124	137	phenobarbital	drug	Drug_3
10003718	139	156	diphenylhydantoin	drug	Drug_4
10003718	158	167	primidone	drug	Drug_5
10003718	170	184	phenylbutazone	drug	Drug_6
10003718	190	205	tricyclic drugs	group	Drug_7
10003718	207	217	imipramine	drug	Drug_8
10003718	219	231	clomipramine	drug	Drug_9
10003718	233	244	desipramine	drug	Drug_10
10003718	mechanism	Drug_0	Drug_8
10003718	mechanism	Drug_0	Drug_5
10003718	mechanism	Drug_0	Drug_6
10003718	mechanism	Drug_0	Drug_10
10003718	mechanism	Drug_0	Drug_3
10003718	mechanism	Drug_0	Drug_7
10003718	mechanism	Drug_0	Drug_1
10003718	mechanism	Drug_0	Drug_9
10003718	mechanism	Drug_0	Drug_2
10003718	mechanism	Drug_0	Drug_4

10003719|t|The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.
10003719	20	35	methylphenidate	drug	Drug_0
10003719	56	65	clonidine	drug	Drug_1
10003719	92	108	alpha-2 agonists	group	Drug_2

10003720|t|Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;
10003720	62	73	cyclosporin	drug	Drug_0
10003720	78	96	methylprednisolone	drug	Drug_1
10003720	mechanism	Drug_0	Drug_1

10003721|t|convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.
10003721	54	72	methylprednisolone	drug	Drug_0
10003721	77	88	cyclosporin	drug	Drug_1
10003721	effect	Drug_0	Drug_1

10003722|t|Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
10003722	42	55	phenobarbital	drug	Drug_0
10003722	57	66	phenytoin	drug	Drug_1
10003722	72	80	rifampin	drug	Drug_2
10003722	159	177	methylprednisolone	drug	Drug_3
10003722	mechanism	Drug_1	Drug_3
10003722	advise	Drug_0	Drug_3
10003722	advise	Drug_2	Drug_3
10003722	mechanism	Drug_2	Drug_3
10003722	mechanism	Drug_0	Drug_3
10003722	advise	Drug_1	Drug_3

10003723|t|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
10003723	14	28	troleandomycin	drug	Drug_0
10003723	33	45	ketoconazole	drug	Drug_1
10003723	76	94	methylprednisolone	drug	Drug_2
10003723	mechanism	Drug_1	Drug_2
10003723	mechanism	Drug_0	Drug_2

10003724|t|Methylprednisolone may increase the clearance of chronic high dose aspirin.
10003724	0	18	Methylprednisolone	drug	Drug_0
10003724	67	74	aspirin	brand	Drug_1
10003724	mechanism	Drug_0	Drug_1

10003725|t|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.
10003725	77	87	salicylate	group	Drug_0
10003725	102	120	methylprednisolone	drug	Drug_1
10003725	effect	Drug_0	Drug_1

10003726|t|Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
10003726	0	7	Aspirin	brand	Drug_0
10003726	54	69	corticosteroids	group	Drug_1
10003726	advise	Drug_0	Drug_1

10003727|t|The effect of methylprednisolone on oral anticoagulants is variable.
10003727	14	32	methylprednisolone	drug	Drug_0
10003727	41	55	anticoagulants	group	Drug_1

10003728|t|There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.
10003728	63	76	anticoagulant	group	Drug_0
10003728	106	121	corticosteroids	group	Drug_1
10003728	effect	Drug_0	Drug_1

10003729|t|Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
10003729	0	15	Methscopolamine	drug	Drug_0
10003729	34	49	antidepressants	group	Drug_1
10003729	51	60	tricyclic	group	Drug_2
10003729	68	82	MAO inhibitors	group	Drug_3
10003729	90	100	phenelzine	drug	Drug_4
10003729	102	111	linezolid	drug	Drug_5
10003729	113	128	tranylcypromine	drug	Drug_6
10003729	130	143	isocarboxazid	drug	Drug_7
10003729	145	155	selegiline	drug	Drug_8
10003729	157	169	furazolidone	drug	Drug_9
10003729	172	181	quinidine	drug	Drug_10
10003729	183	193	amantadine	drug	Drug_11
10003729	195	209	antihistamines	group	Drug_12
10003729	217	232	diphenhydramine	drug	Drug_13
10003729	241	257	anticholinergics	group	Drug_14
10003729	259	277	potassium chloride	drug	Drug_15
10003729	291	299	antacids	group	Drug_16
10003729	301	339	absorbent-type anti-diarrhea medicines	group	Drug_17
10003729	347	353	kaolin	drug	Drug_18
10003729	354	360	pectin	drug	Drug_19
10003729	363	377	phenothiazines	group	Drug_20
10003729	385	399	chlorpromazine	drug	Drug_21
10003729	401	413	promethazine	drug	Drug_22
10003729	int	Drug_0	Drug_4
10003729	int	Drug_0	Drug_16
10003729	int	Drug_0	Drug_6
10003729	int	Drug_0	Drug_21
10003729	int	Drug_0	Drug_19
10003729	int	Drug_0	Drug_2
10003729	int	Drug_0	Drug_9
10003729	int	Drug_0	Drug_17
10003729	int	Drug_0	Drug_13
10003729	int	Drug_0	Drug_12
10003729	int	Drug_0	Drug_10
10003729	int	Drug_0	Drug_8
10003729	int	Drug_0	Drug_18
10003729	int	Drug_0	Drug_15
10003729	int	Drug_0	Drug_7
10003729	int	Drug_0	Drug_3
10003729	int	Drug_0	Drug_11
10003729	int	Drug_0	Drug_20
10003729	int	Drug_0	Drug_14
10003729	int	Drug_0	Drug_22
10003729	int	Drug_0	Drug_5

10003730|t|Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.
10003730	18	25	alcohol	drug	Drug_0
10003730	36	66	CNS depression-producing drugs	group	Drug_1
10003730	110	121	methyprylon	drug	Drug_2
10003730	effect	Drug_1	Drug_2
10003730	effect	Drug_0	Drug_2

10003731|t|Methysergide may reverse the analgesic activity of narcotic analgesics.
10003731	0	12	Methysergide	drug	Drug_0
10003731	51	70	narcotic analgesics	group	Drug_1
10003731	effect	Drug_0	Drug_1

10003732|t|Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
10003732	20	42	vasoconstrictor agents	group	Drug_0
10003732	53	68	ergot alkaloids	group	Drug_1
10003732	70	81	sumatriptan	drug	Drug_2
10003732	87	95	nicotine	drug	Drug_3

10003733|t|The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.
10003733	15	29	metoclopramide	drug	Drug_0
10003733	78	99	anticholinergic drugs	group	Drug_1
10003733	104	123	narcotic analgesics	group	Drug_2
10003733	effect	Drug_0	Drug_1
10003733	effect	Drug_0	Drug_2

10003734|t|Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
10003734	41	55	metoclopramide	drug	Drug_0
10003734	70	77	alcohol	drug	Drug_1
10003734	79	88	sedatives	group	Drug_2
10003734	90	99	hypnotics	group	Drug_3
10003734	101	110	narcotics	group	Drug_4
10003734	115	128	tranquilizers	group	Drug_5
10003734	effect	Drug_0	Drug_3
10003734	effect	Drug_0	Drug_5
10003734	effect	Drug_0	Drug_4
10003734	effect	Drug_0	Drug_2
10003734	effect	Drug_0	Drug_1

10003735|t|The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.
10003735	17	31	metoclopramide	drug	Drug_0
10003735	173	202	monoamine oxi-dase inhibitors	group	Drug_1
10003735	advise	Drug_0	Drug_1

10003736|t|Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).
10003736	62	69	digoxin	drug	Drug_0
10003736	74	88	metoclopramide	drug	Drug_1
10003736	189	202	acetaminophen	drug	Drug_2
10003736	204	216	tetracycline	drug	Drug_3
10003736	218	226	levodopa	drug	Drug_4
10003736	228	235	ethanol	drug	Drug_5
10003736	237	249	cyclosporine	drug	Drug_6
10003736	mechanism	Drug_1	Drug_2
10003736	mechanism	Drug_0	Drug_1

10003737|t|Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.
10003737	22	36	metoclopramide	drug	Drug_0
10003737	124	131	insulin	drug	Drug_1
10003737	advise	Drug_0	Drug_1

10003738|t|Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
10003738	0	9	Diuretics	group	Drug_0
10003738	11	21	Furosemide	drug	Drug_1
10003738	41	55	loop diuretics	group	Drug_2
10003738	81	91	metolazone	drug	Drug_3
10003738	effect	Drug_1	Drug_3
10003738	effect	Drug_2	Drug_3

10003739|t|Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.
10003739	6	23	Antihypertensives	group	Drug_0
10003739	30	36	MYKROX	brand	Drug_1
10003739	65	87	antihypertensive drugs	group	Drug_2
10003739	advise	Drug_1	Drug_2

10003740|t|Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.
10003740	0	7	Alcohol	drug	Drug_0
10003740	9	21	Barbiturates	group	Drug_1
10003740	27	36	Narcotics	group	Drug_2
10003740	150	160	metolazone	drug	Drug_3

10003741|t|Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.
10003741	0	20	Digitalis Glycosides	group	Drug_0
10003741	22	30	Diuretic	group	Drug_1
10003741	101	110	digitalis	group	Drug_2
10003741	effect	Drug_1	Drug_2

10003742|t|Corticosteroids or ACTH: May increase the risk of hypokalemia and increase salt and water retention.
10003742	0	15	Corticosteroids	group	Drug_0
10003742	19	23	ACTH	drug	Drug_1

10003743|t|Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
10003743	93	109	curariform drugs	group	Drug_0
10003743	18	26	Diuretic	group	Drug_1
10003743	119	131	tubocurarine	drug	Drug_2
10003743	effect	Drug_1	Drug_0
10003743	effect	Drug_1	Drug_2

10003744|t|Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.
10003744	0	11	Salicylates	group	Drug_0
10003744	22	59	Non-Steroidal Anti-Inflammatory Drugs	group	Drug_1
10003744	106	112	MYKROX	brand	Drug_2
10003744	effect	Drug_1	Drug_2
10003744	effect	Drug_0	Drug_2

10003745|t|Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
10003745	0	16	Sympathomimetics	group	Drug_0
10003745	18	28	Metolazone	drug	Drug_1
10003745	69	83	norepinephrine	drug	Drug_2
10003745	effect	Drug_1	Drug_2

10003746|t|Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone.
10003746	0	11	Methenamine	drug	Drug_0
10003746	75	85	metolazone	drug	Drug_1
10003746	effect	Drug_0	Drug_1

10003747|t|Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;
10003747	117	131	anticoagulants	group	Drug_0
10003747	16	26	Metolazone	drug	Drug_1
10003747	45	68	thiazide-like diuretics	group	Drug_2
10003747	effect	Drug_1	Drug_0

10003748|t|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
10003748	37	46	reserpine	drug	Drug_0
10003748	92	112	beta-blocking agents	group	Drug_1
10003748	effect	Drug_0	Drug_1

10003749|t|Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.
10003749	5	18	metronidazole	drug	Drug_0
10003749	79	87	coumarin	group	Drug_1
10003749	92	100	warfarin	drug	Drug_2
10003749	effect	Drug_0	Drug_2
10003749	effect	Drug_0	Drug_1

10003750|t|Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.
10003750	46	54	METROGEL	brand	Drug_0
10003750	201	214	metronidazole	drug	Drug_1

10003751|t|The metabolism of Metopirone is accelerated by phenytoin;
10003751	18	28	Metopirone	brand	Drug_0
10003751	47	56	phenytoin	drug	Drug_1
10003751	mechanism	Drug_0	Drug_1

10003752|t|Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.
10003752	0	10	Metopirone	brand	Drug_0
10003752	87	100	acetaminophen	drug	Drug_1
10003752	mechanism	Drug_0	Drug_1
10003752	effect	Drug_0	Drug_1

10003753|t|Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
10003753	44	50	DEMSER	brand	Drug_0
10003753	73	87	phenothiazines	group	Drug_1
10003753	91	102	haloperidol	drug	Drug_2
10003753	advise	Drug_0	Drug_1
10003753	advise	Drug_0	Drug_2

10003754|t|Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.
10003754	18	24	DEMSER	brand	Drug_0
10003754	30	37	alcohol	drug	Drug_1
10003754	47	62	CNS depressants	drug	Drug_2
10003754	effect	Drug_0	Drug_1
10003754	effect	Drug_0	Drug_2

10003755|t|Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.
10003755	6	13	MEXITIL	brand	Drug_0
10003755	171	181	mexiletine	drug	Drug_1

10003756|t|In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.
10003756	74	84	mexiletine	drug	Drug_0
10003756	140	151	fluvoxamine	drug	Drug_1
10003756	mechanism	Drug_0	Drug_1

10003757|t|In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.
10003757	101	112	propafenone	drug	Drug_0
10003757	143	153	mexiletine	drug	Drug_1

10003758|t|In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.
10003758	62	73	propafenone	drug	Drug_0
10003758	137	147	mexiletine	drug	Drug_1

10003759|t|Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.
10003759	12	22	mexiletine	drug	Drug_0
10003759	141	152	propafenone	drug	Drug_1

10003760|t|In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions.
10003760	37	44	Mexitil	brand	Drug_0
10003760	111	127	antihypertensive	group	Drug_1
10003760	133	152	anticoagulant drugs	group	Drug_2

10003761|t|A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy.
10003761	13	28	antiarrhythmics	group	Drug_0
10003761	37	46	quinidine	drug	Drug_1
10003761	50	61	propranolol	drug	Drug_2

10003762|t|When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
10003762	5	14	phenytoin	drug	Drug_0
10003762	56	64	rifampin	drug	Drug_1
10003762	69	82	phenobarbital	drug	Drug_2
10003762	137	144	Mexitil	brand	Drug_3
10003762	mechanism	Drug_0	Drug_3
10003762	mechanism	Drug_1	Drug_3
10003762	mechanism	Drug_2	Drug_3

10003763|t|In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations.
10003763	19	34	benzodiazepines	group	Drug_0
10003763	60	67	Mexitil	brand	Drug_1

10003764|t|ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol.
10003764	64	71	Mexitil	brand	Drug_0
10003764	79	86	digoxin	drug	Drug_1
10003764	88	97	diuretics	group	Drug_2
10003764	102	113	propranolol	drug	Drug_3

10003765|t|Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;
10003765	29	39	cimetidine	drug	Drug_0
10003765	115	122	Mexitil	brand	Drug_1
10003765	mechanism	Drug_0	Drug_1

10003766|t|Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
10003766	133	140	Mexitil	brand	Drug_0
10003766	178	185	digoxin	drug	Drug_1
10003766	51	79	magnesium-aluminum hydroxide	drug	Drug_2
10003766	mechanism	Drug_2	Drug_1

10003767|t|Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels.
10003767	18	25	Mexitil	brand	Drug_0
10003767	75	87	theophylline	drug	Drug_1
10003767	mechanism	Drug_0	Drug_1

10003768|t|This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
10003768	338	345	Mexitil	brand	Drug_0
10003768	269	281	theophylline	drug	Drug_1
10003768	mechanism	Drug_1	Drug_0
10003768	advise	Drug_0	Drug_1

10003769|t|Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .
10003769	99	107	caffeine	drug	Drug_0
10003769	158	165	Mexitil	brand	Drug_1
10003769	mechanism	Drug_0	Drug_1

10003770|t|Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
10003770	0	7	Posicor	brand	Drug_0
10003770	78	89	terfenadine	drug	Drug_1
10003770	91	101	astemizole	drug	Drug_2
10003770	103	112	cisapride	drug	Drug_3
10003770	114	126	cyclosporine	drug	Drug_4
10003770	132	157	tricyclic antidepressants	group	Drug_5
10003770	mechanism	Drug_0	Drug_5
10003770	mechanism	Drug_0	Drug_2
10003770	mechanism	Drug_0	Drug_4
10003770	mechanism	Drug_0	Drug_3
10003770	mechanism	Drug_0	Drug_1

10003771|t|A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
10003771	140	148	MYCAMINE	brand	Drug_0
10003771	153	174	mycophenolate mofetil	drug	Drug_1
10003771	176	188	cyclosporine	drug	Drug_2
10003771	190	200	tacrolimus	drug	Drug_3
10003771	202	214	prednisolone	drug	Drug_4
10003771	216	225	sirolimus	drug	Drug_5
10003771	227	237	nifedipine	drug	Drug_6
10003771	239	250	fluconazole	drug	Drug_7
10003771	252	261	ritonavir	drug	Drug_8
10003771	267	275	rifampin	drug	Drug_9

10003772|t|There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.
10003772	58	66	MYCAMINE	brand	Drug_0
10003772	70	91	mycophenolate mofetil	drug	Drug_1
10003772	93	105	cyclosporine	drug	Drug_2
10003772	107	117	tacrolimus	drug	Drug_3
10003772	119	131	prednisolone	drug	Drug_4
10003772	137	148	fluconazole	drug	Drug_5

10003773|t|Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone.
10003773	113	122	sirolimus	drug	Drug_0
10003773	90	98	MYCAMINE	brand	Drug_1
10003773	mechanism	Drug_0	Drug_1

10003774|t|Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone.
10003774	124	134	nifedipine	drug	Drug_0
10003774	101	109	MYCAMINE	brand	Drug_1
10003774	mechanism	Drug_0	Drug_1

10003775|t|Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
10003775	133	142	sirolimus	drug	Drug_0
10003775	146	156	nifedipine	drug	Drug_1
10003775	63	71	MYCAMINE	brand	Drug_2
10003775	advise	Drug_0	Drug_2
10003775	advise	Drug_1	Drug_2

10003776|t|Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
10003776	74	83	midazolam	drug	Drug_0
10003776	228	246	azole antimycotics	group	Drug_1
10003776	248	267	protease inhibitors	group	Drug_2
10003776	269	296	calcium channel antagonists	group	Drug_3
10003776	302	323	macrolide antibiotics	group	Drug_4
10003776	advise	Drug_0	Drug_2
10003776	advise	Drug_0	Drug_4
10003776	advise	Drug_0	Drug_1
10003776	advise	Drug_0	Drug_3

10003777|t|Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
10003777	14	26	erythromycin	drug	Drug_0
10003777	28	37	diltiazem	drug	Drug_1
10003777	39	48	verapamil	drug	Drug_2
10003777	50	62	ketoconazole	drug	Drug_3
10003777	64	75	fluconazole	drug	Drug_4
10003777	80	92	itraconazole	drug	Drug_5
10003777	171	180	midazolam	drug	Drug_6
10003777	mechanism	Drug_4	Drug_6
10003777	mechanism	Drug_5	Drug_6
10003777	mechanism	Drug_0	Drug_6
10003777	mechanism	Drug_2	Drug_6
10003777	mechanism	Drug_1	Drug_6
10003777	mechanism	Drug_3	Drug_6

10003778|t|Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.
10003778	64	73	ritonavir	drug	Drug_0
10003778	78	88	nelfinavir	drug	Drug_1
10003778	198	207	midazolam	drug	Drug_2
10003778	mechanism	Drug_1	Drug_2
10003778	mechanism	Drug_0	Drug_2

10003779|t|Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
10003779	63	71	rifampin	drug	Drug_0
10003779	73	86	carbamazepine	drug	Drug_1
10003779	92	101	phenytoin	drug	Drug_2
10003779	175	184	midazolam	drug	Drug_3
10003779	mechanism	Drug_2	Drug_3
10003779	mechanism	Drug_1	Drug_3
10003779	mechanism	Drug_0	Drug_3

10003780|t|The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate.
10003780	102	111	sedatives	group	Drug_0
10003780	178	193	methylphenidate	drug	Drug_1

10003781|t|The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
10003781	23	35	VERSED Syrup	brand	Drug_0
10003781	153	162	narcotics	group	Drug_1
10003781	168	176	morphine	drug	Drug_2
10003781	178	188	meperidine	drug	Drug_3
10003781	193	201	fentanyl	drug	Drug_4
10003781	204	212	propofol	drug	Drug_5
10003781	214	222	ketamine	drug	Drug_6
10003781	224	237	nitrous oxide	drug	Drug_7
10003781	239	251	secobarbital	drug	Drug_8
10003781	256	266	droperidol	drug	Drug_9
10003781	effect	Drug_0	Drug_5
10003781	effect	Drug_0	Drug_6
10003781	effect	Drug_0	Drug_1
10003781	effect	Drug_0	Drug_8
10003781	effect	Drug_0	Drug_9
10003781	effect	Drug_0	Drug_3
10003781	effect	Drug_0	Drug_4
10003781	effect	Drug_0	Drug_7
10003781	effect	Drug_0	Drug_2

10003782|t|No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
10003782	72	80	atropine	drug	Drug_0
10003782	82	93	scopolamine	drug	Drug_1
10003782	95	109	glycopyrrolate	drug	Drug_2
10003782	111	119	diazepam	drug	Drug_3
10003782	121	132	hydroxyzine	drug	Drug_4
10003782	144	160	muscle relaxants	group	Drug_5
10003782	171	182	anesthetics	group	Drug_6

10003783|t|When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V.
10003783	37	47	ProAmatine	brand	Drug_0
10003783	52	70	cardiac glycosides	group	Drug_1
10003783	effect	Drug_0	Drug_1

10003784|t|The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
10003784	66	79	phenylephrine	drug	Drug_0
10003784	81	96	pseudoephedrine	drug	Drug_1
10003784	98	107	ephedrine	drug	Drug_2
10003784	109	128	phenylpropanolamine	drug	Drug_3
10003784	132	149	dihydroergotamine	drug	Drug_4
10003784	254	264	ProAmatine	brand	Drug_5
10003784	effect	Drug_3	Drug_5
10003784	effect	Drug_0	Drug_5
10003784	effect	Drug_4	Drug_5
10003784	effect	Drug_1	Drug_5
10003784	effect	Drug_2	Drug_5

10003785|t|ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation.
10003785	0	10	ProAmatine	brand	Drug_0
10003785	105	128	fludrocortisone acetate	drug	Drug_1

10003786|t|ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
10003786	120	130	ProAmatine	brand	Drug_0
10003786	12	44	Alpha-adrenergic blocking agents	group	Drug_1
10003786	54	62	prazosin	drug	Drug_2
10003786	64	73	terazosin	drug	Drug_3
10003786	79	88	doxazosin	drug	Drug_4
10003786	274	289	desglymidodrine	drug_n	Drug_5
10003786	415	424	metformin	drug	Drug_6
10003786	426	436	cimetidine	drug	Drug_7
10003786	438	448	ranitidine	drug	Drug_8
10003786	450	462	procainamide	drug	Drug_9
10003786	464	475	triamterene	drug	Drug_10
10003786	477	487	flecainide	drug	Drug_11
10003786	493	502	quinidine	drug	Drug_12
10003786	mechanism	Drug_5	Drug_9
10003786	effect	Drug_2	Drug_0
10003786	mechanism	Drug_5	Drug_10
10003786	effect	Drug_4	Drug_0
10003786	mechanism	Drug_5	Drug_7
10003786	mechanism	Drug_5	Drug_8
10003786	effect	Drug_3	Drug_0
10003786	mechanism	Drug_5	Drug_11
10003786	effect	Drug_1	Drug_0
10003786	mechanism	Drug_5	Drug_12
10003786	mechanism	Drug_5	Drug_6

10003787|t|Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
10003787	276	288	mifepristone	drug	Drug_0
10003787	158	170	ketoconazole	drug	Drug_1
10003787	172	184	itraconazole	drug	Drug_2
10003787	186	198	erythromycin	drug	Drug_3
10003787	mechanism	Drug_2	Drug_0
10003787	mechanism	Drug_3	Drug_0
10003787	mechanism	Drug_1	Drug_0

10003788|t|Furthermore, rifampin, dexamethasone, St.
10003788	13	21	rifampin	drug	Drug_0
10003788	23	36	dexamethasone	drug	Drug_1

10003789|t|John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
10003789	27	42	anticonvulsants	group	Drug_0
10003789	44	53	phenytoin	drug	Drug_1
10003789	55	68	phenobarbital	drug	Drug_2
10003789	70	83	carbamazepine	drug	Drug_3
10003789	146	158	mifepristone	drug	Drug_4
10003789	mechanism	Drug_1	Drug_4
10003789	mechanism	Drug_0	Drug_4
10003789	mechanism	Drug_3	Drug_4
10003789	mechanism	Drug_2	Drug_4

10003790|t|While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.
10003790	27	34	ZAVESCA	brand	Drug_0
10003790	218	226	Cerezyme	brand	Drug_1
10003790	mechanism	Drug_0	Drug_1

10003791|t|Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.
10003791	25	33	Cerezyme	brand	Drug_0
10003791	38	50	imiglucerase	drug	Drug_1
10003791	56	63	ZAVESCA	brand	Drug_2
10003791	advise	Drug_0	Drug_2
10003791	advise	Drug_1	Drug_2

10003792|t|Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
10003792	8	21	tetracyclines	group	Drug_0
10003792	161	174	anticoagulant	group	Drug_1
10003792	advise	Drug_0	Drug_1

10003793|t|Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.
10003793	162	172	penicillin	drug	Drug_0
10003793	117	141	tetracycline class drugs	group	Drug_1
10003793	advise	Drug_1	Drug_0

10003794|t|Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
10003794	14	27	tetracyclines	group	Drug_0
10003794	43	51	antacids	group	Drug_1
10003794	63	71	aluminum	drug	Drug_2
10003794	73	80	calcium	drug	Drug_3
10003794	84	93	magnesium	drug	Drug_4
10003794	99	103	iron	drug	Drug_5
10003794	mechanism	Drug_0	Drug_4
10003794	mechanism	Drug_0	Drug_5
10003794	mechanism	Drug_0	Drug_3
10003794	mechanism	Drug_0	Drug_2

10003795|t|The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
10003795	22	34	tetracycline	group	Drug_0
10003795	39	53	methoxyflurane	drug	Drug_1
10003795	effect	Drug_0	Drug_1

10003796|t|Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
10003796	18	31	tetracyclines	group	Drug_0
10003796	73	87	contraceptives	group	Drug_1
10003796	effect	Drug_0	Drug_1

10003797|t|Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.
10003797	146	158	guanethidine	drug	Drug_0
10003797	40	49	minoxidil	drug	Drug_1
10003797	effect	Drug_1	Drug_0

10003798|t|If at all possible guanethidine should be discontinued well before minoxidil is begun.
10003798	19	31	guanethidine	drug	Drug_0
10003798	67	76	minoxidil	drug	Drug_1
10003798	advise	Drug_0	Drug_1

10003799|t|Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.
10003799	74	88	REMERON SolTab	brand	Drug_0
10003799	93	104	mirtazapine	drug	Drug_1

10003800|t|While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied.
10003800	121	132	mirtazapine	drug	Drug_0
10003800	309	323	REMERON SolTab	brand	Drug_1

10003801|t|Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.
10003801	39	46	alcohol	drug	Drug_0
10003801	109	120	mirtazapine	drug	Drug_1
10003801	mechanism	Drug_0	Drug_1

10003802|t|However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol.
10003802	66	73	REMERON	brand	Drug_0
10003802	126	133	alcohol	drug	Drug_1
10003802	effect	Drug_0	Drug_1

10003803|t|Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
10003803	49	56	alcohol	drug	Drug_0
10003803	70	84	REMERON SolTab	brand	Drug_1
10003803	126	134	diazepam	drug	Drug_2
10003803	184	195	mirtazapine	drug	Drug_3
10003803	mechanism	Drug_2	Drug_3
10003803	advise	Drug_0	Drug_1

10003804|t|However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.
10003804	52	59	REMERON	brand	Drug_0
10003804	111	119	diazepam	drug	Drug_1
10003804	effect	Drug_0	Drug_1

10003805|t|Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.
10003805	49	57	diazepam	drug	Drug_0
10003805	95	109	REMERON SolTab	brand	Drug_1
10003805	advise	Drug_0	Drug_1

10003806|t|Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.
10003806	0	8	Mitotane	drug	Drug_0
10003806	175	183	warfarin	drug	Drug_1
10003806	mechanism	Drug_0	Drug_1

10003807|t|Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.
10003807	70	83	anticoagulant	group	Drug_0
10003807	123	131	Mitotane	drug	Drug_1
10003807	147	175	coumarin-type anticoagulants	group	Drug_2
10003807	advise	Drug_1	Drug_2

10003808|t|Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied.
10003808	165	173	MIVACRON	brand	Drug_0
10003808	178	193	succinylcholine	drug	Drug_1

10003809|t|Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.
10003809	24	39	succinylcholine	drug	Drug_0
10003809	93	115	nondepolarizing agents	group	Drug_1
10003809	effect	Drug_0	Drug_1

10003810|t|Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON.
10003810	38	53	succinylcholine	drug	Drug_0
10003810	102	110	MIVACRON	brand	Drug_1
10003810	advise	Drug_0	Drug_1

10003811|t|The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
10003811	11	19	MIVACRON	brand	Drug_0
10003811	84	99	succinylcholine	drug	Drug_1

10003812|t|There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents.
10003812	41	49	MIVACRON	brand	Drug_0
10003812	61	106	nondepolarizing neuromuscular blocking agents	group	Drug_1

10003813|t|Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C.
10003813	0	10	Isoflurane	drug	Drug_0
10003813	15	24	enflurane	drug	Drug_1
10003813	44	57	nitrous oxide	drug	Drug_2
10003813	58	64	oxygen	drug	Drug_3

10003814|t|A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane.
10003814	64	72	MIVACRON	brand	Drug_0
10003814	119	128	enflurane	drug	Drug_1
10003814	132	142	isoflurane	drug	Drug_2

10003815|t|Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
10003815	67	89	nondepolarizing agents	drug	Drug_0
10003815	98	106	MIVACRON	brand	Drug_1
10003815	123	134	antibiotics	group	Drug_2
10003815	142	157	aminoglycosides	group	Drug_3
10003815	159	172	tetracyclines	group	Drug_4
10003815	174	184	bacitracin	drug	Drug_5
10003815	186	196	polymyxins	group	Drug_6
10003815	198	208	lincomycin	drug	Drug_7
10003815	210	221	clindamycin	drug	Drug_8
10003815	223	231	colistin	drug	Drug_9
10003815	237	258	sodium colistimethate	drug	Drug_10
10003815	261	270	magnesium	group	Drug_11
10003815	278	285	lithium	drug	Drug_12
10003815	293	304	anesthetics	group	Drug_13
10003815	306	318	procainamide	drug	Drug_14
10003815	324	333	quinidine	drug	Drug_15
10003815	int	Drug_0	Drug_6
10003815	int	Drug_0	Drug_7
10003815	int	Drug_1	Drug_10
10003815	int	Drug_1	Drug_5
10003815	int	Drug_1	Drug_3
10003815	int	Drug_0	Drug_12
10003815	int	Drug_0	Drug_14
10003815	int	Drug_0	Drug_9
10003815	int	Drug_1	Drug_9
10003815	int	Drug_0	Drug_2
10003815	int	Drug_0	Drug_3
10003815	int	Drug_1	Drug_8
10003815	int	Drug_1	Drug_4
10003815	int	Drug_1	Drug_2
10003815	int	Drug_0	Drug_8
10003815	int	Drug_1	Drug_14
10003815	int	Drug_1	Drug_15
10003815	int	Drug_0	Drug_10
10003815	int	Drug_1	Drug_12
10003815	int	Drug_1	Drug_13
10003815	int	Drug_0	Drug_4
10003815	int	Drug_1	Drug_6
10003815	int	Drug_1	Drug_7
10003815	int	Drug_0	Drug_11
10003815	int	Drug_0	Drug_5
10003815	int	Drug_1	Drug_11
10003815	int	Drug_0	Drug_13
10003815	int	Drug_0	Drug_15

10003816|t|The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
10003816	37	45	MIVACRON	brand	Drug_0
10003816	151	165	contraceptives	group	Drug_1
10003816	167	182	glucocorticoids	group	Drug_2
10003816	195	223	monoamine oxidase inhibitors	group	Drug_3
10003816	354	383	neuromuscular blocking agents	group	Drug_4
10003816	443	452	phenytoin	drug	Drug_5
10003816	456	469	carbamazepine	drug	Drug_6
10003816	effect	Drug_0	Drug_2
10003816	effect	Drug_4	Drug_6
10003816	effect	Drug_0	Drug_3
10003816	effect	Drug_4	Drug_5
10003816	effect	Drug_0	Drug_1

10003817|t|While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
10003817	29	38	phenytoin	drug	Drug_0
10003817	42	55	carbamazepine	drug	Drug_1
10003817	81	89	MIVACRON	brand	Drug_2
10003817	effect	Drug_0	Drug_2
10003817	effect	Drug_1	Drug_2

10003818|t|Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
10003818	53	68	corticosteroids	group	Drug_0
10003818	176	185	phenytoin	drug	Drug_1
10003818	189	202	carbamazepine	drug	Drug_2
10003818	213	224	antibiotics	group	Drug_3
10003818	246	255	cisplatin	drug	Drug_4
10003818	258	269	edrophonium	drug	Drug_5
10003818	272	283	neostigmine	drug	Drug_6
10003818	286	297	polymyxin B	drug	Drug_7
10003818	301	311	bacitracin	drug	Drug_8
10003818	359	370	anesthetics	group	Drug_9
10003818	340	348	procaine	drug	Drug_10
10003818	373	388	succinylcholine	drug	Drug_11
10003818	398	414	muscle relaxants	group	Drug_12

10003819|t|Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started.
10003819	0	9	Diuretics	group	Drug_0
10003819	97	111	ACE inhibitors	group	Drug_1

10003820|t|The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced..
10003820	196	203	UNIVASC	brand	Drug_0
10003820	254	262	moexpril	drug	Drug_1

10003821|t|Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion.
10003821	0	9	Potassium	drug	Drug_0
10003821	26	53	Potassium-Sparing Diuretics	group	Drug_1
10003821	55	62	UNIVASC	brand	Drug_2

10003822|t|Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
10003822	7	34	potassium-sparing diuretics	group	Drug_0
10003822	36	50	spironolactone	drug	Drug_1
10003822	52	63	triamterene	drug	Drug_2
10003822	65	74	amiloride	drug	Drug_3
10003822	79	88	potassium	drug	Drug_4
10003822	120	134	ACE inhibitors	group	Drug_5
10003822	effect	Drug_0	Drug_5
10003822	effect	Drug_1	Drug_5
10003822	effect	Drug_3	Drug_5
10003822	effect	Drug_4	Drug_5
10003822	effect	Drug_2	Drug_5

10003823|t|Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.
10003823	5	19	Anticoagulants	group	Drug_0
10003823	46	54	warfarin	drug	Drug_1
10003823	141	154	anticoagulant	group	Drug_2

10003824|t|Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
10003824	149	156	lithium	drug	Drug_0
10003824	114	128	ACE inhibitors	group	Drug_1
10003824	effect	Drug_1	Drug_0

10003825|t|If a diuretic is also used, the risk of lithium toxicity may be increased.
10003825	5	13	diuretic	group	Drug_0
10003825	40	47	lithium	drug	Drug_1
10003825	effect	Drug_0	Drug_1

10003826|t|Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.
10003826	81	88	UNIVASC	brand	Drug_0
10003826	128	147	hydrochlorothiazide	drug	Drug_1
10003826	149	156	digoxin	drug	Drug_2
10003826	161	171	cimetidine	drug	Drug_3

10003827|t|UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
10003827	0	7	UNIVASC	brand	Drug_0
10003827	63	94	calcium-channel-blocking agents	group	Drug_1
10003827	96	105	diuretics	group	Drug_2
10003827	107	118	H2 blockers	group	Drug_3
10003827	120	127	digoxin	drug	Drug_4
10003827	134	153	hypoglycemic agents	group	Drug_5

10003828|t|However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.
10003828	9	21	ketoconazole	drug	Drug_0
10003828	96	114	mometasone furoate	drug	Drug_1
10003828	mechanism	Drug_0	Drug_1

10003829|t|Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate).
10003829	0	11	Montelukast	drug	Drug_0
10003829	176	188	theophylline	drug	Drug_1

10003830|t|- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily.
10003830	218	229	terfenadine	drug	Drug_0
10003830	105	117	fexofenadine	drug	Drug_1

10003831|t|Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.
10003831	0	11	Montelukast	drug	Drug_0
10003831	167	180	contraceptive	group	Drug_1
10003831	192	205	norethindrone	drug	Drug_2
10003831	219	228	estradiol	drug	Drug_3

10003832|t|- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.
10003832	139	149	prednisone	drug	Drug_0
10003832	165	177	prednisolone	drug	Drug_1

10003833|t|Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast.
10003833	0	13	Phenobarbital	drug	Drug_0
10003833	133	144	montelukast	drug	Drug_1

10003834|t|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
10003834	112	125	phenobarbital	drug	Drug_0
10003834	129	137	rifampin	drug	Drug_1
10003834	164	175	montelukast	drug	Drug_2
10003834	advise	Drug_0	Drug_2
10003834	advise	Drug_1	Drug_2

10003835|t|In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
10003835	62	73	montelukast	drug	Drug_0
10003835	164	176	theophylline	drug	Drug_1
10003835	178	188	prednisone	drug	Drug_2
10003835	190	202	prednisolone	drug	Drug_3
10003835	209	223	contraceptives	group	Drug_4
10003835	225	238	norethindrone	drug	Drug_5
10003835	244	261	ethinyl estradiol	drug	Drug_6
10003835	271	282	terfenadine	drug	Drug_7
10003835	284	291	digoxin	drug	Drug_8
10003835	297	305	warfarin	drug	Drug_9

10003836|t|These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.
10003836	27	43	thyroid hormones	group	Drug_0
10003836	45	63	sedative hypnotics	group	Drug_1
10003836	65	103	non-steroidal anti-inflammatory agents	group	Drug_2
10003836	105	120	benzodiazepines	group	Drug_3
10003836	126	139	decongestants	group	Drug_4

10003837|t|Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast.
10003837	0	13	Phenobarbital	drug	Drug_0
10003837	133	144	montelukast	drug	Drug_1

10003838|t|It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
10003838	112	125	phenobarbital	drug	Drug_0
10003838	129	137	rifampin	drug	Drug_1
10003838	164	175	montelukast	drug	Drug_2
10003838	advise	Drug_1	Drug_2
10003838	advise	Drug_0	Drug_2

10003839|t|Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
10003839	15	49	Central Nervous System Depressants	group	Drug_0
10003839	77	85	morphine	drug	Drug_1
10003839	127	142	CNS depressants	group	Drug_2
10003839	151	158	alcohol	drug	Drug_3
10003839	160	169	sedatives	group	Drug_4
10003839	171	186	antihistaminics	group	Drug_5
10003839	191	209	psychotropic drugs	group	Drug_6
10003839	effect	Drug_1	Drug_3
10003839	effect	Drug_1	Drug_5
10003839	effect	Drug_1	Drug_6
10003839	effect	Drug_1	Drug_2
10003839	effect	Drug_1	Drug_4

10003840|t|Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.
10003840	7	19	neuroleptics	group	Drug_0
10003840	45	53	morphine	drug	Drug_1
10003840	effect	Drug_0	Drug_1

10003841|t|Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
10003841	17	59	Mixed Agonist/Antagonist Opioid Analgesics	group	Drug_0
10003841	61	90	Agonist/antagonist analgesics	group	Drug_1
10003841	98	109	pentazocine	drug	Drug_2
10003841	111	121	nalbuphine	drug	Drug_3
10003841	123	134	butorphanol	drug	Drug_4
10003841	139	152	buprenorphine	drug	Drug_5
10003841	261	285	opioid agonist analgesic	group	Drug_6
10003841	advise	Drug_2	Drug_6
10003841	advise	Drug_1	Drug_6
10003841	advise	Drug_5	Drug_6
10003841	advise	Drug_3	Drug_6
10003841	advise	Drug_4	Drug_6

10003842|t|Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
10003842	163	171	antacids	group	Drug_0
10003842	271	279	Myfortic	brand	Drug_1
10003842	133	142	magnesium	drug	Drug_2
10003842	143	151	aluminum	drug	Drug_3
10003842	mechanism	Drug_1	Drug_3
10003842	mechanism	Drug_1	Drug_2

10003843|t|It is recommended that Myfortic and antacids not be administered simultaneously.
10003843	23	31	Myfortic	drug	Drug_0
10003843	36	44	antacids	group	Drug_1
10003843	advise	Drug_0	Drug_1

10003844|t|Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic.
10003844	64	76	cyclosporine	drug	Drug_0
10003844	152	160	Myfortic	brand	Drug_1

10003845|t|Acyclovir/Ganciclovir: may be taken with Myfortic;
10003845	0	9	Acyclovir	drug	Drug_0
10003845	10	21	Ganciclovir	drug	Drug_1
10003845	41	49	Myfortic	brand	Drug_2

10003846|t|Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
10003846	5	14	acyclovir	drug	Drug_0
10003846	15	26	ganciclovir	drug	Drug_1
10003846	31	35	MPAG	drug_n	Drug_2

10003847|t|Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
10003847	184	196	azathioprine	drug	Drug_0
10003847	200	221	mycophenolate mofetil	drug	Drug_1
10003847	136	144	Myfortic	brand	Drug_2
10003847	advise	Drug_2	Drug_0
10003847	advise	Drug_2	Drug_1

10003848|t|Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil.
10003848	0	14	Cholestyramine	drug	Drug_0
10003848	108	111	MPA	drug_n	Drug_1
10003848	146	167	mycophenolate mofetil	drug	Drug_2

10003849|t|Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.
10003849	275	283	Myfortic	brand	Drug_0
10003849	43	57	cholestyramine	drug	Drug_1
10003849	204	222	activated charcoal	drug	Drug_2
10003849	advise	Drug_0	Drug_1
10003849	advise	Drug_0	Drug_2

10003850|t|Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected.
10003850	73	87	contraceptives	group	Drug_0
10003850	55	63	Myfortic	brand	Drug_1

10003851|t|However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil.
10003851	48	63	levonorgesterol	drug	Drug_0
10003851	114	135	mycophenolate mofetil	drug	Drug_1
10003851	mechanism	Drug_0	Drug_1

10003852|t|Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered.
10003852	39	53	contraceptives	group	Drug_0
10003852	80	88	Myfortic	brand	Drug_1
10003852	advise	Drug_0	Drug_1

10003853|t|Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.
10003853	0	13	Live Vaccines	group	Drug_0
10003853	37	45	Myfortic	drug	Drug_1
10003853	58	82	live attenuated vaccines	group	Drug_2
10003853	advise	Drug_1	Drug_2

10003854|t|Interference of MPAG hydrolysis may lead to less MPA available for absorption.
10003854	16	20	MPAG	drug_n	Drug_0
10003854	49	52	MPA	drug_n	Drug_1

10003855|t|Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
10003855	100	109	phenytoin	drug	Drug_0
10003855	111	124	carbamazepine	drug	Drug_1
10003855	130	140	rifampicin	drug	Drug_2
10003855	204	215	ondansetron	drug	Drug_3
10003855	mechanism	Drug_1	Drug_3
10003855	mechanism	Drug_1	Drug_3
10003855	mechanism	Drug_0	Drug_3
10003855	mechanism	Drug_0	Drug_3
10003855	mechanism	Drug_2	Drug_3
10003855	mechanism	Drug_2	Drug_3

10003856|t|However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
10003856	472	483	ondansetron	drug	Drug_0
10003856	360	368	tramadol	drug	Drug_1
10003856	effect	Drug_0	Drug_1

10003857|t|In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
10003857	11	21	carmustine	drug	Drug_0
10003857	23	32	etoposide	drug	Drug_1
10003857	38	47	cisplatin	drug	Drug_2
10003857	86	97	ondansetron	drug	Drug_3

10003858|t|ondansetron did not increase blood levels of high-dose methotrexate.
10003858	0	11	ondansetron	drug	Drug_0
10003858	55	67	methotrexate	drug	Drug_1

10003859|t|Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.
10003859	6	45	beta adrenergic aerosol bronchodilators	group	Drug_0
10003859	84	91	Alupent	brand	Drug_1
10003859	96	118	metaproterenol sulfate	drug	Drug_2
10003859	advise	Drug_0	Drug_2
10003859	advise	Drug_0	Drug_1

10003860|t|Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
10003860	171	195	beta adrenergic agonists	group	Drug_0
10003860	92	120	monoamine oxidase inhibitors	group	Drug_1
10003860	124	149	tricyclic antidepressants	group	Drug_2
10003860	advise	Drug_0	Drug_1
10003860	advise	Drug_0	Drug_2

10003861|t|Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
10003861	188	195	alcohol	drug	Drug_0
10003861	84	91	XENICAL	brand	Drug_1
10003861	287	295	orlistat	drug	Drug_2

10003862|t|Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
10003862	174	186	cyclosporine	drug	Drug_0
10003862	142	149	XENICAL	brand	Drug_1
10003862	mechanism	Drug_1	Drug_0

10003863|t|Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.
10003863	156	163	digoxin	drug	Drug_0
10003863	93	100	XENICAL	brand	Drug_1

10003864|t|Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL.
10003864	0	31	Fat-soluble Vitamin Supplements	group	Drug_0
10003864	109	122	beta-carotene	drug	Drug_1
10003864	182	189	XENICAL	brand	Drug_2
10003864	mechanism	Drug_1	Drug_2

10003865|t|XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%.
10003865	0	7	XENICAL	brand	Drug_0
10003865	34	51	vitamin E acetate	drug	Drug_1
10003865	mechanism	Drug_0	Drug_1

10003866|t|The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time.
10003866	14	22	orlistat	drug	Drug_0
10003866	57	66	vitamin D	group	Drug_1
10003866	68	77	vitamin A	group	Drug_2
10003866	105	114	vitamin K	group	Drug_3

10003867|t|Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.
10003867	187	196	glyburide	drug	Drug_0
10003867	95	103	orlistat	drug	Drug_1

10003868|t|Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).
10003868	168	178	nifedipine	drug	Drug_0
10003868	123	130	XENICAL	brand	Drug_1

10003869|t|Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.
10003869	187	201	contraceptives	group	Drug_0
10003869	75	82	XENICAL	brand	Drug_1

10003870|t|Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.
10003870	165	174	phenytoin	drug	Drug_0
10003870	95	102	XENICAL	brand	Drug_1

10003871|t|Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.
10003871	200	211	pravastatin	drug	Drug_0
10003871	153	160	XENICAL	brand	Drug_1

10003872|t|Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
10003872	142	150	warfarin	drug	Drug_0
10003872	58	65	XENICAL	brand	Drug_1

10003873|t|Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
10003873	14	23	vitamin K	group	Drug_0
10003873	130	137	XENICAL	brand	Drug_1
10003873	102	110	warfarin	drug	Drug_2
10003873	advise	Drug_2	Drug_1
10003873	mechanism	Drug_0	Drug_1

10003874|t|Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
10003874	0	12	Tetracycline	group	Drug_0
10003874	31	41	antibiotic	group	Drug_1
10003874	85	95	penicillin	drug	Drug_2
10003874	effect	Drug_0	Drug_2

10003875|t|No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks.
10003875	48	56	ELOXATIN	brand	Drug_0
10003875	72	76	5-FU	drug	Drug_1

10003876|t|Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks.
10003876	13	17	5-FU	drug	Drug_0
10003876	104	112	ELOXATIN	brand	Drug_1
10003876	mechanism	Drug_0	Drug_1

10003877|t|Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants.
10003877	66	80	anticoagulants	group	Drug_0
10003877	15	32	Anabolic steroids	group	Drug_1
10003877	effect	Drug_1	Drug_0

10003878|t|Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
10003878	117	125	warfarin	drug	Drug_0
10003878	31	42	oxandrolone	drug	Drug_1
10003878	158	168	S-warfarin	drug	Drug_2
10003878	257	267	R-warfarin	drug	Drug_3
10003878	mechanism	Drug_1	Drug_0

10003879|t|When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
10003879	5	16	oxandrolone	drug	Drug_0
10003879	171	179	warfarin	drug	Drug_1
10003879	advise	Drug_0	Drug_1

10003880|t|Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.
10003880	106	114	warfarin	drug	Drug_0
10003880	160	171	oxandrolone	drug	Drug_1
10003880	advise	Drug_0	Drug_1

10003881|t|Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.
10003881	72	91	hypoglycemic agents	group	Drug_0
10003881	25	36	Oxandrolone	drug	Drug_1
10003881	mechanism	Drug_1	Drug_0

10003882|t|Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.
10003882	0	16	Adrenal steroids	group	Drug_0
10003882	110	114	ACTH	drug	Drug_1
10003882	81	106	adrenal cortical steroids	group	Drug_2

10003883|t|The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
10003883	23	33	oxybutynin	drug	Drug_0
10003883	45	66	anticholinergic drugs	group	Drug_1
10003883	effect	Drug_0	Drug_1

10003884|t|Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor.
10003884	5	24	oxybutynin chloride	drug	Drug_0
10003884	85	96	DITROPAN XL	brand	Drug_1
10003884	119	131	ketoconazole	drug	Drug_2
10003884	mechanism	Drug_1	Drug_2

10003885|t|Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
10003885	67	85	antimycotic agents	group	Drug_0
10003885	93	105	itraconazole	drug	Drug_1
10003885	110	120	miconazole	drug	Drug_2
10003885	125	146	macrolide antibiotics	group	Drug_3
10003885	154	166	erythromycin	drug	Drug_4
10003885	171	185	clarithromycin	drug	Drug_5
10003885	198	208	oxybutynin	drug	Drug_6
10003885	mechanism	Drug_3	Drug_6
10003885	mechanism	Drug_5	Drug_6
10003885	mechanism	Drug_2	Drug_6
10003885	mechanism	Drug_0	Drug_6
10003885	mechanism	Drug_1	Drug_6
10003885	mechanism	Drug_4	Drug_6

10003886|t|Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
10003886	42	49	antacid	group	Drug_0
10003886	61	79	aluminum hydroxide	drug	Drug_1
10003886	81	100	magnesium hydroxide	drug	Drug_2
10003886	106	117	simethicone	drug	Drug_3
10003886	164	174	oxybutynin	drug	Drug_4
10003886	178	196	desethyloxybutynin	drug_n	Drug_5

10003887|t|The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..
10003887	30	53	oxycodone hydrochloride	drug	Drug_0
10003887	89	104	CNS depressants	group	Drug_1
10003887	effect	Drug_0	Drug_1

10003888|t|The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
10003888	29	44	CNS depressants	group	Drug_0
10003888	55	64	sedatives	group	Drug_1
10003888	66	75	hypnotics	group	Drug_2
10003888	77	90	tranquilizers	group	Drug_3
10003888	100	111	anesthetics	group	Drug_4
10003888	113	127	phenothiazines	group	Drug_5
10003888	135	142	opioids	group	Drug_6
10003888	144	169	tricyclic antidepressants	group	Drug_7
10003888	171	205	monoamine oxidase (MAO) inhibitors	group	Drug_8
10003888	211	218	alcohol	drug	Drug_9

10003889|t|Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
10003889	0	16	Anticholinergics	group	Drug_0
10003889	96	113	opioid analgesics	group	Drug_1
10003889	effect	Drug_0	Drug_1

10003890|t|It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.
10003890	74	85	oxymorphone	drug	Drug_0
10003890	104	112	propofol	drug	Drug_1
10003890	effect	Drug_0	Drug_1

10003891|t|In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;
10003891	143	153	cimetidine	drug	Drug_0
10003891	159	176	opioid analgesics	group	Drug_1
10003891	effect	Drug_0	Drug_1

10003892|t|Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.
10003892	14	20	INVEGA	brand	Drug_0
10003892	46	58	Paliperidone	drug	Drug_1

10003893|t|Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
10003893	33	45	paliperidone	drug	Drug_0
10003893	47	53	INVEGA	brand	Drug_1
10003893	111	133	centrally acting drugs	group	Drug_2
10003893	138	145	alcohol	drug	Drug_3
10003893	advise	Drug_0	Drug_2
10003893	advise	Drug_0	Drug_3
10003893	advise	Drug_1	Drug_2
10003893	advise	Drug_1	Drug_3

10003894|t|Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
10003894	0	12	Paliperidone	drug	Drug_0
10003894	42	50	levodopa	drug	Drug_1
10003894	61	78	dopamine agonists	group	Drug_2
10003894	effect	Drug_0	Drug_2
10003894	effect	Drug_0	Drug_1

10003895|t|Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.
10003895	36	42	INVEGA	brand	Drug_0
10003895	46	58	Paliperidone	drug	Drug_1

10003896|t|Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
10003896	53	65	pantoprazole	drug	Drug_0
10003896	154	166	theophylline	drug	Drug_1
10003896	168	177	cisapride	drug	Drug_2
10003896	179	189	antipyrine	drug	Drug_3
10003896	191	199	caffeine	drug	Drug_4
10003896	201	214	carbamazepine	drug	Drug_5
10003896	216	224	diazepam	drug	Drug_6
10003896	253	270	desmethyldiazepam	drug_n	Drug_7
10003896	273	283	diclofenac	drug	Drug_8
10003896	285	293	naproxen	drug	Drug_9
10003896	295	304	piroxicam	drug	Drug_10
10003896	306	313	digoxin	drug	Drug_11
10003896	315	322	ethanol	drug	Drug_12
10003896	324	333	glyburide	drug	Drug_13
10003896	343	356	contraceptive	group	Drug_14
10003896	358	372	levonorgestrel	drug	Drug_15
10003896	373	390	ethinyl estradiol	drug	Drug_16
10003896	393	403	metoprolol	drug	Drug_17
10003896	405	415	nifedipine	drug	Drug_18
10003896	417	426	phenytoin	drug	Drug_19
10003896	428	436	warfarin	drug	Drug_20
10003896	438	447	midazolam	drug	Drug_21
10003896	449	463	clarithromycin	drug	Drug_22
10003896	465	478	metronidazole	drug	Drug_23
10003896	483	494	amoxicillin	drug	Drug_24

10003897|t|There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.
10003897	98	120	proton pump inhibitors	group	Drug_0
10003897	132	144	pantoprazole	drug	Drug_1
10003897	150	158	warfarin	drug	Drug_2
10003897	effect	Drug_1	Drug_2
10003897	effect	Drug_0	Drug_2

10003898|t|Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
10003898	22	44	proton pump inhibitors	group	Drug_0
10003898	49	57	warfarin	drug	Drug_1
10003898	advise	Drug_0	Drug_1

10003899|t|Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
10003899	75	87	pantoprazole	drug	Drug_0
10003899	202	214	ketoconazole	drug	Drug_1
10003899	216	226	ampicillin	drug	Drug_2
10003899	239	243	iron	drug	Drug_3
10003899	mechanism	Drug_0	Drug_1
10003899	mechanism	Drug_0	Drug_2
10003899	mechanism	Drug_0	Drug_3

10003900|t|Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole.
10003900	85	105	tetrahydrocannabinol	drug	Drug_0
10003900	107	110	THC	drug	Drug_1
10003900	139	161	proton pump inhibitors	group	Drug_2
10003900	173	185	pantoprazole	drug	Drug_3

10003901|t|A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
10003901	309	321	ketoconazole	drug	Drug_0
10003901	291	303	paricalcitol	drug	Drug_1
10003901	368	378	atazanavir	drug	Drug_2
10003901	380	394	clarithromycin	drug	Drug_3
10003901	396	405	indinavir	drug	Drug_4
10003901	407	419	itraconazole	drug	Drug_5
10003901	421	431	nefazodone	drug	Drug_6
10003901	433	443	nelfinavir	drug	Drug_7
10003901	445	454	ritonavir	drug	Drug_8
10003901	456	466	saquinavir	drug	Drug_9
10003901	468	481	telithromycin	drug	Drug_10
10003901	485	497	voriconazole	drug	Drug_11
10003901	advise	Drug_1	Drug_5
10003901	advise	Drug_1	Drug_8
10003901	advise	Drug_1	Drug_4
10003901	advise	Drug_1	Drug_9
10003901	mechanism	Drug_0	Drug_1
10003901	advise	Drug_1	Drug_10
10003901	advise	Drug_1	Drug_6
10003901	advise	Drug_1	Drug_7
10003901	advise	Drug_1	Drug_0
10003901	advise	Drug_1	Drug_2
10003901	advise	Drug_1	Drug_11
10003901	advise	Drug_1	Drug_3

10003902|t|Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.
10003902	19	26	Zemplar	brand	Drug_0
10003902	209	221	ketoconazole	drug	Drug_1
10003902	advise	Drug_0	Drug_1

10003903|t|Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.
10003903	43	63	fat-soluble vitamins	group	Drug_0
10003903	73	87	cholestyramine	drug	Drug_1
10003903	126	133	Zemplar	brand	Drug_2
10003903	mechanism	Drug_1	Drug_2
10003903	mechanism	Drug_0	Drug_1

10003904|t|patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.
10003904	19	26	lithium	drug	Drug_0
10003904	31	39	Neulasta	brand	Drug_1
10003904	advise	Drug_0	Drug_1

10003905|t|In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;
10003905	193	202	methadone	drug	Drug_0
10003905	112	122	PEG-Intron	brand	Drug_1
10003905	mechanism	Drug_0	Drug_1

10003906|t|Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
10003906	63	70	insulin	drug	Drug_0
10003906	83	95	hypoglycemic	group	Drug_1
10003906	196	204	SOMAVERT	brand	Drug_2
10003906	advise	Drug_0	Drug_2
10003906	advise	Drug_1	Drug_2

10003907|t|In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
10003907	172	179	opioids	group	Drug_0
10003907	67	78	pegvisomant	drug	Drug_1
10003907	mechanism	Drug_0	Drug_1

10003908|t|Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA.
10003908	81	91	probenecid	drug	Drug_0
10003908	142	148	ALIMTA	brand	Drug_1
10003908	mechanism	Drug_0	Drug_1

10003909|t|Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
10003909	182	191	ibuprofen	drug	Drug_0
10003909	210	216	ALIMTA	brand	Drug_1
10003909	advise	Drug_0	Drug_1

10003910|t|Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA.
10003910	71	77	NSAIDs	group	Drug_0
10003910	194	200	ALIMTA	brand	Drug_1
10003910	advise	Drug_0	Drug_1

10003911|t|In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
10003911	223	229	ALIMTA	brand	Drug_0
10003911	131	137	NSAIDs	group	Drug_1
10003911	advise	Drug_1	Drug_0

10003912|t|The interaction of CYLERT (pemoline) with other drugs has not been studied in humans.
10003912	19	25	CYLERT	brand	Drug_0
10003912	27	35	pemoline	drug	Drug_1

10003913|t|Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.
10003913	68	74	CYLERT	brand	Drug_0
10003913	94	119	antiepileptic medications	group	Drug_1
10003913	effect	Drug_0	Drug_1

10003914|t|Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
10003914	29	55	bacteriostatic antibiotics	group	Drug_0
10003914	63	75	erythromycin	drug	Drug_1
10003914	77	89	tetracycline	drug	Drug_2
10003914	132	143	penicillins	group	Drug_3
10003914	effect	Drug_1	Drug_3
10003914	effect	Drug_0	Drug_3
10003914	effect	Drug_2	Drug_3

10003915|t|Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.
10003915	0	10	Penicillin	group	Drug_0
10003915	73	83	probenecid	drug	Drug_1
10003915	128	139	penicillins	group	Drug_2
10003915	mechanism	Drug_0	Drug_1

10003916|t|Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
10003916	80	87	alcohol	drug	Drug_0
10003916	156	167	pentazocine	drug	Drug_1
10003916	advise	Drug_0	Drug_1

10003917|t|Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.
10003917	152	159	TRENTAL	brand	Drug_0
10003917	177	191	anticoagulants	group	Drug_1
10003917	195	226	platelet aggregation inhibitors	group	Drug_2
10003917	effect	Drug_0	Drug_1
10003917	effect	Drug_0	Drug_2

10003918|t|Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
10003918	30	37	TRENTAL	brand	Drug_0
10003918	115	127	theophylline	drug	Drug_1
10003918	mechanism	Drug_0	Drug_1

10003919|t|TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
10003919	0	7	TRENTAL	brand	Drug_0
10003919	40	62	antihypertensive drugs	group	Drug_1
10003919	64	77	beta blockers	group	Drug_2
10003919	79	88	digitalis	group	Drug_3
10003919	90	99	diuretics	group	Drug_4
10003919	101	120	antidiabetic agents	group	Drug_5
10003919	126	141	antiarrhythmics	group	Drug_6

10003920|t|Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
10003920	0	20	Dopamine antagonists	group	Drug_0
10003920	34	46	neuroleptics	group	Drug_1
10003920	48	62	phenothiazines	group	Drug_2
10003920	64	78	butyrophenones	group	Drug_3
10003920	80	93	thioxanthines	group	Drug_4
10003920	99	113	metoclopramide	drug	Drug_5
10003920	171	177	Permax	brand	Drug_6
10003920	181	197	dopamine agonist	group	Drug_7
10003920	advise	Drug_4	Drug_6
10003920	advise	Drug_2	Drug_6
10003920	advise	Drug_3	Drug_6
10003920	advise	Drug_5	Drug_6
10003920	advise	Drug_0	Drug_6
10003920	advise	Drug_1	Drug_6

10003921|t|Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.
10003921	23	32	diuretics	group	Drug_0
10003921	162	167	ACEON	brand	Drug_1
10003921	effect	Drug_0	Drug_1

10003922|t|The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.
10003922	84	92	diuretic	group	Drug_0
10003922	161	172	perindopril	drug	Drug_1
10003922	effect	Drug_0	Drug_1

10003923|t|If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour.
10003923	3	12	diuretics	group	Drug_0
10003923	104	109	ACEON	brand	Drug_1
10003923	advise	Drug_0	Drug_1

10003924|t|The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics.
10003924	23	34	perindopril	drug	Drug_0
10003924	94	103	diuretics	group	Drug_1

10003925|t|The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.
10003925	23	36	perindoprilat	drug_n	Drug_0
10003925	52	61	diuretics	group	Drug_1

10003926|t|Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production.
10003926	0	9	Potassium	drug	Drug_0
10003926	26	53	Potassium-Sparing Diuretics	group	Drug_1
10003926	55	60	ACEON	brand	Drug_2

10003927|t|Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
10003927	7	34	potassium-sparing diuretics	group	Drug_0
10003927	36	50	spironolactone	drug	Drug_1
10003927	52	61	amiloride	drug	Drug_2
10003927	63	74	triamterene	drug	Drug_3
10003927	88	97	potassium	drug	Drug_4
10003927	164	176	indomethacin	drug	Drug_5
10003927	178	185	heparin	drug	Drug_6
10003927	187	199	cyclosporine	drug	Drug_7

10003928|t|Use of a diuretic may further increase the risk of lithium toxicity.
10003928	9	17	diuretic	group	Drug_0
10003928	51	58	lithium	drug	Drug_1

10003929|t|Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
10003929	157	164	digoxin	drug	Drug_0
10003929	122	127	ACEON	brand	Drug_1
10003929	196	207	perindopril	drug	Drug_2
10003929	208	221	perindoprilat	drug_n	Drug_3
10003929	mechanism	Drug_0	Drug_3
10003929	mechanism	Drug_0	Drug_2

10003930|t|Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin.
10003930	94	104	gentamicin	drug	Drug_0
10003930	78	89	perindopril	drug	Drug_1
10003930	int	Drug_1	Drug_0

10003931|t|Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state.
10003931	41	46	ACEON	brand	Drug_0
10003931	119	130	perindopril	drug	Drug_1

10003932|t|However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.
10003932	44	55	perindopril	drug	Drug_0
10003932	82	95	perindoprilat	drug_n	Drug_1

10003933|t|Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.
10003933	19	26	alcohol	drug	Drug_0
10003933	32	57	phentermine hydrochloride	drug	Drug_1
10003933	int	Drug_0	Drug_1

10003934|t|Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
10003934	0	12	Vasopressors	group	Drug_0
10003934	27	38	metaraminol	drug	Drug_1
10003934	85	94	halothane	drug	Drug_2
10003934	effect	Drug_1	Drug_2
10003934	effect	Drug_0	Drug_2

10003935|t|MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
10003935	0	14	MAO Inhibitors	group	Drug_0
10003935	38	68	sympathomimetic pressor amines	group	Drug_1
10003935	115	143	monoamine oxidase inhibitors	group	Drug_2
10003935	145	149	MAOI	group	Drug_3
10003935	effect	Drug_1	Drug_3
10003935	effect	Drug_1	Drug_2

10003936|t|The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
10003936	24	41	adrenergic agents	group	Drug_0
10003936	69	94	tricyclic antidepressants	group	Drug_1
10003936	effect	Drug_0	Drug_1

10003937|t|Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
10003937	0	12	Vasopressors	group	Drug_0
10003937	27	38	metaraminol	drug	Drug_1
10003937	85	94	halothane	drug	Drug_2
10003937	effect	Drug_1	Drug_2
10003937	effect	Drug_0	Drug_2

10003938|t|MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
10003938	0	14	MAO Inhibitors	group	Drug_0
10003938	39	69	sympathomimetic pressor amines	group	Drug_1
10003938	116	144	monoamine oxidase inhibitors	group	Drug_2
10003938	146	150	MAOI	group	Drug_3
10003938	effect	Drug_1	Drug_2
10003938	effect	Drug_1	Drug_3

10003939|t|The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
10003939	24	41	adrenergic agents	group	Drug_0
10003939	69	94	tricyclic antidepressants	group	Drug_1
10003939	effect	Drug_0	Drug_1

10003940|t|Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.
10003940	0	11	Pilocarpine	drug	Drug_0
10003940	67	94	beta adrenergic antagonists	group	Drug_1
10003940	advise	Drug_0	Drug_1

10003941|t|These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).
10003941	146	154	atropine	drug	Drug_0
10003941	164	175	ipratropium	drug	Drug_1

10003942|t|While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
10003942	179	199	acetylsalicylic acid	drug	Drug_0
10003942	219	226	calcium	drug	Drug_1
10003942	228	248	conjugated estrogens	drug	Drug_2
10003942	250	276	hydroxychloroquine sulfate	drug	Drug_3
10003942	278	287	ibuprofen	drug	Drug_4
10003942	289	309	levothyroxine sodium	drug	Drug_5
10003942	311	338	medroxyprogesterone acetate	drug	Drug_6
10003942	340	352	methotrexate	drug	Drug_7
10003942	354	367	multivitamins	group	Drug_8
10003942	369	377	naproxen	drug	Drug_9
10003942	379	389	omeprazole	drug	Drug_10
10003942	391	402	paracetamol	drug	Drug_11
10003942	408	418	prednisone	drug	Drug_12

10003943|t|Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
10003943	37	46	reserpine	drug	Drug_0
10003943	92	112	beta-blocking agents	group	Drug_1
10003943	effect	Drug_0	Drug_1

10003944|t|Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.
10003944	0	8	Pindolol	drug	Drug_0
10003944	41	64	antihypertensive agents	group	Drug_1
10003944	76	95	hydrochlorothiazide	drug	Drug_2
10003944	97	108	hydralazine	drug	Drug_3
10003944	114	126	guanethidine	drug	Drug_4

10003945|t|Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.
10003945	0	8	Pindolol	drug	Drug_0
10003945	42	54	thioridazine	drug	Drug_1
10003945	mechanism	Drug_0	Drug_1

10003946|t|Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.
10003946	6	58	short-acting beta adrenergic aerosol bronchodilators	group	Drug_0
10003946	97	113	MAXAIR AUTOHALER	brand	Drug_1
10003946	advise	Drug_0	Drug_1

10003947|t|Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
10003947	314	342	coumarin-type anticoagulants	group	Drug_0
10003947	291	298	FELDENE	brand	Drug_1
10003947	advise	Drug_1	Drug_0
10003947	int	Drug_0	Drug_1

10003948|t|Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
10003948	217	226	piroxicam	drug	Drug_0
10003948	292	299	FELDENE	brand	Drug_1
10003948	134	141	aspirin	brand	Drug_2
10003948	191	199	antacids	group	Drug_3
10003948	243	280	Nonsteroidal anti-inflammatory agents	group	Drug_4
10003948	352	359	lithium	drug	Drug_5
10003948	mechanism	Drug_1	Drug_2
10003948	mechanism	Drug_1	Drug_5
10003948	mechanism	Drug_4	Drug_5

10003949|t|It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
10003949	30	37	lithium	drug	Drug_0
10003949	103	110	FELDENE	brand	Drug_1
10003949	advise	Drug_0	Drug_1

10003950|t|When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.
10003950	189	197	atropine	drug	Drug_0
10003950	18	29	pralidoxime	drug	Drug_1
10003950	effect	Drug_0	Drug_1

10003951|t|This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed.
10003951	45	53	atropine	drug	Drug_0
10003951	95	106	pralidoxime	drug	Drug_1

10003952|t|2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;
10003952	154	165	pralidoxime	drug	Drug_0
10003952	173	185	barbiturates	group	Drug_1
10003952	209	228	anticholinesterases	group	Drug_2
10003952	effect	Drug_1	Drug_2

10003953|t|morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
10003953	0	8	morphine	drug	Drug_0
10003953	10	22	theophylline	drug	Drug_1
10003953	24	37	aminophylline	drug	Drug_2
10003953	39	54	succinylcholine	drug	Drug_3
10003953	56	65	reserpine	drug	Drug_4
10003953	71	103	phenothiazine-type tranquilizers	group	Drug_5

10003954|t|Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
10003954	20	29	Carbidopa	drug	Drug_0
10003954	30	38	Levodopa	drug	Drug_1
10003954	82	93	pramipexole	drug	Drug_2

10003955|t|Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole.
10003955	43	53	selegiline	drug	Drug_0
10003955	96	107	pramipexole	drug	Drug_1

10003956|t|Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54).
10003956	62	72	amantadine	drug	Drug_0
10003956	116	127	pramipexole	drug	Drug_1

10003957|t|Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).
10003957	12	22	Cimetidine	drug	Drug_0
10003957	146	157	pramipexole	drug	Drug_1
10003957	mechanism	Drug_0	Drug_1

10003958|t|Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12).
10003958	12	22	Probenecid	drug	Drug_0
10003958	144	155	pramipexole	drug	Drug_1

10003959|t|Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
10003959	178	188	cimetidine	drug	Drug_0
10003959	190	200	ranitidine	drug	Drug_1
10003959	202	211	diltiazem	drug	Drug_2
10003959	213	224	triamterene	drug	Drug_3
10003959	226	235	verapamil	drug	Drug_4
10003959	237	246	quinidine	drug	Drug_5
10003959	252	259	quinine	drug	Drug_6
10003959	521	532	pramipexole	drug	Drug_7
10003959	379	393	cephalosporins	group	Drug_8
10003959	395	406	penicillins	group	Drug_9
10003959	408	420	indomethacin	drug	Drug_10
10003959	422	441	hydrochlorothiazide	drug	Drug_11
10003959	447	461	chlorpropamide	drug	Drug_12
10003959	mechanism	Drug_3	Drug_7
10003959	mechanism	Drug_5	Drug_7
10003959	mechanism	Drug_10	Drug_7
10003959	mechanism	Drug_12	Drug_7
10003959	mechanism	Drug_6	Drug_7
10003959	mechanism	Drug_9	Drug_7
10003959	mechanism	Drug_11	Drug_7
10003959	mechanism	Drug_0	Drug_7
10003959	mechanism	Drug_1	Drug_7
10003959	mechanism	Drug_8	Drug_7
10003959	mechanism	Drug_2	Drug_7
10003959	mechanism	Drug_4	Drug_7

10003960|t|Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
10003960	83	103	dopamine antagonists	group	Drug_0
10003960	28	39	pramipexole	drug	Drug_1
10003960	45	61	dopamine agonist	group	Drug_2
10003960	117	129	neuroleptics	group	Drug_3
10003960	131	145	phenothiazines	group	Drug_4
10003960	147	161	butyrophenones	group	Drug_5
10003960	163	176	thioxanthenes	group	Drug_6
10003960	181	195	metoclopramide	group	Drug_7
10003960	231	238	MIRAPEX	brand	Drug_8
10003960	effect	Drug_0	Drug_8
10003960	effect	Drug_4	Drug_8
10003960	effect	Drug_5	Drug_8
10003960	effect	Drug_6	Drug_8
10003960	effect	Drug_3	Drug_8
10003960	effect	Drug_7	Drug_8

10003961|t|Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
10003961	40	46	SYMLIN	brand	Drug_0
10003961	150	172	anticholinergic agents	group	Drug_1
10003961	181	189	atropine	drug	Drug_2
10003961	258	286	alpha glucosidase inhibitors	group	Drug_3
10003961	advise	Drug_0	Drug_2
10003961	advise	Drug_0	Drug_1
10003961	advise	Drug_0	Drug_3

10003962|t|When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection.
10003962	116	126	analgesics	group	Drug_0
10003962	204	210	SYMLIN	brand	Drug_1
10003962	advise	Drug_0	Drug_1

10003963|t|In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN.
10003963	43	56	sulfonylureas	group	Drug_0
10003963	60	70	biguanides	group	Drug_1
10003963	114	120	SYMLIN	brand	Drug_2

10003964|t|No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents.
10003964	74	80	SYMLIN	brand	Drug_0
10003964	105	124	antidiabetic agents	group	Drug_1

10003965|t|Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
10003965	60	66	SYMLIN	brand	Drug_0
10003965	18	25	Insulin	drug	Drug_1
10003965	157	170	human insulin	drug	Drug_2
10003965	mechanism	Drug_0	Drug_2

10003966|t|Thus, SYMLIN and insulin should not be mixed and must be administered separately.
10003966	6	12	SYMLIN	brand	Drug_0
10003966	17	24	insulin	drug	Drug_1

10003967|t|Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
10003967	42	55	phenobarbital	drug	Drug_0
10003967	57	66	phenytoin	drug	Drug_1
10003967	71	79	rifampin	drug	Drug_2
10003967	110	125	corticosteroids	group	Drug_3
10003967	155	169	corticosteroid	group	Drug_4
10003967	mechanism	Drug_1	Drug_4
10003967	mechanism	Drug_0	Drug_3
10003967	mechanism	Drug_2	Drug_4
10003967	mechanism	Drug_1	Drug_3
10003967	mechanism	Drug_0	Drug_4
10003967	mechanism	Drug_2	Drug_3

10003968|t|Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
10003968	14	28	troleandomycin	drug	Drug_0
10003968	33	45	ketoconazole	drug	Drug_1
10003968	76	91	corticosteroids	group	Drug_2
10003968	mechanism	Drug_0	Drug_2
10003968	mechanism	Drug_1	Drug_2

10003969|t|Corticosteroids may increase the clearance of chronic high dose aspirin.
10003969	0	15	Corticosteroids	group	Drug_0
10003969	64	71	aspirin	brand	Drug_1
10003969	mechanism	Drug_0	Drug_1

10003970|t|This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
10003970	77	87	salicylate	group	Drug_0
10003970	102	116	corticosteroid	group	Drug_1
10003970	effect	Drug_0	Drug_1

10003971|t|Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
10003971	0	7	Aspirin	brand	Drug_0
10003971	54	69	corticosteroids	group	Drug_1
10003971	advise	Drug_0	Drug_1

10003972|t|The effect of corticosteroids on oral anticoagulants is variable.
10003972	14	29	corticosteroids	group	Drug_0
10003972	38	52	anticoagulants	group	Drug_1
10003972	effect	Drug_0	Drug_1

10003973|t|There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
10003973	63	77	anticoagulants	group	Drug_0
10003973	107	122	corticosteroids	group	Drug_1
10003973	effect	Drug_0	Drug_1

10003974|t|Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
10003974	140	159	anticholinesterases	group	Drug_0
10003974	185	207	procaine hydrochloride	drug	Drug_1
10003974	66	91	anticholinesterase agents	group	Drug_2
10003974	mechanism	Drug_0	Drug_1
10003974	effect	Drug_1	Drug_2

10003975|t|CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects.
10003975	0	14	CNS depressant	group	Drug_0
10003975	46	68	procaine hydrochloride	drug	Drug_1
10003975	73	99	CNS depressant medications	group	Drug_2
10003975	effect	Drug_1	Drug_2

10003976|t|Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.
10003976	15	28	Hyaluronidase	drug	Drug_0
10003976	64	86	procaine hydrochloride	drug	Drug_1
10003976	mechanism	Drug_0	Drug_1

10003977|t|Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
10003977	109	138	neuromuscular blocking agents	group	Drug_0
10003977	39	61	suxamethonium chloride	drug	Drug_1
10003977	82	104	procaine hydrochloride	drug	Drug_2
10003977	effect	Drug_2	Drug_0

10003978|t|Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.
10003978	59	71	sulfonamides	group	Drug_0
10003978	32	54	procaine hydrochloride	drug	Drug_1
10003978	133	144	sulfonamide	group	Drug_2
10003978	effect	Drug_1	Drug_0

10003979|t|Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.
10003979	33	46	acetazolamide	drug	Drug_0
10003979	51	73	procaine hydrochloride	drug	Drug_1
10003979	109	117	procaine	drug	Drug_2
10003979	mechanism	Drug_0	Drug_1

10003980|t|To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.
10003980	54	66	barbiturates	group	Drug_0
10003980	68	82	antihistamines	group	Drug_1
10003980	84	93	narcotics	group	Drug_2
10003980	95	113	hypotensive agents	group	Drug_3
10003980	117	131	phenothiazines	group	Drug_4

10003981|t|Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
10003981	8	16	Matulane	brand	Drug_0
10003981	70	91	sympathomimetic drugs	group	Drug_1
10003981	93	117	tricyclic antidepressant	group	Drug_2
10003981	131	148	amitriptyline HCl	drug	Drug_3
10003981	150	164	imipramine HCl	drug	Drug_4
10003981	208	216	tyramine	drug_n	Drug_5
10003981	advise	Drug_0	Drug_2
10003981	advise	Drug_0	Drug_3
10003981	advise	Drug_0	Drug_5
10003981	advise	Drug_0	Drug_1
10003981	advise	Drug_0	Drug_4

10003982|t|No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.
10003982	31	54	chemotherapeutic agents	group	Drug_0
10003982	72	80	steroids	group	Drug_1

10003983|t|Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.
10003983	0	18	Thiazide diuretics	group	Drug_0
10003983	82	96	phenothiazines	group	Drug_1
10003983	effect	Drug_0	Drug_1

10003984|t|Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.
10003984	28	40	guanethidine	drug	Drug_0
10003984	88	102	phenothiazines	group	Drug_1
10003984	effect	Drug_0	Drug_1

10003985|t|Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.
10003985	30	41	propranolol	drug	Drug_0
10003985	47	61	phenothiazines	group	Drug_1
10003985	mechanism	Drug_0	Drug_1

10003986|t|The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
10003986	35	43	DIPRIVAN	brand	Drug_0
10003986	158	167	narcotics	group	Drug_1
10003986	173	181	morphine	drug	Drug_2
10003986	183	193	meperidine	drug	Drug_3
10003986	199	207	fentanyl	drug	Drug_4
10003986	effect	Drug_0	Drug_1
10003986	effect	Drug_0	Drug_2
10003986	effect	Drug_0	Drug_3
10003986	effect	Drug_0	Drug_4

10003987|t|and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).
10003987	20	27	opioids	group	Drug_0
10003987	32	41	sedatives	group	Drug_1
10003987	47	62	benzodiazepines	group	Drug_2
10003987	64	76	barbiturates	group	Drug_3
10003987	78	93	chloral hydrate	drug	Drug_4
10003987	95	105	droperidol	drug	Drug_5

10003988|t|During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).
10003988	58	66	DIPRIVAN	brand	Drug_0
10003988	229	245	analgesic agents	group	Drug_1
10003988	251	264	nitrous oxide	drug	Drug_2
10003988	268	275	opioids	group	Drug_3
10003988	advise	Drug_0	Drug_1
10003988	advise	Drug_0	Drug_3
10003988	advise	Drug_0	Drug_2

10003989|t|The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.
10003989	65	75	isoflurane	drug	Drug_0
10003989	77	86	enflurane	drug	Drug_1
10003989	92	101	halothane	drug	Drug_2
10003989	127	135	DIPRIVAN	brand	Drug_3

10003990|t|DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).
10003990	0	8	DIPRIVAN	brand	Drug_0
10003990	140	169	neuromuscular blocking agents	group	Drug_1
10003990	175	190	succinylcholine	drug	Drug_2
10003990	195	227	nondepolarizing muscle relaxants	group	Drug_3

10003991|t|No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.
10003991	136	152	muscle relaxants	group	Drug_0
10003991	175	191	analgesic agents	group	Drug_1
10003991	203	220	anesthetic agents	group	Drug_2

10003992|t|The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.
10003992	29	41	propoxyphene	drug	Drug_0
10003992	73	88	CNS depressants	group	Drug_1
10003992	100	107	alcohol	drug	Drug_2
10003992	effect	Drug_0	Drug_2
10003992	effect	Drug_0	Drug_1

10003993|t|Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.
10003993	41	53	propoxyphene	drug	Drug_0
10003993	86	101	antidepressants	group	Drug_1
10003993	103	118	anticonvulsants	group	Drug_2
10003993	123	131	warfarin	drug	Drug_3

10003994|t|MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.
10003994	0	14	MAO inhibitors	group	Drug_0
10003994	19	43	beta adrenergic blockers	group	Drug_1
10003994	68	83	pseudoephedrine	drug	Drug_2
10003994	effect	Drug_1	Drug_2
10003994	effect	Drug_0	Drug_2

10003995|t|Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
10003995	0	16	Sympathomimetics	group	Drug_0
10003995	60	70	methyldopa	drug	Drug_1
10003995	72	84	mecamylamine	drug	Drug_2
10003995	86	95	reserpine	drug	Drug_3
10003995	100	118	veratrum alkaloids	group	Drug_4
10003995	effect	Drug_0	Drug_3
10003995	effect	Drug_0	Drug_2
10003995	effect	Drug_0	Drug_4
10003995	effect	Drug_0	Drug_1

10003996|t|Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.
10003996	0	13	Pyrimethamine	drug	Drug_0
10003996	31	43	sulfonamides	group	Drug_1
10003996	45	52	quinine	drug	Drug_2
10003996	63	76	antimalarials	group	Drug_3
10003996	93	104	antibiotics	group	Drug_4

10003997|t|Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.
10003997	0	12	Folinic acid	drug	Drug_0
10003997	14	24	leucovorin	drug	Drug_1

10003998|t|Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
10003998	60	69	lorazepam	drug	Drug_0
10003998	74	87	pyrimethamine	drug	Drug_1
10003998	effect	Drug_0	Drug_1

10003999|t|Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.
10003999	16	30	Cholestyramine	drug	Drug_0
10003999	101	111	raloxifene	drug	Drug_1
10003999	150	156	EVISTA	brand	Drug_2
10003999	mechanism	Drug_0	Drug_1
10003999	advise	Drug_0	Drug_2

10004000|t|Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions.
10004000	45	53	warfarin	drug	Drug_0
10004000	34	40	EVISTA	brand	Drug_1

10004001|t|If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.
10004001	3	9	EVISTA	brand	Drug_0
10004001	37	45	warfarin	drug	Drug_1
10004001	advise	Drug_0	Drug_1

10004002|t|In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.
10004002	10	20	raloxifene	drug	Drug_0
10004002	51	59	warfarin	drug	Drug_1
10004002	61	70	phenytoin	drug	Drug_2
10004002	75	84	tamoxifen	drug	Drug_3

10004003|t|Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
10004003	28	34	EVISTA	brand	Drug_0
10004003	100	110	clofibrate	drug	Drug_1
10004003	112	124	indomethacin	drug	Drug_2
10004003	126	134	naproxen	drug	Drug_3
10004003	136	145	ibuprofen	drug	Drug_4
10004003	147	155	diazepam	drug	Drug_5
10004003	161	170	diazoxide	drug	Drug_6
10004003	advise	Drug_0	Drug_6
10004003	advise	Drug_0	Drug_1
10004003	advise	Drug_0	Drug_3
10004003	advise	Drug_0	Drug_2
10004003	advise	Drug_0	Drug_5
10004003	advise	Drug_0	Drug_4

10004004|t|Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
10004004	20	26	TRITEC	brand	Drug_0
10004004	32	46	clarithromycin	drug	Drug_1
10004004	76	86	ranitidine	drug	Drug_2
10004004	177	204	14- hydroxy- clarithromycin	drug_n	Drug_3
10004004	mechanism	Drug_0	Drug_1

10004005|t|Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant.
10004005	22	29	aspirin	brand	Drug_0
10004005	74	84	salicylate	group	Drug_1

10004006|t|Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.
10004006	37	44	antacid	group	Drug_0
10004006	109	119	ranitidine	drug	Drug_1
10004006	175	181	TRITEC	brand	Drug_2
10004006	mechanism	Drug_0	Drug_1
10004006	mechanism	Drug_0	Drug_2

10004007|t|For information on drug interactions associated with ranitidine, refer to the ZANTAC     package insert.
10004007	53	63	ranitidine	drug	Drug_0
10004007	78	84	ZANTAC	brand	Drug_1

10004008|t|Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.
10004008	26	38	ketoconazole	drug	Drug_0
10004008	150	161	retapamulin	drug	Drug_1
10004008	mechanism	Drug_0	Drug_1

10004009|t|Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole.
10004009	110	121	retapamulin	drug	Drug_0
10004009	191	203	ketoconazole	drug	Drug_1

10004010|t|Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates.
10004010	114	121	ALTABAX	brand	Drug_0
10004010	123	134	retapamulin	drug	Drug_1

10004011|t|In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
10004011	40	47	heparin	drug	Drug_0
10004011	52	73	vitamin K antagonists	group	Drug_1
10004011	119	126	aspirin	brand	Drug_2
10004011	128	140	dipyridamole	drug	Drug_3
10004011	146	155	abciximab	drug	Drug_4
10004011	225	233	Retavase	brand	Drug_5
10004011	effect	Drug_4	Drug_5
10004011	effect	Drug_0	Drug_5
10004011	effect	Drug_3	Drug_5
10004011	effect	Drug_1	Drug_5
10004011	effect	Drug_2	Drug_5

10004012|t|Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin
10004012	17	27	Vitamin B2	drug	Drug_0
10004012	90	100	riboflavin	drug	Drug_1
10004012	43	50	Alcohol	drug	Drug_2
10004012	mechanism	Drug_2	Drug_1

10004013|t|Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;
10004013	0	10	Probenecid	drug	Drug_0
10004013	69	79	riboflavin	drug	Drug_1
10004013	mechanism	Drug_0	Drug_1

10004014|t|requirements for riboflavin may be increased in patients receiving probenecid.
10004014	17	27	riboflavin	drug	Drug_0
10004014	67	77	probenecid	drug	Drug_1
10004014	effect	Drug_0	Drug_1

10004015|t|Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known.
10004015	35	45	cimetidine	drug	Drug_0
10004015	71	82	rimantadine	drug	Drug_1

10004016|t|When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
10004016	29	44	rimantadine HCl	drug	Drug_0
10004016	331	341	cimetidine	drug	Drug_1
10004016	270	281	rimantadine	drug	Drug_2
10004016	mechanism	Drug_0	Drug_1

10004017|t|Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers.
10004017	0	13	Acetaminophen	drug	Drug_0
10004017	15	30	Rimantadine HCl	drug	Drug_1

10004018|t|Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%.
10004018	22	35	acetaminophen	drug	Drug_0
10004018	86	97	rimantadine	drug	Drug_1
10004018	mechanism	Drug_0	Drug_1

10004019|t|Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.
10004019	0	7	Aspirin	brand	Drug_0
10004019	9	24	Rimantadine HCl	drug	Drug_1

10004020|t|Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.
10004020	38	49	rimantadine	drug	Drug_0
10004020	100	107	aspirin	brand	Drug_1
10004020	mechanism	Drug_0	Drug_1

10004021|t|Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases.
10004021	33	39	Exelon	brand	Drug_0
10004021	44	65	rivastigmine tartrate	drug	Drug_1
10004021	101	113	Rivastigmine	drug	Drug_2

10004022|t|No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.
10004022	52	64	rivastigmine	drug	Drug_0
10004022	69	76	digoxin	drug	Drug_1
10004022	78	86	warfarin	drug	Drug_2
10004022	88	96	diazepam	drug	Drug_3
10004022	101	111	fluoxetine	drug	Drug_4

10004023|t|The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon.
10004023	45	53	warfarin	drug	Drug_0
10004023	91	97	Exelon	brand	Drug_1

10004024|t|Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine.
10004024	43	49	Exelon	brand	Drug_0
10004024	142	154	rivastigmine	drug	Drug_1

10004025|t|Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.
10004025	72	84	rivastigmine	drug	Drug_0
10004025	147	154	digoxin	drug	Drug_1
10004025	156	164	warfarin	drug	Drug_2
10004025	166	174	diazepam	drug	Drug_3
10004025	179	189	fluoxetine	drug	Drug_4

10004026|t|Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
10004026	91	103	rivastigmine	drug	Drug_0
10004026	167	175	antacids	group	Drug_1
10004026	184	201	antihypertensives	group	Drug_2
10004026	210	234	calcium channel blockers	group	Drug_3
10004026	243	256	antidiabetics	group	Drug_4
10004026	265	301	nonsteroidal anti-inflammatory drugs	group	Drug_5
10004026	310	319	estrogens	group	Drug_6
10004026	328	349	salicylate analgesics	group	Drug_7
10004026	359	371	antianginals	group	Drug_8
10004026	384	398	antihistamines	group	Drug_9

10004027|t|Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
10004027	9	25	Anticholinergics	group	Drug_0
10004027	65	90	cholinesterase inhibitors	group	Drug_1
10004027	144	171	anticholinergic medications	group	Drug_2
10004027	int	Drug_1	Drug_2

10004028|t|Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
10004028	9	24	Cholinomimetics	group	Drug_0
10004028	104	129	cholinesterase inhibitors	group	Drug_1
10004028	158	173	succinylcholine	drug	Drug_2
10004028	183	212	neuromuscular blocking agents	group	Drug_3
10004028	216	236	cholinergic agonists	group	Drug_4
10004028	245	256	bethanechol	drug	Drug_5
10004028	effect	Drug_1	Drug_3
10004028	effect	Drug_1	Drug_2
10004028	effect	Drug_1	Drug_4
10004028	effect	Drug_1	Drug_5

10004029|t|Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
10004029	30	37	ZEMURON	brand	Drug_0
10004029	42	60	rocuronium bromide	drug	Drug_1
10004029	155	170	succinylcholine	drug	Drug_2

10004030|t|If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.
10004030	3	10	ZEMURON	brand	Drug_0
10004030	118	133	succinylcholine	drug	Drug_1
10004030	advise	Drug_0	Drug_1

10004031|t|The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.
10004031	33	40	ZEMURON	brand	Drug_0
10004031	91	106	succinylcholine	drug	Drug_1

10004032|t|There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants.
10004032	55	62	ZEMURON	brand	Drug_0
10004032	88	120	nondepolarizing muscle relaxants	group	Drug_1

10004033|t|Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.
10004033	0	11	Ropivacaine	drug	Drug_0
10004033	74	85	anesthetics	group	Drug_1
10004033	120	148	amide-type local anesthetics	group	Drug_2
10004033	advise	Drug_0	Drug_1

10004034|t|In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.
10004034	33	44	ropivacaine	drug	Drug_0
10004034	91	102	fluvoxamine	drug	Drug_1
10004034	mechanism	Drug_0	Drug_1

10004035|t|Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels.
10004035	54	65	fluvoxamine	drug	Drug_0
10004035	176	187	ropivacaine	drug	Drug_1
10004035	int	Drug_0	Drug_1

10004036|t|Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur.
10004036	102	114	theophylline	drug	Drug_0
10004036	119	129	imipramine	drug	Drug_1

10004037|t|Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
10004037	152	164	ketoconazole	drug	Drug_0
10004037	220	231	ropivacaine	drug	Drug_1
10004037	mechanism	Drug_0	Drug_1

10004038|t|An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.
10004038	32	43	gemfibrozil	drug	Drug_0
10004038	151	164	rosiglitazone	drug	Drug_1
10004038	117	125	rifampin	drug	Drug_2
10004038	mechanism	Drug_0	Drug_1
10004038	mechanism	Drug_2	Drug_1

10004039|t|Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
10004039	109	120	terfenadine	drug	Drug_0
10004039	125	135	astemizole	drug	Drug_1
10004039	84	94	macrolides	group	Drug_2
10004039	int	Drug_2	Drug_1
10004039	int	Drug_2	Drug_0

10004040|t|Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.
10004040	101	114	roxithromycin	drug	Drug_0
10004040	120	131	terfenadine	drug	Drug_1
10004040	135	145	astemizole	drug	Drug_2
10004040	advise	Drug_0	Drug_1
10004040	advise	Drug_0	Drug_2

10004041|t|- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
10004041	43	52	cisapride	drug	Drug_0
10004041	56	64	pimozide	drug	Drug_1
10004041	352	376	macrolide antibacterials	group	Drug_2
10004041	mechanism	Drug_0	Drug_2
10004041	mechanism	Drug_1	Drug_2

10004042|t|however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.
10004042	48	61	diphosphonate	group	Drug_0
10004042	116	135	Calcitonin (salmon)	drug	Drug_1
10004042	effect	Drug_0	Drug_1

10004043|t|ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
10004043	0	7	ASPIRIN	brand	Drug_0
10004043	18	34	SALICYLATE DRUGS	group	Drug_1
10004043	55	63	DISALCID	brand	Drug_2
10004043	106	120	SALICYLIC ACID	drug	Drug_3
10004043	effect	Drug_0	Drug_2
10004043	effect	Drug_1	Drug_2

10004044|t|Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.
10004044	0	11	Salicylates	group	Drug_0
10004044	37	56	anticoagulant drugs	group	Drug_1
10004044	effect	Drug_0	Drug_1

10004045|t|Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.
10004045	0	11	Salicylates	group	Drug_0
10004045	56	74	antidiabetic drugs	group	Drug_1
10004045	effect	Drug_0	Drug_1

10004046|t|Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
10004046	0	10	Salicylate	group	Drug_0
10004046	78	88	penicillin	drug	Drug_1
10004046	90	100	thiopental	drug	Drug_2
10004046	102	111	thyroxine	drug	Drug_3
10004046	113	129	triiodothyronine	drug	Drug_4
10004046	131	140	phenytoin	drug	Drug_5
10004046	142	156	sulfinpyrazone	drug	Drug_6
10004046	158	166	naproxen	drug	Drug_7
10004046	168	176	warfarin	drug	Drug_8
10004046	178	190	methotrexate	drug	Drug_9
10004046	205	220	corticosteroids	group	Drug_10
10004046	mechanism	Drug_0	Drug_4
10004046	mechanism	Drug_0	Drug_5
10004046	mechanism	Drug_0	Drug_8
10004046	mechanism	Drug_0	Drug_7
10004046	mechanism	Drug_0	Drug_2
10004046	mechanism	Drug_0	Drug_1
10004046	mechanism	Drug_0	Drug_6
10004046	mechanism	Drug_0	Drug_9
10004046	mechanism	Drug_0	Drug_10
10004046	mechanism	Drug_0	Drug_3

10004047|t|Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.
10004047	61	68	Leukine	brand	Drug_0
10004047	78	85	lithium	drug	Drug_1
10004047	90	105	corticosteroids	group	Drug_2
10004047	effect	Drug_0	Drug_1
10004047	effect	Drug_0	Drug_2

10004048|t|Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.
10004048	0	11	Scopolamine	drug	Drug_0
10004048	116	125	sedatives	group	Drug_1
10004048	127	140	tranquilizers	group	Drug_2
10004048	145	152	alcohol	drug	Drug_3
10004048	advise	Drug_0	Drug_2
10004048	advise	Drug_0	Drug_3
10004048	advise	Drug_0	Drug_1

10004049|t|e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.
10004049	12	32	belladonna alkaloids	group	Drug_0
10004049	34	48	antihistamines	group	Drug_1
10004049	60	69	meclizine	drug	Drug_2
10004049	72	97	tricyclic antidepressants	group	Drug_3
10004049	103	119	muscle relaxants	group	Drug_4

10004050|t|Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
10004050	0	12	Barbiturates	group	Drug_0
10004050	52	66	contraceptives	group	Drug_1
10004050	76	87	antibiotics	group	Drug_2
10004050	89	98	quinidine	group	Drug_3
10004050	100	112	theophylline	drug	Drug_4
10004050	114	129	corticosteroids	group	Drug_5
10004050	131	145	anticoagulants	group	Drug_6
10004050	151	164	beta blockers	group	Drug_7
10004050	int	Drug_0	Drug_6
10004050	int	Drug_0	Drug_4
10004050	int	Drug_0	Drug_1
10004050	int	Drug_0	Drug_7
10004050	int	Drug_0	Drug_2
10004050	int	Drug_0	Drug_3
10004050	int	Drug_0	Drug_5

10004051|t|The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.
10004051	152	162	selegiline	drug	Drug_0
10004051	167	177	meperidine	drug	Drug_1
10004051	effect	Drug_0	Drug_1

10004052|t|This is typical of the interaction of meperidine and MAOIs.
10004052	38	48	meperidine	drug	Drug_0
10004052	53	58	MAOIs	group	Drug_1
10004052	int	Drug_0	Drug_1

10004053|t|Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.
10004053	80	105	tricyclic antidepressants	group	Drug_0
10004053	167	175	ELDEPRYL	brand	Drug_1
10004053	123	162	selective serotonin reuptake inhibitors	group	Drug_2
10004053	effect	Drug_0	Drug_1
10004053	effect	Drug_2	Drug_1

10004054|t|One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
10004054	95	105	selegiline	drug	Drug_0
10004054	112	138	sympathomimetic medication	group	Drug_1
10004054	140	149	ephedrine	drug	Drug_2
10004054	effect	Drug_0	Drug_2
10004054	effect	Drug_0	Drug_1

10004055|t|Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.
10004055	124	131	digoxin	drug	Drug_0
10004055	169	180	sitagliptin	drug	Drug_1
10004055	mechanism	Drug_0	Drug_1

10004056|t|No dosage adjustment of digoxin or JANUVIA is recommended.
10004056	24	31	digoxin	drug	Drug_0
10004056	35	42	JANUVIA	brand	Drug_1

10004057|t|norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.
10004057	0	14	norepinephrine	drug	Drug_0
10004057	19	29	dobutamine	drug	Drug_1
10004057	52	70	sodium bicarbonate	drug	Drug_2
10004057	int	Drug_0	Drug_2
10004057	int	Drug_1	Drug_2

10004058|t|The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established.
10004058	16	34	sodium bicarbonate	drug	Drug_0
10004058	70	77	calcium	drug	Drug_1

10004059|t|Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors.
10004059	35	43	VESIcare	brand	Drug_0
10004059	88	100	ketoconazole	drug	Drug_1
10004059	advise	Drug_0	Drug_1

10004060|t|Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
10004060	273	284	solifenacin	drug	Drug_0
10004060	347	359	moxifloxacin	drug	Drug_1

10004061|t|Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man.
10004061	37	39	GH	drug	Drug_0
10004061	93	103	antipyrine	drug	Drug_1
10004061	mechanism	Drug_0	Drug_1

10004062|t|These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
10004062	24	26	GH	drug	Drug_0
10004062	133	148	corticosteroids	group	Drug_1
10004062	150	162	sex steroids	group	Drug_2
10004062	164	179	anticonvulsants	group	Drug_3
10004062	181	192	cyclosporin	drug	Drug_4
10004062	mechanism	Drug_0	Drug_3
10004062	mechanism	Drug_0	Drug_4
10004062	mechanism	Drug_0	Drug_1
10004062	mechanism	Drug_0	Drug_2

10004063|t|Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan).
10004063	42	49	NEXAVAR	brand	Drug_0
10004063	139	149	irinotecan	drug	Drug_1
10004063	advise	Drug_0	Drug_1

10004064|t|Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin.
10004064	27	34	NEXAVAR	brand	Drug_0
10004064	76	87	doxorubicin	drug	Drug_1
10004064	mechanism	Drug_0	Drug_1

10004065|t|Caution is recommended when administering doxorubicin with NEXAVAR.
10004065	42	53	doxorubicin	drug	Drug_0
10004065	59	66	NEXAVAR	brand	Drug_1
10004065	advise	Drug_0	Drug_1

10004066|t|Zidovudine competitively inhibits the intracellular phosphorylation of stavudine.
10004066	0	10	Zidovudine	drug	Drug_0
10004066	71	80	stavudine	drug	Drug_1
10004066	effect	Drug_0	Drug_1

10004067|t|Therefore, use of zidovudine in combination with ZERIT should be avoided.
10004067	18	28	zidovudine	drug	Drug_0
10004067	49	54	ZERIT	brand	Drug_1
10004067	advise	Drug_0	Drug_1

10004068|t|In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.
10004068	51	60	stavudine	drug	Drug_0
10004068	109	120	doxorubicin	drug	Drug_1
10004068	125	134	ribavirin	drug	Drug_2
10004068	effect	Drug_0	Drug_1
10004068	effect	Drug_0	Drug_2

10004069|t|The interaction of Streptase, Streptokinase, with other drugs has not been well studied.
10004069	19	28	Streptase	brand	Drug_0
10004069	30	43	Streptokinase	drug	Drug_1

10004070|t|Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
10004070	128	142	anticoagulants	group	Drug_0
10004070	104	123	antiplatelet agents	group	Drug_1
10004070	49	58	Streptase	brand	Drug_2
10004070	60	73	Streptokinase	drug	Drug_3
10004070	effect	Drug_3	Drug_1
10004070	effect	Drug_2	Drug_1
10004070	effect	Drug_3	Drug_0
10004070	effect	Drug_2	Drug_0

10004071|t|In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ).
10004071	30	37	aspirin	brand	Drug_0
10004071	103	116	Streptokinase	drug	Drug_1

10004072|t|Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke.
10004072	20	33	Antiplatelets	group	Drug_0
10004072	139	146	aspirin	brand	Drug_1

10004073|t|The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
10004073	16	23	aspirin	brand	Drug_0
10004073	27	40	Streptokinase	drug	Drug_1
10004073	effect	Drug_0	Drug_1

10004074|t|Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;
10004074	0	12	Streptozocin	drug	Drug_0
10004074	71	82	doxorubicin	drug	Drug_1
10004074	mechanism	Drug_0	Drug_1

10004075|t|a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently.
10004075	19	30	doxorubicin	drug	Drug_0
10004075	81	88	ZANOSAR	brand	Drug_1
10004075	advise	Drug_0	Drug_1

10004076|t|The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.
10004076	100	112	streptozocin	drug	Drug_0
10004076	39	48	phenytoin	drug	Drug_1
10004076	effect	Drug_0	Drug_1

10004077|t|CHEMET is not known to interact with other drugs including iron supplements;
10004077	0	6	CHEMET	brand	Drug_0
10004077	59	63	iron	drug	Drug_1

10004078|t|Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended.
10004078	30	36	CHEMET	brand	Drug_0
10004078	75	86	CaNa 2 EDTA	drug	Drug_1
10004078	advise	Drug_0	Drug_1

10004079|t|Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.
10004079	0	14	Sulfamethizole	drug	Drug_0
10004079	43	55	barbiturates	group	Drug_1
10004079	57	68	tolbutamide	drug	Drug_2
10004079	74	85	uricosurics	group	Drug_3
10004079	effect	Drug_0	Drug_2
10004079	effect	Drug_0	Drug_1
10004079	effect	Drug_0	Drug_3

10004080|t|It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
10004080	26	35	thiazides	group	Drug_0
10004080	66	78	cyclosporine	drug	Drug_1
10004080	107	126	sulfonylurea agents	group	Drug_2
10004080	162	170	warfarin	drug	Drug_3
10004080	248	260	methotrexate	drug	Drug_4
10004080	305	314	phenytoin	drug	Drug_5

10004081|t|In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported.
10004081	51	60	diuretics	group	Drug_0
10004081	72	81	thiazides	group	Drug_1

10004082|t|It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.
10004082	26	42	sulfamethoxazole	drug	Drug_0
10004082	110	123	anticoagulant	group	Drug_1
10004082	124	132	warfarin	drug	Drug_2
10004082	effect	Drug_0	Drug_2

10004083|t|Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.
10004083	0	16	Sulfamethoxazole	drug	Drug_0
10004083	55	64	phenytoin	drug	Drug_1
10004083	mechanism	Drug_0	Drug_1

10004084|t|At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.
10004084	17	33	sulfamethoxazole	drug	Drug_0
10004084	97	106	phenytoin	drug	Drug_1
10004084	mechanism	Drug_0	Drug_1

10004085|t|Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.
10004085	0	12	Sulfonamides	group	Drug_0
10004085	100	112	methotrexate	drug	Drug_1
10004085	mechanism	Drug_0	Drug_1

10004086|t|Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.
10004086	22	32	folic acid	drug	Drug_0
10004086	37	44	digoxin	drug	Drug_1
10004086	119	132	sulfasalazine	drug	Drug_2
10004086	mechanism	Drug_1	Drug_2
10004086	mechanism	Drug_0	Drug_2

10004087|t|When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.
10004087	20	33	sulfasalazine	drug	Drug_0
10004087	58	70	methotrexate	drug	Drug_1

10004088|t|Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.
10004088	15	28	sulfasalazine	drug	Drug_0
10004088	67	79	methotrexate	drug	Drug_1

10004089|t|Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.
10004089	0	9	Sulfoxone	drug	Drug_0
10004089	38	50	barbiturates	group	Drug_1
10004089	52	63	tolbutamide	drug	Drug_2
10004089	69	80	uricosurics	group	Drug_3
10004089	effect	Drug_0	Drug_3
10004089	effect	Drug_0	Drug_2
10004089	effect	Drug_0	Drug_1

10004090|t|It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
10004090	26	35	thiazides	group	Drug_0
10004090	66	78	cyclosporine	drug	Drug_1
10004090	107	126	sulfonylurea agents	group	Drug_2
10004090	162	170	warfarin	drug	Drug_3
10004090	248	260	methotrexate	drug	Drug_4
10004090	305	314	phenytoin	drug	Drug_5

10004091|t|Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
10004091	80	90	ergotamine	drug	Drug_0
10004091	105	127	ergot-type medications	group	Drug_1
10004091	134	151	dihydroergotamine	drug	Drug_2
10004091	155	167	methysergide	drug	Drug_3
10004091	173	184	sumatriptan	drug	Drug_4
10004091	advise	Drug_0	Drug_4
10004091	advise	Drug_2	Drug_4
10004091	advise	Drug_3	Drug_4
10004091	advise	Drug_1	Drug_4

10004092|t|MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.
10004092	0	16	MAO-A inhibitors	group	Drug_0
10004092	24	35	sumatriptan	drug	Drug_1
10004092	mechanism	Drug_0	Drug_1

10004093|t|Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
10004093	22	43	sumatriptan succinate	drug	Drug_0
10004093	74	90	MAO-A inhibitors	group	Drug_1
10004093	112	151	Selective serotonin reuptake inhibitors	group	Drug_2
10004093	153	158	SSRIs	group	Drug_3
10004093	167	177	fluoxetine	drug	Drug_4
10004093	179	190	fluvoxamine	drug	Drug_5
10004093	192	202	paroxetine	drug	Drug_6
10004093	204	214	sertraline	drug	Drug_7
10004093	322	333	sumatriptan	drug	Drug_8
10004093	effect	Drug_4	Drug_8
10004093	effect	Drug_2	Drug_8
10004093	effect	Drug_5	Drug_8
10004093	effect	Drug_7	Drug_8
10004093	effect	Drug_6	Drug_8
10004093	advise	Drug_0	Drug_1
10004093	effect	Drug_3	Drug_8

10004094|t|If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
10004094	30	41	sumatriptan	drug	Drug_0
10004094	49	53	SSRI	group	Drug_1
10004094	advise	Drug_0	Drug_1

10004095|t|Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
10004095	21	27	SUTENT	brand	Drug_0
10004095	79	91	ketoconazole	drug	Drug_1
10004095	93	105	itraconazole	drug	Drug_2
10004095	107	121	clarithromycin	drug	Drug_3
10004095	123	133	atazanavir	drug	Drug_4
10004095	135	144	indinavir	drug	Drug_5
10004095	146	156	nefazodone	drug	Drug_6
10004095	158	168	nelfinavir	drug	Drug_7
10004095	170	179	ritonavir	drug	Drug_8
10004095	181	191	saquinavir	drug	Drug_9
10004095	193	206	telithromycin	drug	Drug_10
10004095	208	220	voriconizole	drug	Drug_11
10004095	236	245	sunitinib	drug	Drug_12
10004095	mechanism	Drug_0	Drug_8
10004095	mechanism	Drug_0	Drug_9
10004095	mechanism	Drug_0	Drug_3
10004095	mechanism	Drug_0	Drug_7
10004095	mechanism	Drug_0	Drug_5
10004095	mechanism	Drug_0	Drug_1
10004095	mechanism	Drug_0	Drug_4
10004095	mechanism	Drug_0	Drug_10
10004095	mechanism	Drug_0	Drug_2
10004095	mechanism	Drug_0	Drug_6
10004095	mechanism	Drug_0	Drug_11

10004096|t|Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
10004096	21	27	SUTENT	brand	Drug_0
10004096	70	83	dexamethasone	drug	Drug_1
10004096	85	94	phenytoin	drug	Drug_2
10004096	96	109	carbamazepine	drug	Drug_3
10004096	111	119	rifampin	drug	Drug_4
10004096	121	130	rifabutin	drug	Drug_5
10004096	132	142	rifapentin	drug	Drug_6
10004096	144	157	phenobarbital	drug	Drug_7
10004096	188	197	sunitinib	drug	Drug_8
10004096	mechanism	Drug_0	Drug_2
10004096	mechanism	Drug_0	Drug_6
10004096	mechanism	Drug_0	Drug_5
10004096	mechanism	Drug_0	Drug_3
10004096	mechanism	Drug_0	Drug_4
10004096	mechanism	Drug_0	Drug_7
10004096	mechanism	Drug_0	Drug_1

10004097|t|Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
10004097	39	61	acetylcholine chloride	drug	Drug_0
10004097	63	70	Miochol	brand	Drug_1
10004097	76	85	carbachol	drug	Drug_2
10004097	87	96	Carboptic	brand	Drug_3
10004097	98	114	Isopto Carbachol	brand	Drug_4
10004097	144	152	suprofen	drug	Drug_5
10004097	effect	Drug_3	Drug_5
10004097	effect	Drug_2	Drug_5
10004097	effect	Drug_0	Drug_5
10004097	effect	Drug_4	Drug_5
10004097	effect	Drug_1	Drug_5

10004098|t|Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined.
10004098	85	91	FLOMAX	brand	Drug_0
10004098	111	143	alpha-adrenergic blocking agents	group	Drug_1

10004099|t|However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents.
10004099	42	48	FLOMAX	brand	Drug_0
10004099	103	135	alpha-adrenergic blocking agents	group	Drug_1
10004099	advise	Drug_0	Drug_1

10004100|t|The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated.
10004100	40	50	cimetidine	drug	Drug_0
10004100	55	61	FLOMAX	brand	Drug_1

10004101|t|Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.
10004101	11	17	FLOMAX	brand	Drug_0
10004101	75	85	cimetidine	drug	Drug_1
10004101	advise	Drug_0	Drug_1

10004102|t|Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive.
10004102	80	94	tamsulosin HCI	drug	Drug_0
10004102	99	107	warfarin	drug	Drug_1

10004103|t|Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.
10004103	74	82	warfarin	drug	Drug_0
10004103	87	93	FLOMAX	brand	Drug_1
10004103	advise	Drug_0	Drug_1

10004104|t|Administration of valproic acid decreases oral clearance of temozolomide by about 5%.
10004104	18	31	valproic acid	drug	Drug_0
10004104	60	72	temozolomide	drug	Drug_1
10004104	mechanism	Drug_0	Drug_1

10004105|t|Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin.
10004105	39	45	TNKase	brand	Drug_0
10004105	74	81	heparin	drug	Drug_1
10004105	86	93	aspirin	brand	Drug_2

10004106|t|Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
10004106	0	14	Anticoagulants	group	Drug_0
10004106	24	31	heparin	drug	Drug_1
10004106	36	57	vitamin K antagonists	group	Drug_2
10004106	107	127	acetylsalicylic acid	drug	Drug_3
10004106	129	141	dipyridamole	drug	Drug_4
10004106	248	254	TNKase	brand	Drug_5
10004106	effect	Drug_3	Drug_5
10004106	effect	Drug_0	Drug_5
10004106	effect	Drug_2	Drug_5
10004106	effect	Drug_1	Drug_5
10004106	effect	Drug_4	Drug_5

10004107|t|In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
10004107	95	106	tolbutamide	drug	Drug_0
10004107	108	125	sodium salicylate	drug	Drug_1
10004107	130	144	sulfamethizole	drug	Drug_2
10004107	169	179	teniposide	drug	Drug_3
10004107	mechanism	Drug_0	Drug_3
10004107	mechanism	Drug_1	Drug_3
10004107	mechanism	Drug_2	Drug_3

10004108|t|Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents.
10004108	51	56	VUMON	brand	Drug_0
10004108	58	68	teniposide	drug	Drug_1

10004109|t|There was no change in the plasma kinetics of teniposide when coadministered with methotrexate.
10004109	46	56	teniposide	drug	Drug_0
10004109	82	94	methotrexate	drug	Drug_1

10004110|t|An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.
10004110	39	51	methotrexate	drug	Drug_0
10004110	93	103	teniposide	drug	Drug_1
10004110	mechanism	Drug_0	Drug_1

10004111|t|In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.
10004111	57	68	terbinafine	drug	Drug_0
10004111	104	115	tolbutamide	drug	Drug_1
10004111	117	133	ethinylestradiol	drug	Drug_2
10004111	135	149	ethoxycoumarin	drug_n	Drug_3
10004111	155	167	cyclosporine	drug	Drug_4

10004112|t|This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
10004112	98	123	tricyclic antidepressants	group	Drug_0
10004112	139	178	selective serotonin reuptake inhibitors	group	Drug_1
10004112	180	185	SSRIs	group	Drug_2
10004112	192	236	monoamine oxidase inhibitors (MAO-Is) Type B	group	Drug_3

10004113|t|In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.
10004113	89	100	terbinafine	drug	Drug_0
10004113	134	144	antipyrine	drug	Drug_1
10004113	148	155	digoxin	drug	Drug_2

10004114|t|Terbinafine decreases the clearance of caffeine by 19%.
10004114	0	11	Terbinafine	drug	Drug_0
10004114	39	47	caffeine	drug	Drug_1
10004114	mechanism	Drug_0	Drug_1

10004115|t|Terbinafine increases the clearance of cyclosporine by 15%.
10004115	0	11	Terbinafine	drug	Drug_0
10004115	39	51	cyclosporine	drug	Drug_1
10004115	mechanism	Drug_0	Drug_1

10004116|t|There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.
10004116	119	130	terbinafine	drug	Drug_0
10004116	135	143	warfarin	drug	Drug_1
10004116	184	191	LAMISIL	brand	Drug_2
10004116	effect	Drug_0	Drug_1

10004117|t|Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.
10004117	0	11	Terbinafine	drug	Drug_0
10004117	43	51	rifampin	drug	Drug_1
10004117	99	109	cimetidine	drug	Drug_2
10004117	mechanism	Drug_0	Drug_2
10004117	mechanism	Drug_0	Drug_1

10004118|t|Terbinafine clearance is unaffected by cyclosporine.
10004118	0	11	Terbinafine	drug	Drug_0
10004118	39	51	cyclosporine	drug	Drug_1

10004119|t|There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
10004119	120	134	contraceptives	group	Drug_0
10004119	167	180	hypoglycemics	group	Drug_1
10004119	182	195	theophyllines	drug	Drug_2
10004119	197	207	phenytoins	drug	Drug_3
10004119	209	227	thiazide diuretics	group	Drug_4
10004119	229	242	beta blockers	group	Drug_5
10004119	248	272	calcium channel blockers	group	Drug_6

10004120|t|Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.
10004120	82	94	ketoconazole	drug	Drug_0
10004120	121	132	terfenadine	drug	Drug_1
10004120	effect	Drug_0	Drug_1

10004121|t|Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.
10004121	35	47	ketoconazole	drug	Drug_0
10004121	126	137	terfenadine	drug	Drug_1
10004121	mechanism	Drug_0	Drug_1

10004122|t|Concomitant administration of ketoconazole and terfenadine is contraindicated.
10004122	30	42	ketoconazole	drug	Drug_0
10004122	47	58	terfenadine	drug	Drug_1
10004122	advise	Drug_0	Drug_1

10004123|t|Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
10004123	169	181	itraconazole	drug	Drug_0
10004123	118	129	terfenadine	drug	Drug_1
10004123	mechanism	Drug_1	Drug_0

10004124|t|Concomitant administration of itraconazole and terfenadine is contraindicated.
10004124	30	42	itraconazole	drug	Drug_0
10004124	47	58	terfenadine	drug	Drug_1
10004124	advise	Drug_0	Drug_1

10004125|t|Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
10004125	40	68	azole-type antifungal agents	group	Drug_0
10004125	80	91	fluconazole	drug	Drug_1
10004125	93	106	metronidazole	drug	Drug_2
10004125	112	122	miconazole	drug	Drug_3
10004125	127	139	ketoconazole	drug	Drug_4
10004125	145	157	itraconazole	drug	Drug_5
10004125	198	209	terfenadine	drug	Drug_6
10004125	advise	Drug_2	Drug_6
10004125	advise	Drug_3	Drug_6
10004125	advise	Drug_0	Drug_6
10004125	advise	Drug_1	Drug_6

10004126|t|Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
10004126	0	10	Macrolides	group	Drug_0
10004126	60	72	erythromycin	drug	Drug_1
10004126	77	91	clarithromycin	drug	Drug_2
10004126	115	126	terfenadine	drug	Drug_3
10004126	185	197	ketoconazole	drug	Drug_4
10004126	mechanism	Drug_2	Drug_3
10004126	mechanism	Drug_1	Drug_3

10004127|t|A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin.
10004127	155	167	erythromycin	drug	Drug_0
10004127	171	185	troleandomycin	drug	Drug_1

10004128|t|Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
10004128	202	213	terfenadine	drug	Drug_0
10004128	47	61	clarithromycin	drug	Drug_1
10004128	63	75	erythromycin	drug	Drug_2
10004128	80	94	troleandomycin	drug	Drug_3
10004128	225	246	macrolide antibiotics	group	Drug_4
10004128	258	270	azithromycin	drug	Drug_5
10004128	advise	Drug_0	Drug_5
10004128	advise	Drug_0	Drug_4
10004128	advise	Drug_0	Drug_2
10004128	advise	Drug_0	Drug_3
10004128	advise	Drug_0	Drug_1

10004129|t|Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.
10004129	46	57	terfenadine	drug	Drug_0
10004129	63	75	azithromycin	drug	Drug_1

10004130|t|When administered concurrently, testolactone may increase the effects of oral anticoagulants;
10004130	32	44	testolactone	drug	Drug_0
10004130	78	92	anticoagulants	group	Drug_1
10004130	effect	Drug_0	Drug_1

10004131|t|Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.
10004131	0	11	Thalidomide	drug	Drug_0
10004131	66	78	barbiturates	group	Drug_1
10004131	80	87	alcohol	drug	Drug_2
10004131	89	103	chlorpromazine	drug	Drug_3
10004131	109	118	reserpine	drug	Drug_4
10004131	effect	Drug_0	Drug_1

10004132|t|Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.
10004132	5	19	Contraceptives	group	Drug_0
10004132	74	87	norethindrone	drug	Drug_1
10004132	210	227	ethinyl estradiol	drug	Drug_2
10004132	173	194	norethindrone acetate	drug	Drug_3

10004133|t|Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
10004133	14	25	Thalidomide	drug	Drug_0
10004133	70	93	Hormonal Contraceptives	group	Drug_1
10004133	114	137	HIV-protease inhibitors	group	Drug_2
10004133	139	151	griseofulvin	drug	Drug_3
10004133	153	162	modafinil	drug	Drug_4
10004133	164	175	penicillins	group	Drug_5
10004133	177	185	rifampin	drug	Drug_6
10004133	187	196	rifabutin	drug	Drug_7
10004133	198	207	phenytoin	drug	Drug_8
10004133	209	222	carbamazepine	drug	Drug_9

10004134|t|John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.
10004134	0	11	John's Wort	drug_n	Drug_0
10004134	17	46	hormonal contraceptive agents	group	Drug_1
10004134	effect	Drug_0	Drug_1

10004135|t|Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
10004135	0	13	Thiabendazole	drug	Drug_0
10004135	52	64	theophylline	drug	Drug_1
10004135	mechanism	Drug_0	Drug_1

10004136|t|Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
10004136	35	48	thiabendazole	drug	Drug_0
10004136	53	73	xanthine derivatives	group	Drug_1
10004136	advise	Drug_0	Drug_1

10004137|t|Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
10004137	17	27	Vitamin B1	drug	Drug_0
10004137	29	37	Thiamine	drug	Drug_1
10004137	41	55	Loop Diuretics	group	Drug_2
10004137	62	76	Contraceptives	group	Drug_3
10004137	78	87	Stavudine	drug	Drug_4
10004137	89	114	Tricyclic Antidepressants	group	Drug_5
10004137	int	Drug_1	Drug_4
10004137	int	Drug_1	Drug_5
10004137	int	Drug_0	Drug_2
10004137	int	Drug_1	Drug_2
10004137	int	Drug_1	Drug_3
10004137	int	Drug_0	Drug_5
10004137	int	Drug_0	Drug_4
10004137	int	Drug_0	Drug_3

10004138|t|Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
10004138	0	14	Phenothiazines	group	Drug_0
10004138	43	58	CNS depressants	group	Drug_1
10004138	66	78	barbiturates	group	Drug_2
10004138	80	91	anesthetics	group	Drug_3
10004138	93	100	opiates	group	Drug_4
10004138	102	109	alcohol	drug	Drug_5
10004138	effect	Drug_0	Drug_3
10004138	effect	Drug_0	Drug_4
10004138	effect	Drug_0	Drug_5
10004138	effect	Drug_0	Drug_1
10004138	effect	Drug_0	Drug_2

10004139|t|as well as atropine and phosphorous insecticides.
10004139	11	19	atropine	drug	Drug_0
10004139	24	48	phosphorous insecticides	drug_n	Drug_1

10004140|t|There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
10004140	51	61	PURINETHOL	brand	Drug_0
10004140	63	77	mercaptopurine	drug	Drug_1
10004140	83	90	TABLOID	brand	Drug_2
10004140	97	108	Thioguanine	drug	Drug_3
10004140	effect	Drug_1	Drug_2
10004140	effect	Drug_0	Drug_3
10004140	effect	Drug_0	Drug_2
10004140	effect	Drug_1	Drug_3

10004141|t|As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
10004141	35	62	aminosalicylate derivatives	group	Drug_0
10004141	70	80	olsalazine	drug	Drug_1
10004141	82	92	mesalazine	drug	Drug_2
10004141	97	111	sulphasalazine	drug	Drug_3
10004141	212	223	thioguanine	drug	Drug_4
10004141	mechanism	Drug_3	Drug_4
10004141	mechanism	Drug_1	Drug_4
10004141	mechanism	Drug_0	Drug_4
10004141	mechanism	Drug_2	Drug_4

10004142|t|Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs.
10004142	47	54	ZADAXIN	brand	Drug_0
10004142	89	111	immunomodulating drugs	group	Drug_1
10004142	advise	Drug_0	Drug_1

10004143|t|Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.
10004143	79	90	tigecycline	drug	Drug_0
10004143	112	120	warfarin	drug	Drug_1
10004143	advise	Drug_0	Drug_1

10004144|t|Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.
10004144	18	37	antibacterial drugs	group	Drug_0
10004144	79	93	contraceptives	group	Drug_1
10004144	effect	Drug_0	Drug_1

10004145|t|The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
10004145	210	216	SKELID	brand	Drug_0
10004145	64	71	calcium	drug	Drug_1
10004145	134	142	aluminum	drug	Drug_2
10004145	147	156	magnesium	drug	Drug_3
10004145	168	176	antacids	drug	Drug_4
10004145	mechanism	Drug_3	Drug_0
10004145	mechanism	Drug_2	Drug_0
10004145	mechanism	Drug_0	Drug_1

10004146|t|Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID.
10004146	0	7	Aspirin	brand	Drug_0
10004146	85	91	SKELID	brand	Drug_1
10004146	mechanism	Drug_0	Drug_1

10004147|t|The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.
10004147	23	29	SKELID	brand	Drug_0
10004147	55	67	indomethacin	drug	Drug_1
10004147	124	134	diclofenac	drug	Drug_2
10004147	mechanism	Drug_0	Drug_1

10004148|t|The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration.
10004148	34	41	digoxin	drug	Drug_0
10004148	76	82	SKELID	brand	Drug_1

10004149|t|In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.
10004149	27	38	tiludronate	drug	Drug_0
10004149	57	65	warfarin	drug	Drug_1

10004150|t|These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.
10004150	14	45	sympathomimetic bronchodilators	group	Drug_0
10004150	47	62	methylxanthines	group	Drug_1
10004150	85	93	steroids	group	Drug_2

10004151|t|However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
10004151	36	43	SPIRIVA	brand	Drug_0
10004151	55	70	anticholinergic	group	Drug_1
10004151	97	108	ipratropium	drug	Drug_2
10004151	advise	Drug_0	Drug_2
10004151	advise	Drug_0	Drug_1

10004152|t|AGGRASTAT has been studied on a background of aspirin and heparin.
10004152	0	9	AGGRASTAT	brand	Drug_0
10004152	46	53	aspirin	brand	Drug_1
10004152	58	65	heparin	drug	Drug_2

10004153|t|The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
10004153	11	20	AGGRASTAT	brand	Drug_0
10004153	124	131	heparin	drug	Drug_1
10004153	136	143	aspirin	drug	Drug_2
10004153	effect	Drug_0	Drug_2
10004153	effect	Drug_0	Drug_1

10004154|t|In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
10004154	45	49	TOBI	brand	Drug_0
10004154	69	81	dornase alfa	drug	Drug_1
10004154	83	92	PULMOZYME	brand	Drug_2
10004154	109	124	(beta)-agonists	group	Drug_3
10004154	134	149	corticosteroids	group	Drug_4
10004154	157	185	anti-pseudomonal antibiotics	group	Drug_5
10004154	201	216	aminoglycosides	group	Drug_6
10004154	effect	Drug_0	Drug_4
10004154	effect	Drug_0	Drug_3
10004154	effect	Drug_0	Drug_5
10004154	effect	Drug_0	Drug_2
10004154	effect	Drug_0	Drug_6
10004154	effect	Drug_0	Drug_1

10004155|t|Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.
10004155	5	14	diuretics	group	Drug_0
10004155	27	41	aminoglycoside	group	Drug_1
10004155	63	73	antibiotic	group	Drug_2
10004155	effect	Drug_0	Drug_1

10004156|t|TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
10004156	0	4	TOBI	brand	Drug_0
10004156	51	66	ethacrynic acid	drug	Drug_1
10004156	68	78	furosemide	drug	Drug_2
10004156	80	84	urea	drug	Drug_3
10004156	89	97	mannitol	drug	Drug_4
10004156	advise	Drug_0	Drug_4
10004156	advise	Drug_0	Drug_3
10004156	advise	Drug_0	Drug_1
10004156	advise	Drug_0	Drug_2

10004157|t|The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers.
10004157	24	32	warfarin	drug	Drug_0
10004157	89	97	tolmetin	drug	Drug_1

10004158|t|However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy.
10004158	95	103	TOLECTIN	brand	Drug_0
10004158	108	116	warfarin	drug	Drug_1
10004158	effect	Drug_0	Drug_1

10004159|t|Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants.
10004159	58	66	TOLECTIN	brand	Drug_0
10004159	82	96	anticoagulants	group	Drug_1
10004159	advise	Drug_0	Drug_1

10004160|t|In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents.
10004160	55	68	sulfonylureas	group	Drug_0
10004160	72	79	insulin	drug	Drug_1
10004160	133	141	TOLECTIN	brand	Drug_2
10004160	149	168	hypoglycemic agents	group	Drug_3

10004161|t|Caution should be used if TOLECTIN is administered concomitantly with methotrexate.
10004161	26	34	TOLECTIN	brand	Drug_0
10004161	70	82	methotrexate	drug	Drug_1
10004161	advise	Drug_0	Drug_1

10004162|t|TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.
10004162	0	8	TOLECTIN	brand	Drug_0
10004162	19	55	nonsteroidal anti-inflammatory drugs	group	Drug_1
10004162	178	190	methotrexate	drug	Drug_2
10004162	mechanism	Drug_0	Drug_2
10004162	mechanism	Drug_1	Drug_2

10004163|t|CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
10004163	19	31	Ketoconazole	drug	Drug_0
10004163	135	146	tolterodine	drug	Drug_1
10004163	mechanism	Drug_0	Drug_1

10004164|t|For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
10004164	23	35	ketoconazole	drug	Drug_0
10004164	84	101	azole antifungals	group	Drug_1
10004164	107	119	itraconazole	drug	Drug_2
10004164	121	131	miconazole	drug	Drug_3
10004164	136	157	macrolide antibiotics	group	Drug_4
10004164	163	175	erythromycin	drug	Drug_5
10004164	177	191	clarithromycin	drug	Drug_6
10004164	196	208	cyclosporine	drug	Drug_7
10004164	212	223	vinblastine	drug	Drug_8
10004164	249	258	DETROL LA	brand	Drug_9
10004164	advise	Drug_8	Drug_9
10004164	advise	Drug_3	Drug_9
10004164	advise	Drug_4	Drug_9
10004164	advise	Drug_0	Drug_9
10004164	advise	Drug_5	Drug_9
10004164	advise	Drug_6	Drug_9
10004164	advise	Drug_2	Drug_9
10004164	advise	Drug_7	Drug_9
10004164	advise	Drug_1	Drug_9

10004165|t|Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
10004165	18	28	paclitaxel	drug	Drug_0
10004165	173	182	HERCEPTIN	brand	Drug_1
10004165	mechanism	Drug_0	Drug_1

10004166|t|Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).
10004166	0	10	Trilostane	drug	Drug_0
10004166	29	46	aminoglutethimide	drug	Drug_1
10004166	50	58	mitotane	drug	Drug_2
10004166	int	Drug_0	Drug_2
10004166	int	Drug_0	Drug_1

10004167|t|Trimethoprim may inhibit the hepatic metabolism of phenytoin.
10004167	0	12	Trimethoprim	drug	Drug_0
10004167	51	60	phenytoin	drug	Drug_1
10004167	mechanism	Drug_0	Drug_1

10004168|t|Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
10004168	0	12	Trimethoprim	drug	Drug_0
10004168	108	117	phenytoin	drug	Drug_1
10004168	mechanism	Drug_0	Drug_1
10004168	mechanism	Drug_0	Drug_1

10004169|t|Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
10004169	41	53	trimetrexate	drug	Drug_0
10004169	133	145	erythromycin	drug	Drug_1
10004169	147	155	rifampin	drug	Drug_2
10004169	157	166	rifabutin	drug	Drug_3
10004169	168	180	ketoconazole	drug	Drug_4
10004169	186	197	fluconazole	drug	Drug_5
10004169	effect	Drug_0	Drug_1
10004169	effect	Drug_0	Drug_4
10004169	effect	Drug_0	Drug_5
10004169	effect	Drug_0	Drug_3
10004169	effect	Drug_0	Drug_2

10004170|t|In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
10004170	56	66	cimetidine	drug	Drug_0
10004170	101	113	trimetrexate	drug	Drug_1
10004170	134	147	acetaminophen	drug	Drug_2
10004170	mechanism	Drug_0	Drug_1

10004171|t|Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
10004171	59	74	imidazole drugs	group	Drug_0
10004171	76	88	clotrimazole	drug	Drug_1
10004171	90	102	ketoconazole	drug	Drug_2
10004171	104	114	miconazole	drug	Drug_3
10004171	159	171	trimetrexate	drug	Drug_4
10004171	mechanism	Drug_1	Drug_4
10004171	mechanism	Drug_3	Drug_4
10004171	mechanism	Drug_2	Drug_4
10004171	mechanism	Drug_0	Drug_4

10004172|t|Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
10004172	0	12	Triprolidine	drug	Drug_0
10004172	49	83	central nervous system depressants	group	Drug_1
10004172	94	101	alcohol	drug	Drug_2
10004172	103	115	barbiturates	group	Drug_3
10004172	117	126	hypnotics	group	Drug_4
10004172	128	147	narcotic analgesics	group	Drug_5
10004172	149	158	sedatives	group	Drug_6
10004172	164	178	tranquillisers	group	Drug_7
10004172	effect	Drug_0	Drug_3
10004172	effect	Drug_0	Drug_2
10004172	effect	Drug_0	Drug_4
10004172	effect	Drug_0	Drug_1
10004172	effect	Drug_0	Drug_6
10004172	effect	Drug_0	Drug_7
10004172	effect	Drug_0	Drug_5

10004173|t|The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
10004173	15	36	anticholinergic drugs	group	Drug_0
10004173	46	54	atropine	drug	Drug_1
10004173	59	84	tricyclic antidepressants	group	Drug_2
10004173	138	150	triprolidine	drug	Drug_3
10004173	effect	Drug_0	Drug_3
10004173	effect	Drug_2	Drug_3
10004173	effect	Drug_1	Drug_3

10004174|t|The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
10004174	23	31	Sanctura	brand	Drug_0
10004174	43	65	anticholinergic agents	group	Drug_1
10004174	effect	Drug_0	Drug_1

10004175|t|Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
10004175	135	143	Sanctura	brand	Drug_0
10004175	266	273	digoxin	drug	Drug_1
10004175	275	287	procainamide	drug	Drug_2
10004175	289	300	pancuronium	drug	Drug_3
10004175	302	310	morphine	drug	Drug_4
10004175	312	322	vancomycin	drug	Drug_5
10004175	324	333	metformin	drug	Drug_6
10004175	338	347	tenofovir	drug	Drug_7
10004175	mechanism	Drug_0	Drug_5
10004175	mechanism	Drug_0	Drug_3
10004175	mechanism	Drug_0	Drug_1
10004175	mechanism	Drug_0	Drug_2
10004175	mechanism	Drug_0	Drug_7
10004175	mechanism	Drug_0	Drug_6
10004175	mechanism	Drug_0	Drug_4

10004176|t|Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.
10004176	30	40	vancomycin	drug	Drug_0
10004176	45	62	anesthetic agents	group	Drug_1
10004176	effect	Drug_0	Drug_1

10004177|t|Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
10004177	119	133	amphotericin B	drug	Drug_0
10004177	135	150	aminoglycosides	group	Drug_1
10004177	152	162	bacitracin	drug	Drug_2
10004177	164	175	polymyxin B	drug	Drug_3
10004177	177	185	colistin	drug	Drug_4
10004177	187	195	viomycin	drug	Drug_5
10004177	200	209	cisplatin	drug	Drug_6

10004178|t|A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.
10004178	37	47	vigabatrin	drug	Drug_0
10004178	115	128	carbamazepine	drug	Drug_1
10004178	mechanism	Drug_0	Drug_1

10004179|t|In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
10004179	87	97	vigabatrin	drug	Drug_0
10004179	131	140	phenytoin	drug	Drug_1
10004179	mechanism	Drug_0	Drug_1

10004180|t|Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
10004180	0	9	Vindesine	drug	Drug_0
10004180	310	319	Phenytoin	drug	Drug_1
10004180	353	372	Live virus vaccines	group	Drug_2
10004180	650	657	vaccine	group	Drug_3
10004180	526	537	Mitomycin-C	drug	Drug_4
10004180	588	609	Killed virus vaccines	group	Drug_5
10004180	int	Drug_0	Drug_5
10004180	int	Drug_0	Drug_4
10004180	int	Drug_0	Drug_2
10004180	int	Drug_0	Drug_1

10004181|t|Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.
10004181	33	47	contraceptives	group	Drug_0
10004181	92	101	vitamin A	group	Drug_1
10004181	mechanism	Drug_0	Drug_1

10004182|t|Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.
10004182	31	44	ascorbic acid	drug	Drug_0
10004182	99	117	bishydroxycoumarin	drug	Drug_1
10004182	mechanism	Drug_0	Drug_1

10004183|t|Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants.
10004183	178	212	coumarin-derivative anticoagulants	group	Drug_0
10004183	151	158	ZOLINZA	brand	Drug_1
10004183	effect	Drug_1	Drug_0

10004184|t|Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives.
10004184	85	92	ZOLINZA	brand	Drug_0
10004184	97	117	coumarin derivatives	group	Drug_1
10004184	advise	Drug_0	Drug_1

10004185|t|Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).
10004185	137	152	HDAC inhibitors	group	Drug_0
10004185	119	126	ZOLINZA	brand	Drug_1
10004185	160	173	valproic acid	drug	Drug_2
10004185	effect	Drug_1	Drug_0
10004185	effect	Drug_1	Drug_2

10004186|t|In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
10004186	106	154	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_0
10004186	281	325	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_1

10004187|t|Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
10004187	422	466	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_0
10004187	366	414	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_1

10004188|t|After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
10004188	200	244	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_0
10004188	245	293	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_1
10004188	effect	Drug_0	Drug_1

10004189|t|These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.
10004189	467	511	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_0
10004189	394	442	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_1
10004189	effect	Drug_0	Drug_1

10004190|t|The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.
10004190	4	52	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_0
10004190	100	144	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_1
10004190	effect	Drug_0	Drug_1

10004191|t|In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.
10004191	283	327	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_0
10004191	328	376	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_1
10004191	effect	Drug_0	Drug_1

10004192|t|Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.
10004192	99	147	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	Drug_0
10004192	171	215	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	Drug_1
10004192	effect	Drug_0	Drug_1

10004193|t|Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
10004193	10	22	ketoconazole	drug	Drug_0
10004193	82	94	panobinostat	drug	Drug_1
10004193	96	102	LBH589	drug	Drug_2
10004193	122	151	histone deacetylase inhibitor	group	Drug_3

10004194|t|This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.
10004194	61	73	ketoconazole	drug	Drug_0
10004194	113	125	panobinostat	drug	Drug_1

10004195|t|On day 8, a single panobinostat dose was co-administered with ketoconazole.
10004195	19	31	panobinostat	drug	Drug_0
10004195	62	74	ketoconazole	drug	Drug_1

10004196|t|In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively.
10004196	19	31	ketoconazole	drug	Drug_0
10004196	92	104	panobinostat	drug	Drug_1
10004196	mechanism	Drug_0	Drug_1

10004197|t|Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
10004197	21	33	moxifloxacin	drug	Drug_0
10004197	38	50	lomefloxacin	drug	Drug_1

10004198|t|Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.
10004198	0	12	Moxifloxacin	drug	Drug_0
10004198	17	29	lomefloxacin	drug	Drug_1
10004198	34	61	fluoroquinolone antibiotics	group	Drug_2

10004199|t|Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.
10004199	6	18	moxifloxacin	drug	Drug_0
10004199	36	52	fluoroquinolones	group	Drug_1
10004199	99	109	sucralfate	drug	Drug_2
10004199	111	118	gelusil	brand	Drug_3
10004199	120	132	erythromycin	drug	Drug_4
10004199	137	151	multi minerals	group	Drug_5

10004200|t|The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.
10004200	16	28	moxifloxacin	drug	Drug_0
10004200	33	45	lomefloxacin	drug	Drug_1

10004201|t|Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
10004201	0	12	Moxifloxacin	drug	Drug_0
10004201	17	29	Lomefloxacin	drug	Drug_1
10004201	49	59	sucralfate	drug	Drug_2
10004201	64	71	gelusil	brand	Drug_3
10004201	101	113	erythromycin	drug	Drug_4
10004201	133	147	multi-minerals	group	Drug_5
10004201	mechanism	Drug_0	Drug_4
10004201	mechanism	Drug_1	Drug_2
10004201	mechanism	Drug_0	Drug_3
10004201	mechanism	Drug_0	Drug_5
10004201	mechanism	Drug_0	Drug_2
10004201	mechanism	Drug_1	Drug_3
10004201	mechanism	Drug_1	Drug_5
10004201	mechanism	Drug_1	Drug_4

10004202|t|Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
10004202	17	27	S-ketamine	drug	Drug_0
10004202	45	57	itraconazole	drug	Drug_1
10004202	83	94	ticlopidine	drug	Drug_2
10004202	effect	Drug_0	Drug_2

10004203|t|This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole.
10004203	51	61	S-ketamine	drug	Drug_0
10004203	107	118	ticlopidine	drug	Drug_1
10004203	143	155	itraconazole	drug	Drug_2

10004204|t|In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.
10004204	87	97	S-ketamine	drug	Drug_0
10004204	128	139	ticlopidine	drug	Drug_1
10004204	162	174	itraconazole	drug	Drug_2

10004205|t|Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.
10004205	0	11	Ticlopidine	drug	Drug_0
10004205	134	142	ketamine	drug	Drug_1
10004205	164	176	itraconazole	drug	Drug_2
10004205	220	230	S-ketamine	drug	Drug_3
10004205	mechanism	Drug_0	Drug_1

10004206|t|The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.
10004206	13	24	norketamine	drug_n	Drug_0
10004206	39	47	ketamine	drug	Drug_1
10004206	94	105	ticlopidine	drug	Drug_2
10004206	125	137	itraconazole	drug	Drug_3

10004207|t|In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).
10004207	7	18	ticlopidine	drug	Drug_0
10004207	23	35	itraconazole	drug	Drug_1

10004208|t|The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.
10004208	40	50	S-ketamine	drug	Drug_0
10004208	91	102	ticlopidine	drug	Drug_1
10004208	advise	Drug_0	Drug_1

10004209|t|The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.
10004209	4	23	3-Deazaneplanocin A	drug_n	Drug_0
10004209	25	30	DZNep	drug_n	Drug_1

10004210|t|We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
10004210	195	200	DZNep	drug_n	Drug_0
10004210	102	109	ABT-737	drug_n	Drug_1
10004210	effect	Drug_0	Drug_1

10004211|t|In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis.
10004211	118	123	DZNep	drug_n	Drug_0
10004211	106	113	ABT-737	drug_n	Drug_1
10004211	effect	Drug_1	Drug_0

10004212|t|Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.
10004212	0	8	Implanon	brand	Drug_0
10004212	47	61	antiretroviral	group	Drug_1
10004212	effect	Drug_0	Drug_1

10004213|t|We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.
10004213	59	73	antiretroviral	group	Drug_0
10004213	138	146	Implanon	brand	Drug_1
10004213	effect	Drug_0	Drug_1

10004214|t|Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
10004214	0	14	Antidepressant	group	Drug_0
10004214	15	23	warfarin	drug	Drug_1

10004215|t|We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.
10004215	47	61	antidepressant	group	Drug_0
10004215	133	141	warfarin	drug	Drug_1

10004216|t|Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
10004216	0	8	Warfarin	drug	Drug_0
10004216	91	101	citalopram	drug	Drug_1
10004216	139	149	fluoxetine	drug	Drug_2
10004216	187	197	paroxetine	drug	Drug_3
10004216	235	248	amitriptyline	drug	Drug_4
10004216	effect	Drug_0	Drug_3
10004216	effect	Drug_0	Drug_2
10004216	effect	Drug_0	Drug_1
10004216	effect	Drug_0	Drug_4

10004217|t|Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).
10004217	5	16	mirtazapine	drug	Drug_0
10004217	57	65	warfarin	drug	Drug_1
10004217	effect	Drug_0	Drug_1

10004218|t|Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
10004218	0	8	Warfarin	drug	Drug_0
10004218	29	39	citalopram	drug	Drug_1
10004218	41	51	fluoxetine	drug	Drug_2
10004218	53	63	paroxetine	drug	Drug_3
10004218	65	78	amitriptyline	drug	Drug_4
10004218	83	94	mirtazapine	drug	Drug_5
10004218	effect	Drug_0	Drug_1
10004218	effect	Drug_0	Drug_4
10004218	effect	Drug_0	Drug_2
10004218	effect	Drug_0	Drug_5
10004218	effect	Drug_0	Drug_3

10004219|t|The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors.
10004219	94	114	1-aminobenzotriazole	drug_n	Drug_0
10004219	116	119	ABT	drug_n	Drug_1

10004220|t|ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.
10004220	0	3	ABT	drug_n	Drug_0
10004220	30	41	precocene I	drug_n	Drug_1
10004220	effect	Drug_0	Drug_1

10004221|t|Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.
10004221	67	78	precocene I	drug_n	Drug_0
10004221	104	119	tranylcypromine	drug	Drug_1

10004222|t|With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole.
10004222	71	74	ABT	drug_n	Drug_0
10004222	75	97	diethyldithiocarbamate	drug_n	Drug_1
10004222	98	113	tranylcypromine	drug	Drug_2
10004222	114	126	ketoconazole	drug	Drug_3

10004223|t|Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity.
10004223	0	11	Furafylline	drug_n	Drug_0
10004223	16	30	sulfaphenazole	drug_n	Drug_1
10004223	52	61	quinidine	drug	Drug_2
10004223	82	93	precocene I	drug_n	Drug_3
10004223	effect	Drug_2	Drug_3

10004224|t|To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).
10004224	145	169	adeno-associated virus-2	drug_n	Drug_0
10004224	171	175	AAV2	drug_n	Drug_1

10004225|t|AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase.
10004225	0	4	AAV2	drug_n	Drug_0
10004225	214	225	collagenase	drug_n	Drug_1
10004225	227	243	hyaluronan lyase	drug_n	Drug_2
10004225	245	259	heparinase III	drug_n	Drug_3
10004225	264	285	chondroitin ABC lyase	drug_n	Drug_4

10004226|t|The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.
10004226	16	30	heparinase III	drug_n	Drug_0
10004226	34	55	chondroitin ABC lyase	drug_n	Drug_1

10004227|t|Hyaluronan lyase had a limited effect and collagenase was ineffective.
10004227	0	16	Hyaluronan lyase	drug_n	Drug_0
10004227	42	53	collagenase	drug_n	Drug_1

10004228|t|Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction.
10004228	58	72	heparinase III	drug_n	Drug_0
10004228	77	98	chondroitin ABC lyase	drug_n	Drug_1

10004229|t|AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase.
10004229	0	4	AAV2	drug_n	Drug_0
10004229	66	80	heparinase III	drug_n	Drug_1
10004229	84	105	chondroitin ABC lyase	drug_n	Drug_2
10004229	effect	Drug_0	Drug_2
10004229	effect	Drug_0	Drug_1

10004230|t|Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
10004230	71	79	ketamine	drug	Drug_0
10004230	84	92	propofol	drug	Drug_1

10004231|t|We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.
10004231	95	103	ketamine	drug	Drug_0
10004231	124	132	propofol	drug	Drug_1

10004232|t|EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.
10004232	183	191	propofol	drug	Drug_0
10004232	161	169	ketamine	drug	Drug_1

10004233|t|Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.
10004233	51	59	ketamine	drug	Drug_0
10004233	156	164	propofol	drug	Drug_1
10004233	effect	Drug_0	Drug_1

10004234|t|Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer.
10004234	0	9	Tamoxifen	drug	Drug_0
10004234	14	33	estrogen antagonist	group	Drug_1

10004235|t|Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.
10004235	0	10	Paroxetine	drug	Drug_0
10004235	15	25	fluoxetine	drug	Drug_1
10004235	61	70	endoxifen	drug_n	Drug_2
10004235	mechanism	Drug_0	Drug_2
10004235	mechanism	Drug_1	Drug_2

10004236|t|It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine.
10004236	85	94	tamoxifen	drug	Drug_0
10004236	125	145	SSRI antidepressants	group	Drug_1
10004236	154	164	paroxetine	drug	Drug_2
10004236	169	179	fluoxetine	drug	Drug_3
10004236	advise	Drug_0	Drug_1
10004236	advise	Drug_0	Drug_2
10004236	advise	Drug_0	Drug_3

10004237|t|Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause.
10004237	35	54	antidepressant drug	group	Drug_0
10004237	68	83	antidepressants	group	Drug_1

10004238|t|If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.
10004238	24	38	antidepressant	group	Drug_0
10004238	95	104	tamoxifen	drug	Drug_1
10004238	110	121	anastrozole	drug	Drug_2
10004238	advise	Drug_0	Drug_1

10004239|t|Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
10004239	0	11	Amphetamine	drug	Drug_0
10004239	128	138	quinpirole	drug_n	Drug_1

10004240|t|The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures.
10004240	53	63	quinpirole	drug_n	Drug_0
10004240	88	99	amphetamine	drug	Drug_1

10004241|t|In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.
10004241	105	115	quinpirole	drug_n	Drug_0
10004241	144	155	amphetamine	drug	Drug_1
10004241	effect	Drug_0	Drug_1

10004242|t|Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole.
10004242	40	51	amphetamine	drug	Drug_0
10004242	136	146	quinpirole	drug_n	Drug_1

10004243|t|Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
10004243	106	116	quinpirole	drug_n	Drug_0
10004243	203	214	amphetamine	drug	Drug_1

10004244|t|In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
10004244	49	61	cyclosporine	drug	Drug_0
10004244	87	97	tacrolimus	drug	Drug_1

10004245|t|In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors.
10004245	33	45	cyclosporine	drug	Drug_0
10004245	50	60	tacrolimus	drug	Drug_1

10004246|t|Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).
10004246	27	36	midazolam	drug	Drug_0
10004246	181	193	cyclosporine	drug	Drug_1
10004246	236	246	tacrolimus	drug	Drug_2
10004246	mechanism	Drug_0	Drug_1

10004247|t|The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).
10004247	21	30	midazolam	drug	Drug_0
10004247	95	105	tacrolimus	drug	Drug_1
10004247	168	189	calcineurin inhibitor	group	Drug_2

10004248|t|This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.
10004248	228	240	cyclosporine	drug	Drug_0
10004248	149	159	tacrolimus	drug	Drug_1

10004249|t|Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
10004249	40	50	cinacalcet	drug	Drug_0
10004249	83	94	darbepoetin	drug	Drug_1

10004250|t|Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance.
10004250	75	89	erythropoietin	drug	Drug_0
10004250	91	94	EPO	drug	Drug_1

10004251|t|Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown.
10004251	23	33	cinacalcet	drug	Drug_0
10004251	118	129	darbepoetin	drug	Drug_1

10004252|t|The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy.
10004252	70	81	darbepoetin	drug	Drug_0
10004252	127	137	cinacalcet	drug	Drug_1

10004253|t|Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement.
10004253	20	30	cinacalcet	drug	Drug_0
10004253	64	75	darbepoetin	drug	Drug_1
10004253	effect	Drug_0	Drug_1

10004254|t|Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
10004254	15	24	celecoxib	drug	Drug_0
10004254	40	57	anti-cancer drugs	group	Drug_1
10004254	effect	Drug_0	Drug_1

10004255|t|This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents.
10004255	39	66	cyclooxygenase-2 inhibitors	group	Drug_0
10004255	120	143	chemotherapeutic agents	group	Drug_1

10004256|t|The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.
10004256	130	134	5-FU	drug	Drug_0
10004256	136	145	cisplatin	drug	Drug_1
10004256	147	158	doxorubicin	drug	Drug_2
10004256	163	172	etoposide	drug	Drug_3
10004256	175	184	celecoxib	drug	Drug_4

10004257|t|We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells.
10004257	136	145	celecoxib	drug	Drug_0
10004257	150	161	doxorubicin	drug	Drug_1
10004257	effect	Drug_0	Drug_1

10004258|t|These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers.
10004258	51	60	celecoxib	drug	Drug_0
10004258	121	132	doxorubicin	drug	Drug_1

10004259|t|[Interaction between clopidogrel and proton pump inhibitors].
10004259	21	32	clopidogrel	drug	Drug_0
10004259	37	59	proton pump inhibitors	group	Drug_1

10004260|t|The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years.
10004260	29	51	proton pump inhibitors	group	Drug_0
10004260	56	67	clopidogrel	drug	Drug_1

10004261|t|Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature.
10004261	46	68	proton pump inhibitors	group	Drug_0
10004261	119	130	clopidogrel	drug	Drug_1

10004262|t|Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
10004262	203	213	omeprazole	drug	Drug_0
10004262	34	45	clopidogrel	drug	Drug_1
10004262	mechanism	Drug_0	Drug_1

10004263|t|Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use.
10004263	0	12	Pantoprazole	drug	Drug_0
10004263	41	52	clopidogrel	drug	Drug_1
10004263	mechanism	Drug_0	Drug_1

10004264|t|The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies.
10004264	27	49	proton pump inhibitors	group	Drug_0
10004264	80	91	clopidogrel	drug	Drug_1

10004265|t|Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided.
10004265	50	61	clopidogrel	drug	Drug_0
10004265	89	99	omeprazole	drug	Drug_1
10004265	104	116	esomeprazole	drug	Drug_2
10004265	advise	Drug_0	Drug_2
10004265	advise	Drug_0	Drug_1

10004266|t|To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.
10004266	97	119	proton pump inhibitors	group	Drug_0
10004266	124	135	clopidogrel	drug	Drug_1

10004267|t|In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
10004267	21	32	minocycline	drug	Drug_0
10004267	47	57	fosfomycin	drug	Drug_1
10004267	87	98	methicillin	drug	Drug_2

10004268|t|This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA).
10004268	54	65	minocycline	drug	Drug_0
10004268	80	90	fosfomycin	drug	Drug_1
10004268	111	122	methicillin	drug	Drug_2

10004269|t|The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria.
10004269	31	42	minocycline	drug	Drug_0
10004269	47	57	fosfomycin	drug	Drug_1

10004270|t|The combination of minocycline and fosfomycin can be synergistic against MRSA.
10004270	19	30	minocycline	drug	Drug_0
10004270	35	45	fosfomycin	drug	Drug_1
10004270	effect	Drug_0	Drug_1

10004271|t|The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone.
10004271	85	98	levothyroxine	drug	Drug_0
10004271	148	158	simeticone	drug	Drug_1
10004271	int	Drug_0	Drug_1

10004272|t|Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine.
10004272	42	49	Infacol	brand	Drug_0
10004272	78	91	levothyroxine	drug	Drug_1

10004273|t|Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children.
10004273	20	29	thyroxine	drug	Drug_0
10004273	35	45	simeticone	drug	Drug_1

10004274|t|Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.
10004274	0	7	Calcium	drug	Drug_0
10004274	59	79	nonheme iron	drug	Drug_1
10004274	70	79	heme iron	drug	Drug_2

10004275|t|Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.
10004275	0	7	Calcium	drug	Drug_0
10004275	83	104	nonheme iron	drug	Drug_1
10004275	95	104	heme iron	drug	Drug_2
10004275	mechanism	Drug_0	Drug_1
10004275	mechanism	Drug_0	Drug_2

10004276|t|However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
10004276	123	130	calcium	drug	Drug_0
10004276	46	50	iron	drug	Drug_1
10004276	mechanism	Drug_0	Drug_1

10004277|t|Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal.
10004277	52	59	calcium	drug	Drug_0
10004277	77	98	nonheme iron	drug	Drug_1
10004277	89	98	heme iron	drug	Drug_2

10004278|t|We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate).
10004278	28	35	calcium	drug	Drug_0
10004278	88	100	nonheme iron	drug	Drug_1
10004278	105	120	ferrous sulfate	drug	Drug_2

10004279|t|We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)].
10004279	33	40	calcium	drug	Drug_0
10004279	92	101	heme iron	drug	Drug_1

10004280|t|Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach.
10004280	0	7	Calcium	drug	Drug_0
10004280	28	44	calcium chloride	drug	Drug_1
10004280	64	72	minerals	group	Drug_2

10004281|t|Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.
10004281	0	7	Calcium	drug	Drug_0
10004281	35	47	nonheme iron	drug	Drug_1
10004281	mechanism	Drug_0	Drug_1

10004282|t|A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%.
10004282	2	9	calcium	drug	Drug_0
10004282	55	64	heme iron	drug	Drug_1
10004282	mechanism	Drug_0	Drug_1

10004283|t|In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron.
10004283	53	60	calcium	drug	Drug_0
10004283	117	161	nonheme iron	drug	Drug_1
10004283	142	161	heme iron	drug	Drug_2
10004283	mechanism	Drug_0	Drug_2
10004283	mechanism	Drug_0	Drug_1

10004284|t|Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
10004284	32	41	sunitinib	drug	Drug_0
10004284	46	55	docetaxel	drug	Drug_1
10004284	int	Drug_0	Drug_1

10004285|t|This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.
10004285	131	140	sunitinib	drug	Drug_0
10004285	145	154	docetaxel	drug	Drug_1

10004286|t|NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations.
10004286	84	93	sunitinib	drug	Drug_0
10004286	97	106	docetaxel	drug	Drug_1

10004287|t|Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase.
10004287	0	9	Sunitinib	drug	Drug_0
10004287	118	127	docetaxel	drug	Drug_1

10004288|t|Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.
10004288	37	46	sunitinib	drug	Drug_0
10004288	51	60	docetaxel	drug	Drug_1
10004288	effect	Drug_0	Drug_1

10004289|t|When cells were exposed to docetaxel followed by sunitinib, synergism was observed.
10004289	27	36	docetaxel	drug	Drug_0
10004289	49	58	sunitinib	drug	Drug_1
10004289	effect	Drug_0	Drug_1

10004290|t|The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib.
10004290	102	111	docetaxel	drug	Drug_0
10004290	179	188	sunitinib	drug	Drug_1
10004290	effect	Drug_0	Drug_1

10004291|t|Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
10004291	213	222	sunitinib	drug	Drug_0
10004291	235	244	docetaxel	drug	Drug_1
10004291	effect	Drug_1	Drug_0

10004292|t|Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
10004292	31	43	piperacillin	drug	Drug_0
10004292	48	61	methylglyoxal	drug_n	Drug_1

10004293|t|Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.
10004293	84	96	piperacillin	drug	Drug_0
10004293	98	111	carbenicillin	drug	Drug_1
10004293	113	121	amikacin	drug	Drug_2
10004293	126	139	ciprofloxacin	drug	Drug_3

10004294|t|Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects.
10004294	70	83	methylglyoxal	drug_n	Drug_0
10004294	88	100	piperacillin	drug	Drug_1
10004294	effect	Drug_0	Drug_1

10004295|t|Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.
10004295	30	43	methylglyoxal	drug_n	Drug_0
10004295	62	75	carbenicillin	drug	Drug_1
10004295	80	88	amikacin	drug	Drug_2
10004295	effect	Drug_0	Drug_1
10004295	effect	Drug_0	Drug_2

10004296|t|Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.
10004296	21	39	acetyl-l-carnitine	drug	Drug_0
10004296	45	62	alpha lipoic acid	drug_n	Drug_1

10004297|t|(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.
10004297	5	23	acetyl-l-carnitine	drug	Drug_0
10004297	115	132	alpha-lipoic acid	drug	Drug_1
10004297	effect	Drug_0	Drug_1

10004298|t|[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
10004298	14	23	hemantane	drug_n	Drug_0
10004298	28	39	doxycycline	drug	Drug_1

10004299|t|The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)
10004299	15	37	anti-parkinsonian drug	group	Drug_0
10004299	38	47	hemantane	drug_n	Drug_1
10004299	49	79	(2-adamantyl)hexamethylenimine	drug_n	Drug_2

10004300|t|and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.)
10004300	7	22	antibiotic drug	group	Drug_0
10004300	23	34	doxycycline	drug	Drug_1
10004300	85	129	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	Drug_2
10004300	131	135	MPTP	drug_n	Drug_3

10004301|t|Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity.
10004301	24	33	hemantane	drug_n	Drug_0
10004301	37	48	doxycycline	drug	Drug_1
10004301	effect	Drug_0	Drug_1

10004302|t|The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
10004302	25	34	dasatinib	drug	Drug_0
10004302	44	54	paclitaxel	drug	Drug_1
10004302	effect	Drug_0	Drug_1

10004303|t|The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts.
10004303	14	23	dasatinib	drug	Drug_0
10004303	65	75	paclitaxel	drug	Drug_1

10004304|t|The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.
10004304	64	73	dasatinib	drug	Drug_0
10004304	78	88	paclitaxel	drug	Drug_1

10004305|t|HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone.
10004305	23	32	dasatinib	drug	Drug_0
10004305	38	48	paclitaxel	drug	Drug_1
10004305	effect	Drug_0	Drug_1

10004306|t|Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
10004306	171	180	dasatinib	drug	Drug_0
10004306	197	207	paclitaxel	drug	Drug_1
10004306	effect	Drug_0	Drug_1

10004307|t|dasatinib + paclitaxel vs.
10004307	0	9	dasatinib	drug	Drug_0
10004307	12	22	paclitaxel	drug	Drug_1

10004308|t|The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).
10004308	43	52	dasatinib	drug	Drug_0
10004308	58	68	paclitaxel	drug	Drug_1

10004309|t|Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.
10004309	82	91	dasatinib	drug	Drug_0
10004309	133	143	paclitaxel	drug	Drug_1
10004309	effect	Drug_0	Drug_1

10004310|t|Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
10004310	63	72	dasatinib	drug	Drug_0
10004310	82	92	paclitaxel	drug	Drug_1
10004310	effect	Drug_0	Drug_1

10004311|t|Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
10004311	99	111	lenalidomide	drug	Drug_0
10004311	112	119	CCI-779	drug	Drug_1

10004312|t|The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.
10004312	31	43	lenalidomide	drug	Drug_0
10004312	68	75	CCI-779	drug	Drug_1
10004312	effect	Drug_0	Drug_1

10004313|t|Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
10004313	77	101	avian influenza vaccines	group	Drug_0
10004313	128	158	ginseng stem-and-leaf saponins	drug_n	Drug_1

10004314|t|The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines.
10004314	81	111	ginseng stem-and-leaf saponins	drug_n	Drug_0
10004314	113	117	GSLS	drug_n	Drug_1
10004314	166	196	inactivated ND vaccines	drug	Drug_2
10004314	166	196	inactivated AI vaccines	drug	Drug_3

10004315|t|In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated.
10004315	40	44	GSLS	drug_n	Drug_0
10004315	145	167	inactivated ND vaccine	drug	Drug_1

10004316|t|In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed.
10004316	37	41	GSLS	drug_n	Drug_0
10004316	87	110	inactivated AI vaccines	drug	Drug_1
10004316	effect	Drug_0	Drug_1

10004317|t|Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
10004317	15	26	dacarbazine	drug	Drug_0
10004317	31	37	imexon	drug_n	Drug_1

10004318|t|We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.
10004318	67	78	dacarbazine	drug	Drug_0
10004318	80	84	DTIC	drug	Drug_1
10004318	107	113	imexon	drug	Drug_2

10004319|t|The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).
10004319	14	18	DTIC	drug	Drug_0
10004319	23	29	imexon	drug	Drug_1

10004320|t|There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC.
10004320	69	75	imexon	drug	Drug_0
10004320	84	88	DTIC	drug	Drug_1

10004321|t|Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.
10004321	0	6	Imexon	drug	Drug_0
10004321	11	22	dacarbazine	drug	Drug_1
10004321	effect	Drug_0	Drug_1

10004322|t|Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
10004322	0	9	Lapatinib	drug	Drug_0
10004322	19	28	herceptin	brand	Drug_1
10004322	effect	Drug_0	Drug_1

10004323|t|Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
10004323	133	142	lapatinib	drug	Drug_0
10004323	167	176	Herceptin	brand	Drug_1
10004323	effect	Drug_0	Drug_1

10004324|t|We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC).
10004324	17	26	lapatinib	drug	Drug_0
10004324	111	120	Herceptin	brand	Drug_1

10004325|t|In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC.
10004325	22	31	lapatinib	drug	Drug_0
10004325	149	158	Herceptin	brand	Drug_1
10004325	effect	Drug_0	Drug_1

10004326|t|Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.
10004326	56	65	Herceptin	brand	Drug_0
10004326	86	95	lapatinib	drug	Drug_1
10004326	effect	Drug_0	Drug_1

10004327|t|Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
10004327	0	9	Lapatinib	drug	Drug_0
10004327	68	77	Herceptin	brand	Drug_1

10004328|t|The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197).
10004328	180	207	cross-reacting material 197	drug_n	Drug_0
10004328	209	215	CRM197	drug_n	Drug_1

10004329|t|We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent.
10004329	88	94	CRM197	drug_n	Drug_0
10004329	139	155	anticancer agent	group	Drug_1

10004330|t|CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line.
10004330	62	68	CRM197	drug_n	Drug_0
10004330	74	85	doxorubicin	drug	Drug_1
10004330	effect	Drug_0	Drug_1

10004331|t|Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
10004331	0	9	Ephedrine	drug	Drug_0
10004331	49	64	dexmedetomidine	drug	Drug_1
10004331	effect	Drug_0	Drug_1

10004332|t|The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.
10004332	75	84	ephedrine	drug	Drug_0
10004332	103	118	dexmedetomidine	drug	Drug_1

10004333|t|saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
10004333	93	102	ephedrine	drug	Drug_0
10004333	118	133	dexmedetomidine	drug	Drug_1

10004334|t|In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.
10004334	205	220	dexmedetomidine	drug	Drug_0
10004334	96	105	ephedrine	drug	Drug_1
10004334	effect	Drug_0	Drug_1

10004335|t|At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine.
10004335	53	68	dexmedetomidine	drug	Drug_0
10004335	89	98	ephedrine	drug	Drug_1
10004335	effect	Drug_0	Drug_1

10004336|t|We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
10004336	183	198	dexmedetomidine	drug	Drug_0
10004336	70	79	ephedrine	drug	Drug_1
10004336	205	214	analgesic	group	Drug_2
10004336	effect	Drug_0	Drug_1

10004337|t|[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]
10004337	31	41	amlodipine	drug	Drug_0
10004337	42	51	valsartan	drug	Drug_1

10004338|t|Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.
10004338	35	45	amlodipine	drug	Drug_0
10004338	46	55	valsartan	drug	Drug_1

10004339|t|All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43).
10004339	106	116	amlodipine	drug	Drug_0
10004339	117	126	valsartan	drug	Drug_1

10004340|t|Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%).
10004340	56	66	amlodipine	drug	Drug_0
10004340	67	76	valsartan	drug	Drug_1

10004341|t|But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
10004341	33	43	amlodipine	drug	Drug_0
10004341	44	53	valsartan	drug	Drug_1
10004341	247	269	antihypertensive drugs	group	Drug_2
10004341	effect	Drug_0	Drug_1

10004342|t|We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.
10004342	75	85	amlodipine	drug	Drug_0
10004342	86	95	valsartan	drug	Drug_1
10004342	192	214	antihypertensive drugs	group	Drug_2
10004342	effect	Drug_0	Drug_1

10004343|t|Ticagrelor (Brilinta)--better than clopidogrel (Plavix)
10004343	0	10	Ticagrelor	drug	Drug_0
10004343	12	20	Brilinta	brand	Drug_1
10004343	35	46	clopidogrel	drug	Drug_2
10004343	48	54	Plavix	brand	Drug_3

10004344|t|The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
10004344	21	31	ticagrelor	drug	Drug_0
10004344	33	41	Brilinta	brand	Drug_1
10004344	64	81	antiplatelet drug	group	Drug_2
10004344	105	112	aspirin	brand	Drug_3
10004344	effect	Drug_0	Drug_3
10004344	effect	Drug_1	Drug_3

10004345|t|It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use.
10004345	21	32	clopidogrel	drug	Drug_0
10004345	34	40	Plavix	brand	Drug_1
10004345	46	55	prasugrel	drug	Drug_2
10004345	57	64	Effient	brand	Drug_3

10004346|t|Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.
10004346	13	21	piperine	drug_n	Drug_0
10004346	25	34	ibuprofen	drug	Drug_1

10004347|t|In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.
10004347	21	29	piperine	drug_n	Drug_0
10004347	210	219	ibuprofen	drug	Drug_1
10004347	140	151	acetic acid	drug	Drug_2
10004347	effect	Drug_0	Drug_1

10004348|t|Ibuprofen plasma concentration was also increased when it was administered with piperine.
10004348	0	9	Ibuprofen	drug	Drug_0
10004348	80	88	piperine	drug_n	Drug_1
10004348	mechanism	Drug_0	Drug_1

10004349|t|The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.
10004349	141	150	ibuprofen	drug	Drug_0
10004349	77	85	piperine	drug_n	Drug_1
10004349	mechanism	Drug_0	Drug_1

10004350|t|From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.
10004350	41	49	piperine	drug_n	Drug_0
10004350	90	99	ibuprofen	drug	Drug_1
10004350	effect	Drug_0	Drug_1

10004351|t|Drugs that may decrease the effects of this medicine include: Rifampin barbiturates phenytoin (Dilantin) carbamazepine (Tegretol) Estrogens may decrease the effects of benzodiazepines (lorezepam oxezepam temezepam).
10004351	62	70	Rifampin	drug	Drug_0
10004351	71	83	barbiturates	group	Drug_1
10004351	84	93	phenytoin	drug	Drug_2
10004351	95	103	Dilantin	brand	Drug_3
10004351	105	118	carbamazepine	drug	Drug_4
10004351	120	128	Tegretol	brand	Drug_5
10004351	130	139	Estrogens	group	Drug_6
10004351	168	183	benzodiazepines	group	Drug_7
10004351	185	194	lorezepam	drug	Drug_8
10004351	195	203	oxezepam	drug	Drug_9
10004351	204	213	temezepam	drug	Drug_10

10004352|t|Consult your doctor or pharmacist if you are taking any of the following: seizure medications antibiotics warfarin medications to help you sleep
10004352	94	105	antibiotics	group	Drug_0
10004352	106	114	warfarin	drug	Drug_1

10004353|t|Interactions for Dronabinol:  In studies involving patients with AIDS and/or cancer, MARINOL (Dronabinol) Capsules has been co-administered with a variety of medications (e.g., cytotoxic agents, anti-infective agents, sedatives, or opioid analgesics) without resulting in any clinically significant drug/drug interactions.
10004353	94	104	Dronabinol	drug	Drug_0
10004353	85	92	MARINOL	brand	Drug_1
10004353	195	209	anti-infective	drug	Drug_2
10004353	218	227	sedatives	group	Drug_3
10004353	232	249	opioid analgesics	group	Drug_4

10004354|t|Although no drug/drug interactions were discovered during the clinical trials of MARINOL Capsules, cannabinoids may interact with other medications through both metabolic and pharmacodynamic mechanisms.
10004354	81	88	MARINOL	brand	Drug_0
10004354	99	111	cannabinoids	group	Drug_1

10004355|t|Concomitant Therapy  Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents such as anthralin, coal tar or coal tar derivatives, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal and methyl orange.
10004355	191	200	anthralin	drug	Drug_0
10004355	202	210	coal tar	drug_n	Drug_1
10004355	214	234	coal tar derivatives	drug_n	Drug_2
10004355	236	248	griseofulvin	drug	Drug_3
10004355	250	264	phenothiazines	group	Drug_4
10004355	266	280	nalidixic acid	drug	Drug_5
10004355	282	309	halogenated salicylanilides	group	Drug_6
10004355	334	346	sulfonamides	drug	Drug_7
10004355	348	361	tetracyclines	group	Drug_8
10004355	363	372	thiazides	group	Drug_9
10004355	416	430	methylene blue	drug_n	Drug_10
10004355	432	446	toluidine blue	drug_n	Drug_11

10004356|t|There have been no studies of the interaction of methyl aminolevulinate cream with any other drugs, including local anesthetics.
10004356	49	71	methyl aminolevulinate	drug	Drug_0
10004356	116	127	anesthetics	group	Drug_1

10004357|t|No untoward clinical manifestations have been observed in limited experience with patients in whom PRIMACOR was used concurrently with the following drugs: digitalis glycosides;
10004357	99	107	PRIMACOR	brand	Drug_0
10004357	156	176	digitalis glycosides	group	Drug_1

10004358|t|lidocaine, quinidine;
10004358	0	9	lidocaine	drug	Drug_0
10004358	11	20	quinidine	drug	Drug_1

10004359|t|hydralazine, prazosin;
10004359	0	11	hydralazine	drug	Drug_0
10004359	13	21	prazosin	drug	Drug_1

10004360|t|isosorbide dinitrate, nitroglycerin;
10004360	0	20	isosorbide dinitrate	drug	Drug_0
10004360	22	35	nitroglycerin	drug	Drug_1

10004361|t|chlorthalidone, furosemide, hydrochlorothiazide, spironolactone;
10004361	0	14	chlorthalidone	drug	Drug_0
10004361	16	26	furosemide	drug	Drug_1
10004361	28	47	hydrochlorothiazide	drug	Drug_2
10004361	49	63	spironolactone	drug	Drug_3

10004362|t|heparin, warfarin, diazepam, insulin;
10004362	0	7	heparin	drug	Drug_0
10004362	9	17	warfarin	drug	Drug_1
10004362	19	27	diazepam	drug	Drug_2
10004362	29	36	insulin	drug	Drug_3

10004363|t|Chemical Interactions There is an immediate chemical interaction which is evidenced by the formation of a precipitate when furosemide is injected into an intravenous line of an infusion of PRIMACOR.
10004363	123	133	furosemide	drug	Drug_0
10004363	189	197	PRIMACOR	brand	Drug_1

10004364|t|Therefore, furosemide should not be administered in intravenous lines containing PRIMACOR.
10004364	11	21	furosemide	drug	Drug_0
10004364	81	89	PRIMACOR	brand	Drug_1

10004365|t|Misoprostol has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis.
10004365	0	11	Misoprostol	drug	Drug_0
10004365	75	82	aspirin	brand	Drug_1

10004366|t|Misoprostol does not exert clinically significant effects on the absorption, blood levels, and anti-platelet effects of therapeutic doses of aspirin.
10004366	0	11	Misoprostol	drug	Drug_0
10004366	141	148	aspirin	brand	Drug_1

10004367|t|Misoprostol has no clinically significant effect on the kinetics of diclofenac or ibuprofen.
10004367	0	11	Misoprostol	drug	Drug_0
10004367	68	78	diclofenac	drug	Drug_1
10004367	82	91	ibuprofen	drug	Drug_2

10004368|t|Following concurrent administration of NOVANTRONE    with corticosteroids, no evidence of drug interactions has been observed.
10004368	39	49	NOVANTRONE	brand	Drug_0
10004368	58	73	corticosteroids	group	Drug_1

10004369|t|May interact with cimetidine, digoxin, medicines to control heart rhythm, sevelamer, and theophylline.
10004369	18	28	cimetidine	drug	Drug_0
10004369	30	37	digoxin	drug	Drug_1
10004369	74	83	sevelamer	drug	Drug_2
10004369	89	101	theophylline	drug	Drug_3

10004370|t|No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin or warfarin in healthy volunteers.
10004370	67	87	olmesartan medoxomil	drug	Drug_0
10004370	113	120	digoxin	drug	Drug_1
10004370	124	132	warfarin	drug	Drug_2

10004371|t|The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)3/Mg(OH)2].
10004371	23	33	olmesartan	drug	Drug_0
10004371	92	100	antacids	group	Drug_1

10004372|t|Severe hypertension has been reported when oxytocin was given three to four hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia.
10004372	43	51	oxytocin	drug	Drug_0
10004372	125	140	vasoconstrictor	group	Drug_1

10004373|t|In Trial 1, the proportions of patients in the placebo and Synagis    groups who received routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents.
10004373	59	66	Synagis	brand	Drug_0
10004373	108	116	vaccines	group	Drug_1
10004373	118	135	influenza vaccine	group	Drug_2
10004373	137	152	bronchodilators	group	Drug_3
10004373	156	171	corticosteroids	group	Drug_4

10004374|t|A study in healthy volunteers involving single-dose IV palonosetron (0.75 mg) and steady state oral metoclopramide (10 mg four times daily) demonstrated no significant pharmacokinetic interaction.
10004374	55	67	palonosetron	drug	Drug_0
10004374	100	114	metoclopramide	drug	Drug_1

10004375|t|In controlled clinical trials, ALOXI injection has been safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics and anticholinergic agents.
10004375	31	36	ALOXI	brand	Drug_0
10004375	81	96	corticosteroids	group	Drug_1
10004375	98	108	analgesics	group	Drug_2
10004375	110	121	antiemetics	group	Drug_3
10004375	122	135	antinauseants	group	Drug_4
10004375	137	151	antispasmodics	group	Drug_5
10004375	156	178	anticholinergic agents	group	Drug_6

10004376|t|Palonosetron did not inhibit the antitumor activity of the five chemotherapeutic agents tested (cisplatin, cyclophosphamide, cytarabine, doxorubicin and mitomycin C) in murine tumor models.
10004376	0	12	Palonosetron	drug	Drug_0
10004376	64	87	chemotherapeutic agents	group	Drug_1
10004376	96	105	cisplatin	drug	Drug_2
10004376	107	123	cyclophosphamide	drug	Drug_3
10004376	125	135	cytarabine	drug	Drug_4
10004376	137	148	doxorubicin	drug	Drug_5
10004376	153	164	mitomycin C	drug	Drug_6

10004377|t|Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of Aredia.
10004377	32	45	loop diuretic	group	Drug_0
10004377	94	100	Aredia	brand	Drug_1

10004378|t|Not compatible with CNS depressants or trycyclic antidepressants
10004378	20	35	CNS depressants	group	Drug_0
10004378	39	64	trycyclic antidepressants	group	Drug_1

10004379|t|Two early clinical studies conducted in patients who received Macugen alone and in combination with PDT revealed no apparent difference in the plasma pharmacokinetics of pegaptanib.
10004379	62	69	Macugen	brand	Drug_0
10004379	170	180	pegaptanib	drug	Drug_1

10004380|t|Interactions with cylcopholsphamide, fludarabine and vidarabine
10004380	37	48	fludarabine	drug	Drug_0
10004380	53	63	vidarabine	drug	Drug_1

10004381|t|Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.
10004381	32	44	erythromycin	drug	Drug_0
10004381	46	58	itraconazole	drug	Drug_1
10004381	60	72	ketoconazole	drug	Drug_2
10004381	74	85	fluconazole	drug	Drug_3
10004381	87	111	calcium channel blockers	group	Drug_4
10004381	116	126	cimetidine	drug	Drug_5

10004382|t|- Antacids - Diarrhea medicine containing kaolin or attapulgite - Ketoconazole - Central nervous system (CNS) depressants - Other anticholinergics - Tricyclic antidepressants (e.g., Elavil, Asendin, Anafranil, Pertofrane, Sinequan, Tofranil, Aventyl, Surmontil) - Potassium chloride (e.g., Kay Ciel)
10004382	2	10	Antacids	group	Drug_0
10004382	42	48	kaolin	drug	Drug_1
10004382	52	63	attapulgite	drug	Drug_2
10004382	66	78	Ketoconazole	drug	Drug_3
10004382	81	121	Central nervous system (CNS) depressants	group	Drug_4
10004382	130	146	anticholinergics	group	Drug_5
10004382	149	174	Tricyclic antidepressants	group	Drug_6
10004382	182	188	Elavil	brand	Drug_7
10004382	190	197	Asendin	brand	Drug_8
10004382	199	208	Anafranil	brand	Drug_9
10004382	210	220	Pertofrane	brand	Drug_10
10004382	222	230	Sinequan	brand	Drug_11
10004382	232	240	Tofranil	brand	Drug_12
10004382	242	249	Aventyl	brand	Drug_13
10004382	251	260	Surmontil	brand	Drug_14
10004382	264	282	Potassium chloride	drug	Drug_15
10004382	290	298	Kay Ciel	brand	Drug_16

10004383|t|However, it is possible that concomitant use of other photosensitizing agents (e.g., tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemia agents, thiazide diuretics, and griseofulvin) could increase the photosensitivity reaction.
10004383	54	77	photosensitizing agents	group	Drug_0
10004383	85	98	tetracyclines	group	Drug_1
10004383	100	112	sulfonamides	group	Drug_2
10004383	114	128	phenothiazines	group	Drug_3
10004383	130	142	sulfonylurea	group	Drug_4
10004383	164	182	thiazide diuretics	group	Drug_5
10004383	188	200	griseofulvin	drug	Drug_6

10004384|t|Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sufloxide, b-carotene, ethanol, formate and mannitol would be expected to decrease PDT activity.
10004384	74	92	dimethyl sufloxide	drug_n	Drug_0
10004384	94	104	b-carotene	drug	Drug_1
10004384	106	113	ethanol	drug	Drug_2
10004384	115	122	formate	drug_n	Drug_3
10004384	127	135	mannitol	drug	Drug_4

10004385|t|Preclinical data also suggest that tissue ischemia, allopurinol, calcium channel blockers and some prostaglandin synthesis inhibitors could interfere with PHOTOFRIN    PDT.
10004385	52	63	allopurinol	drug	Drug_0
10004385	65	89	calcium channel blockers	group	Drug_1

10004386|t|May increase the effect of oral blood thinners, for example warfarin (Coumadin).
10004386	32	46	blood thinners	group	Drug_0
10004386	60	68	warfarin	drug	Drug_1
10004386	70	78	Coumadin	brand	Drug_2

10004387|t|Alcohol (this combination may make you very sick) and primaquine
10004387	0	7	Alcohol	drug	Drug_0
10004387	54	64	primaquine	drug	Drug_1

10004388|t|LUCENTIS intravitreal injection has been used adjunctively with verteporfin photodynamic therapy (PDT).
10004388	0	8	LUCENTIS	brand	Drug_0
10004388	64	75	verteporfin	drug	Drug_1

10004389|t|in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (   2 days) after verteporfin PDT.
10004389	45	53	LUCENTIS	brand	Drug_0
10004389	96	107	verteporfin	drug	Drug_1

10004390|t|In animals the duration of muscle paralysis from succinylcholine is not prolonged by remifentanil.
10004390	49	64	succinylcholine	drug	Drug_0
10004390	85	97	remifentanil	drug	Drug_1

10004391|t|Remifentanil clearance is not altered by concomitant administration of thiopental, isoflurane, propofol, or temazepam during anesthesia.
10004391	0	12	Remifentanil	drug	Drug_0
10004391	71	81	thiopental	drug	Drug_1
10004391	83	93	isoflurane	drug	Drug_2
10004391	95	103	propofol	drug	Drug_3
10004391	108	117	temazepam	drug	Drug_4

10004392|t|In vitro studies with atracurium, mivacurium, esmolol, echothiophate, neostigmine, physostigmine, and midazolam revealed no inhibition of remifentanil hydrolysis in whole human blood by these drugs.
10004392	22	32	atracurium	drug	Drug_0
10004392	34	44	mivacurium	drug	Drug_1
10004392	46	53	esmolol	drug	Drug_2
10004392	55	68	echothiophate	drug	Drug_3
10004392	70	81	neostigmine	drug	Drug_4
10004392	83	96	physostigmine	drug	Drug_5
10004392	102	111	midazolam	drug	Drug_6
10004392	138	150	remifentanil	drug	Drug_7

10004393|t|Clinical studies of interactions of VIRAZOLE with other drugs commonly used to treat infants with RSV infections, such as digoxin, bronchodilators, other antiviral agents, antibiotics, or anti-metabolites have not been conducted.
10004393	36	44	VIRAZOLE	brand	Drug_0
10004393	122	129	digoxin	drug	Drug_1
10004393	131	146	bronchodilators	group	Drug_2
10004393	154	170	antiviral agents	group	Drug_3
10004393	172	183	antibiotics	group	Drug_4
10004393	188	204	anti-metabolites	group	Drug_5

10004394|t|Drug-Drug Interactions Although in vitro studies demonstrated the potential of rifaximin to interact with cytochrome P450 3A4 (CYP3A4), a clinical drug-drug interaction study demonstrated that rifaximin did not significantly affect the pharmacokinetics of midazolam either presystemically or systemically.
10004394	193	202	rifaximin	drug	Drug_0
10004394	256	265	midazolam	drug	Drug_1

10004395|t|An additional clinical drug-drug interaction study showed no effect of rifaximin on the presystemic metabolism of an oral contraceptive containing ethinyl estradiol and norgestimate.
10004395	71	80	rifaximin	drug	Drug_0
10004395	122	135	contraceptive	group	Drug_1
10004395	147	164	ethinyl estradiol	drug	Drug_2
10004395	169	181	norgestimate	drug	Drug_3

10004396|t|Heparin should not be included in the same syringe as Sodium Tetradecyl Sulfate, since the two are incompatible.
10004396	0	7	Heparin	drug	Drug_0
10004396	54	79	Sodium Tetradecyl Sulfate	drug	Drug_1

10004397|t|Digoxin: Sparfloxacin has no effect on the pharmacokinetics of digoxin.
10004397	63	70	digoxin	drug	Drug_0
10004397	9	21	Sparfloxacin	drug	Drug_1

10004398|t|Methylxanthines: Sparfloxacin does not increase plasma theophylline concentrations.
10004398	0	15	Methylxanthines	group	Drug_0
10004398	17	29	Sparfloxacin	drug	Drug_1
10004398	55	67	theophylline	drug	Drug_2

10004399|t|Since there is no interaction with theophylline, interaction with other methylxanthines such as caffeine is unlikely.
10004399	35	47	theophylline	drug	Drug_0
10004399	72	87	methylxanthines	group	Drug_1
10004399	96	104	caffeine	drug	Drug_2

10004400|t|Warfarin: Sparfloxacin does not increase the anti-coagulant effect of warfarin.
10004400	70	78	warfarin	drug	Drug_0
10004400	10	22	Sparfloxacin	drug	Drug_1

10004401|t|Cimetidine: Cimetidine does not affect the pharmacokinetics of sparfloxacin.
10004401	12	22	Cimetidine	drug	Drug_0
10004401	63	75	sparfloxacin	drug	Drug_1

10004402|t|The oral bioavailability of sparfloxacin is not reduced when the aluminum-magnesium suspension is administered 4 hours following sparfloxacin administration.
10004402	28	40	sparfloxacin	drug	Drug_0
10004402	65	73	aluminum	drug	Drug_1
10004402	74	83	magnesium	drug	Drug_2

10004403|t|Zinc/iron salts: Absorption of quinolones is reduced significantly by these preparations.
10004403	0	4	Zinc	drug	Drug_0
10004403	5	9	iron	drug	Drug_1
10004403	31	41	quinolones	group	Drug_2

10004404|t|Probenecid: Probenecid does not alter the pharmacokinetics of sparfloxacin.
10004404	12	22	Probenecid	drug	Drug_0
10004404	62	74	sparfloxacin	drug	Drug_1

10004405|t|This medicine is generally safe with other medications, but patient should consult doctor or pharmacist if patient is taking a blood thinner (anticoagulant), cyclosporin, phenytoin, or methotrexate.
10004405	142	155	anticoagulant	group	Drug_0
10004405	158	169	cyclosporin	drug	Drug_1
10004405	171	180	phenytoin	drug	Drug_2
10004405	185	197	methotrexate	drug	Drug_3

10004406|t|Some examples of such drugs are erythromycin, itraconazole, ketoconazole, fluconazole, calcium channel blockers and cimetidine.
10004406	32	44	erythromycin	drug	Drug_0
10004406	46	58	itraconazole	drug	Drug_1
10004406	60	72	ketoconazole	drug	Drug_2
10004406	74	85	fluconazole	drug	Drug_3
10004406	87	111	calcium channel blockers	group	Drug_4
10004406	116	126	cimetidine	drug	Drug_5

10004407|t|The pharmacokinetic profile of temazepam does not appear to be altered by orally administered cimetidine dosed according to labeling.
10004407	31	40	temazepam	drug	Drug_0
10004407	94	104	cimetidine	drug	Drug_1

10004408|t|TERAZOL 7 Vaginal Cream 0.4% and TERAZOL 3 Vaginal Suppositories 80 mg The therapeutic effect of these products is not affected by oral contraceptive usage.
10004408	33	40	TERAZOL	brand	Drug_0
10004408	136	149	contraceptive	group	Drug_1

10004409|t|TERAZOL 3 Vaginal Cream 0.8% The levels of estradiol (E2) and progesterone did not differ significantly when 0.8% terconazole vaginal cream was administered to healthy female volunteers established on a low dose oral contraceptive.
10004409	0	7	TERAZOL	brand	Drug_0
10004409	43	52	estradiol	drug	Drug_1
10004409	62	74	progesterone	drug	Drug_2
10004409	114	125	terconazole	drug	Drug_3
10004409	217	230	contraceptive	group	Drug_4

10004410|t|Interactions  Interaction may occur with Antacids, Calcium supplements, Cholestyramine, Choline and magnesium salicylates, Colestipol, Iron-containing drugs, Laxatives, Magnesium salicylate: these drugs may decrease the potency of tetracyclines.
10004410	41	49	Antacids	group	Drug_0
10004410	51	58	Calcium	drug	Drug_1
10004410	72	86	Cholestyramine	drug	Drug_2
10004410	88	120	Choline salicylate	drug	Drug_3
10004410	169	189	Magnesium salicylate	drug	Drug_4
10004410	123	133	Colestipol	drug	Drug_5
10004410	135	139	Iron	drug	Drug_6
10004410	158	167	Laxatives	group	Drug_7
10004410	231	244	tetracyclines	group	Drug_8

10004411|t|Oral contraceptives containing estrogen: tetracyclines may decrease the contraceptive effect and increase the chance of unwanted pregnancy.
10004411	5	19	contraceptives	group	Drug_0
10004411	31	39	estrogen	drug	Drug_1
10004411	41	54	tetracyclines	group	Drug_2

10004412|t|- Decreased absorption of colestipol, cholestyramine, mineral oil, and sucralfate.
10004412	26	36	colestipol	drug	Drug_0
10004412	38	52	cholestyramine	drug	Drug_1
10004412	54	65	mineral oil	drug	Drug_2
10004412	71	81	sucralfate	drug	Drug_3

10004413|t|Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
10004413	37	52	fenofibric acid	drug	Drug_0
10004413	75	86	fenofibrate	drug	Drug_1

10004414|t|Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety.
10004414	0	11	Fenofibrate	drug	Drug_0
10004414	70	85	fenofibric acid	drug_n	Drug_1

10004415|t|A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate.
10004415	33	48	fenofibric acid	drug	Drug_0
10004415	85	96	fenofibrate	drug	Drug_1

10004416|t|Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid.
10004416	248	263	fenofibric acid	drug	Drug_0
10004416	98	109	fenofibrate	drug	Drug_1

10004417|t|In study 1 (fasted), during each study period, volunteers received a single 105-mg dose of fenofibric acid or single 145-mg dose of fenofibrate (depending on their randomization scheme) after an overnight fast (a minimum fast of 10 hours).
10004417	91	106	fenofibric acid	drug	Drug_0
10004417	132	143	fenofibrate	drug	Drug_1

10004418|t|The criterion for a lack of difference between products was a 90% CI between 0.80 and 1.25 for the fenofibric acid:fenofibrate ratios for AUC(0-t), AUC(0-   ), and C(max.)
10004418	99	114	fenofibric acid	drug	Drug_0
10004418	115	126	fenofibrate	drug	Drug_1

10004419|t|The 90% CIs about the ratio of the fenofibric acid geometric mean to the fenofibrate geometric mean were within the 80% and 125% limits for the pharmacokinetic parameters C(max), AUC(0-t), and AUC(0-   ) of the ln-transformed data in both study 1 (fasted) and study 2.
10004419	35	50	fenofibric acid	drug	Drug_0
10004419	73	84	fenofibrate	drug	Drug_1

10004420|t|In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states.
10004420	294	309	fenofibric acid	drug	Drug_0
10004420	235	246	fenofibrate	drug	Drug_1

10004421|t|Conventional therapeutic drug monitoring based on measuring immunosupressive drug concentrations in blood is important in the clinical management of immunosuppressive therapy in transplantation medicine.
10004421	60	81	immunosupressive drug	group	Drug_0
10004421	149	166	immunosuppressive	group	Drug_1

10004422|t|The treatment of coinfected patients requires antituberculosis and antiretroviral drugs to be administered concomittantly;
10004422	46	87	antituberculosis drugs	group	Drug_0
10004422	67	87	antiretroviral drugs	group	Drug_1

10004423|t|Current guidelines recommend starting antiretroviral treatment within a few weeks of antituberculosis therapy for patients with CD4 cell counts
10004423	38	52	antiretroviral	group	Drug_0
10004423	85	101	antituberculosis	group	Drug_1

10004424|t|Effects of neferine on the pharmacokinetics of amiodarone in rats.
10004424	11	19	neferine	drug_n	Drug_0
10004424	47	57	amiodarone	drug	Drug_1

10004425|t|The purpose of this study was to assess the potential of neferine, an effective anti-pulmonary fibrosis drug isolated from the embryo of Nelumbo nucifera Gaertner's seeds, to alter the pharmacokinetic profile of amiodarone.
10004425	57	65	neferine	drug_n	Drug_0
10004425	212	222	amiodarone	drug	Drug_1

10004426|t|In groups 1 and 2, amiodarone was given to rats by intragastric and intravenous administration, respectively, while neferine was co-administratered by intragastric administration.
10004426	19	29	amiodarone	drug	Drug_0
10004426	116	124	neferine	drug_n	Drug_1

10004427|t|There were no significant differences between the pharmacokinetics parameters of amiodarone administered intravenously or intragastrically and the control (without neferine) group (with ratios of 0.7-1.4 in all experimental groups), suggesting that neferine had no effect on amiodarone plasma pharmacokinetics.
10004427	275	285	amiodarone	drug	Drug_0
10004427	249	257	neferine	drug_n	Drug_1

10004428|t|The dosage regimen of amiodarone does not need to be taken into consideration when combined with neferine.
10004428	22	32	amiodarone	drug	Drug_0
10004428	97	105	neferine	drug_n	Drug_1

10004429|t|We observed that GLIC recapitulates bimodal modulation by n-alcohols, similar to some eukaryotic pLGICs: methanol and ethanol weakly potentiated proton-activated currents in GLIC, whereas n-alcohols larger than ethanol inhibited them.
10004429	105	113	methanol	drug_n	Drug_0
10004429	118	125	ethanol	drug	Drug_1

10004430|t|Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease.
10004430	38	42	MPTP	drug_n	Drug_0
10004430	44	89	1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine	drug_n	Drug_1

10004431|t|The biochemical and cellular alterations that occur after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) treatment are remarkably similar to that observed in idiopathic PD.
10004431	58	103	1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine	drug_n	Drug_0
10004431	105	109	MPTP	drug_n	Drug_1

10004432|t|According to the calculated level of risk, guidelines recommend patients with atrial fibrillation receive antithrombotic therapy either as a vitamin K antagonist or aspirin.
10004432	106	120	antithrombotic	group	Drug_0
10004432	141	161	vitamin K antagonist	group	Drug_1
10004432	165	172	aspirin	brand	Drug_2

10004433|t|The novel oral anticoagulants in development may overcome some of the limitations of vitamin K antagonists and address their underuse and safety concerns.
10004433	15	29	anticoagulants	group	Drug_0
10004433	85	106	vitamin K antagonists	group	Drug_1

10004434|t|All mRPCs of 20 passages or less were transplanted into the subretinal space of B6 mice together with chondroitinase ABC, and into Rho(-/-) mice combined with chondroitinase ABC, N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), and insulin growth factor (IGF)-1.
10004434	179	249	N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester	drug_n	Drug_0
10004434	251	255	DAPT	drug_n	Drug_1
10004434	262	283	insulin growth factor	drug_n	Drug_2
10004434	284	291	(IGF)-1	drug_n	Drug_3

10004435|t|The risk of gastrointestinal bleeding during the treatment with antiagregants and anticoagulants, the risk of bradycardia in beta-blockade, possible interactions with other medications lowering the heart rate are discussed.
10004435	64	77	antiagregants	group	Drug_0
10004435	82	96	anticoagulants	group	Drug_1

10004436|t|Attention is paid to calcium channel blockers, diuretics and digoxin.
10004436	21	45	calcium channel blockers	group	Drug_0
10004436	47	56	diuretics	group	Drug_1
10004436	61	68	digoxin	drug	Drug_2

10004437|t|Post-exposure prophylaxis for H1N1 with oseltamivir in renal allograft recipient--safe and effective without any immunosuppresive drug interaction.
10004437	40	51	oseltamivir	drug	Drug_0
10004437	113	134	immunosuppresive drug	group	Drug_1

10004438|t|Post-exposure prophylaxis of H1N1 with oseltamivir was safe, effective and well tolerated to prevent H1N1 influenza A virus infection in newly transplanted renal allograft recipient receiving triple immunosuppression without any interaction with tacrolimus level.
10004438	39	50	oseltamivir	drug	Drug_0
10004438	246	256	tacrolimus	drug	Drug_1

10004439|t|Improvement of colchicine oral bioavailability by incorporating eugenol in the nanoemulsion as an oil excipient and enhancer.
10004439	15	25	colchicine	drug	Drug_0
10004439	64	71	eugenol	drug	Drug_1

10004440|t|The effect of eugenol on colchicine transport across an isolated rat intestinal membrane was studied using an in vitro diffusion chamber system.
10004440	14	21	eugenol	drug	Drug_0
10004440	25	35	colchicine	drug	Drug_1

10004441|t|The effect of eugenol on intestinal absorption of colchicine in an oral administrative nanoemulsion formulation was also demonstrated in vivo.
10004441	14	21	eugenol	drug	Drug_0
10004441	50	60	colchicine	drug	Drug_1

10004442|t|The colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation;
10004442	4	14	colchicine	drug	Drug_0
10004442	46	65	isopropyl myristate	drug_n	Drug_1
10004442	108	115	eugenol	drug	Drug_2
10004442	76	83	Tween80	drug_n	Drug_3
10004442	85	92	ethanol	drug	Drug_4

10004443|t|Finally, co-administration of eugenol in colchicine nanoemulsion to enhance the colchicine bioavailability was investigated by an oral administration method.
10004443	30	37	eugenol	drug	Drug_0
10004443	80	90	colchicine	drug	Drug_1

10004444|t|After oral administration of colchicine (8 mg/kg) in the form of either the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and eugenol-nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with free colchicine solution.
10004444	266	276	colchicine	drug	Drug_0
10004444	170	177	eugenol	drug	Drug_1

10004445|t|The procedure indicated that the intestinal absorption of colchicine was enhanced significantly by eugenol in the tested nanoemulsion.
10004445	58	68	colchicine	drug	Drug_0
10004445	99	106	eugenol	drug	Drug_1

10004446|t|All the results suggested that eugenol is an efficient component in an oral administrative formulation for improving the intestinal absorption of colchicine.
10004446	31	38	eugenol	drug	Drug_0
10004446	146	156	colchicine	drug	Drug_1

10004447|t|[Protective effects of ginseng-ginko extracts combination on rat primary cultured neurons induced by Abeta(1-40)].
10004447	23	30	ginseng	drug	Drug_0
10004447	31	36	ginko	drug	Drug_1
10004447	101	112	Abeta(1-40)	drug_n	Drug_2

10004448|t|To observe the injury in rat primary cultured neurons induced by Abeta(1-40) and the protective effects of combination of ginseng and ginko extracts.
10004448	65	76	Abeta(1-40)	drug_n	Drug_0
10004448	122	129	ginseng	drug	Drug_1
10004448	134	139	ginko	drug	Drug_2

10004449|t|The effects of extracts of ginseng and ginko (EGGB) on cellular proliferative activity, apoptotic rate, ultrastructure and caspase-3 expression were detected.
10004449	27	34	ginseng	drug	Drug_0
10004449	39	44	ginko	drug	Drug_1
10004449	46	50	EGGB	drug	Drug_2

10004450|t|[Effects of glycyrrhiza extract on pharmacokinetics property of daphnetin in rats].
10004450	12	31	glycyrrhiza extract	drug_n	Drug_0
10004450	64	73	daphnetin	drug_n	Drug_1

10004451|t|To research the influence of glycyrrhiza extract on the pharmacokinetics characteristic parameters of daphnetin, which was aimed to explore the rationality of concert application of drugs.
10004451	29	48	glycyrrhiza extract	drug_n	Drug_0
10004451	102	111	daphnetin	drug_n	Drug_1

10004452|t|The rats received intragastric administration of daphnetin and glycyrrhiza extract containing the same daphnetin respectively.
10004452	103	112	daphnetin	drug_n	Drug_0
10004452	63	82	glycyrrhiza extract	drug_n	Drug_1

10004453|t|Antimicrobial effects of o-cymen-5-ol and zinc, alone &
10004453	25	37	o-cymen-5-ol	drug_n	Drug_0
10004453	42	46	zinc	drug	Drug_1

10004454|t|This study aimed to evaluate antimicrobial effects of an o-cymen-5-ol/zinc system.
10004454	57	69	o-cymen-5-ol	drug_n	Drug_0
10004454	70	74	zinc	drug	Drug_1

10004455|t|o-Cymen-5-ol and zinc gluconate minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined against Streptococcus mutans, Actinomyces viscosus, Porphyromonas gingivalis, Fusobacterium nucleatum and Candida albicans.
10004455	0	12	o-Cymen-5-ol	drug_n	Drug_0
10004455	17	31	zinc gluconate	drug	Drug_1

10004456|t|nucleatum, with MIC of 0.42 mM/0.69 mM for o-cymen-5-ol/zinc gluconate, respectively.
10004456	43	55	o-cymen-5-ol	drug_n	Drug_0
10004456	56	70	zinc gluconate	drug	Drug_1

10004457|t|Zinc inhibited glycolysis and protease to a greater degree than o-cymen-5-ol;
10004457	0	4	Zinc	drug	Drug_0
10004457	64	76	o-cymen-5-ol	drug_n	Drug_1

10004458|t|o-Cymen-5-ol/zinc chloride in toothpaste showed greater effects than placebo (120s log10 kill=7.35  0.40 and 4.02  0.40, respectively).
10004458	0	12	o-Cymen-5-ol	drug_n	Drug_0
10004458	13	26	zinc chloride	drug	Drug_1

10004459|t|The zinc/o-cymen-5-ol system has direct antimicrobial effects and inhibits oral disease-related processes.
10004459	4	8	zinc	drug	Drug_0
10004459	9	21	o-cymen-5-ol	drug_n	Drug_1

10004460|t|A system combining o-cymen-5-ol and zinc shows properties desirable for incorporation in toothpastes.
10004460	19	31	o-cymen-5-ol	drug_n	Drug_0
10004460	36	40	zinc	drug	Drug_1

10004461|t|The aim of this study was to assess the influence of manganese gluconate, a chemical activator of bleaching agents, at a concentration of 0.01% on the efficiency of a 10% carbamide peroxide-based bleaching agent.
10004461	53	72	manganese gluconate	drug_n	Drug_0
10004461	171	189	carbamide peroxide	drug_n	Drug_1

10004462|t|Group 2 consisted of 10% carbamide peroxide-based bleaching gel and 0.01% manganese gluconate.
10004462	25	43	carbamide peroxide	drug_n	Drug_0
10004462	74	93	manganese gluconate	drug_n	Drug_1

10004463|t|Adding 0.01% manganese gluconate to 10% carbamide peroxide bleaching gel increased the degree of tooth bleaching after a seven-day treatment and did not influence the resulting shade after 14 days.
10004463	13	32	manganese gluconate	drug_n	Drug_0
10004463	40	58	carbamide peroxide	drug_n	Drug_1

10004464|t|An increase in serum osmolality and serum osmolal gap with or without high-anion-gap metabolic acidosis is an important clue to exposure to one of the toxic alcohols, which include methanol, ethylene glycol, diethylene glycol, propylene glycol, or isopropanol.
10004464	181	189	methanol	drug_n	Drug_0
10004464	191	206	ethylene glycol	drug_n	Drug_1
10004464	208	225	diethylene glycol	drug_n	Drug_2
10004464	227	243	propylene glycol	drug_n	Drug_3
10004464	248	259	isopropanol	drug	Drug_4

10004465|t|[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
10004465	1	11	Ticagrelor	drug	Drug_0
10004465	21	39	antiplatelet agent	group	Drug_1

10004466|t|In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome.
10004466	23	41	antiplatelet agent	group	Drug_0
10004466	125	136	clopidogrel	drug	Drug_1

10004467|t|In most cases, the application of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) together with a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor (II) is recommended.
10004467	38	95	nucleoside or nucleotide reverse transcriptase inhibitors	group	Drug_0
10004467	97	101	NRTI	group	Drug_1
10004467	119	165	non-nucleoside reverse transcriptase inhibitor	group	Drug_2
10004467	167	172	NNRTI	group	Drug_3
10004467	177	195	protease inhibitor	group	Drug_4
10004467	197	199	PI	group	Drug_5
10004467	207	226	integrase inhibitor	group	Drug_6
10004467	228	230	II	group	Drug_7

10004468|t|Single-unit in vivo extracellular recordings performed in neurons of the NAc confirmed an opiate-state-dependent role for BLA D1/D2 transmission in NAc neuronal response patterns to morphine.
10004468	90	96	opiate	group	Drug_0
10004468	182	190	morphine	drug	Drug_1

10004469|t|Selective serotonin reuptake inhibitors were the most commonly prescribed antidepressant.
10004469	0	39	Selective serotonin reuptake inhibitors	group	Drug_0
10004469	74	88	antidepressant	group	Drug_1

10004470|t|Having moderate to severe pain (ARRR=1.54, 95% CI=1.08-2.20) and the prescribing of an anxiolytic or hypnotic (ARRR=1.33, 95% CI=1.02-1.74) increased the risk of potential inappropriate antidepressant use.
10004470	87	97	anxiolytic	group	Drug_0
10004470	101	109	hypnotic	group	Drug_1
10004470	186	200	antidepressant	group	Drug_2

10004471|t|Treatment of nicotine dependence with Chantix (varenicline).
10004471	13	21	nicotine	drug	Drug_0
10004471	38	45	Chantix	brand	Drug_1
10004471	47	58	varenicline	drug	Drug_2

10004472|t|Varenicline is the generic name for Chantix, the newest drug available for the treatment of tobacco dependence.
10004472	0	11	Varenicline	drug	Drug_0
10004472	36	43	Chantix	brand	Drug_1

10004473|t|In a randomized controlled clinical trial, the abstinence rate at 1 year for patients using varencline was superior to that of patients in the group using bupropion SR (Zyban) and in the placebo group (11).
10004473	92	102	varencline	drug	Drug_0
10004473	155	167	bupropion SR	drug	Drug_1
10004473	169	174	Zyban	brand	Drug_2

10004474|t|Varenicline reduces nicotine withdrawal symptoms, cigarette craving and nicotine satisfaction.
10004474	0	11	Varenicline	drug	Drug_0
10004474	72	80	nicotine	drug	Drug_1

10004475|t|This complex has a unique ability to deliver bio-available calcium and phosphate when they are needed most.
10004475	59	66	calcium	drug	Drug_0
10004475	71	80	phosphate	drug	Drug_1

10004476|t|The purpose of this study was to investigate both the effect and mechanisms of IGF1R inhibition by tyrphostin AG1024 in the presence or absence of doxorubicin in a panel of six osteosarcoma cell lines and a self-established doxorubicin-resistant cell line.
10004476	99	116	tyrphostin AG1024	drug_n	Drug_0
10004476	224	235	doxorubicin	drug	Drug_1

10004477|t|Different chemical structures of precursors, smoking dynamics, pyrolysis of phytocannabinoids and frequency of drug use affect the amount of THC absorbed.
10004477	76	93	phytocannabinoids	drug_n	Drug_0
10004477	141	144	THC	drug_n	Drug_1

10004478|t|Pharmacological effects of other cannabinoids or medication on the pharmacokinetics of THC have not yet been studied in detail.
10004478	33	45	cannabinoids	drug_n	Drug_0
10004478	87	90	THC	drug_n	Drug_1

10004479|t|[Cyclooxygenase inhibitors and antiplatelet effect of acetylsalicylic acid. selective approach to nonsteroidal anti-inflammatory drugs in cardiological practice].
10004479	1	26	Cyclooxygenase inhibitors	group	Drug_0
10004479	54	74	acetylsalicylic acid	drug	Drug_1
10004479	98	134	nonsteroidal anti-inflammatory drugs	group	Drug_2

10004480|t|Nonsteroidal anti-inflammatory drugs (NSAIDs) represent class of medicines which is wide concerning chemical structure and mechanism of action.
10004480	0	36	Nonsteroidal anti-inflammatory drugs	group	Drug_0
10004480	38	44	NSAIDs	group	Drug_1

10004481|t|In the light of contradictory data on efficacy and safety of NSAID in cardiovascular patients selection of most appropriate NSAID (basing on profile of efficacy and safety) in patients receiving continuous therapy with low dose aspirin appears to be a problem.
10004481	124	129	NSAID	group	Drug_0
10004481	228	235	aspirin	brand	Drug_1

10004482|t|In this paper we discuss peculiarities of drug interaction between cyclooxygenase inhibitors and acetylsalicylic acid, and principles of selection of adequate NSAI.
10004482	67	92	cyclooxygenase inhibitors	group	Drug_0
10004482	97	117	acetylsalicylic acid	drug	Drug_1
10004482	159	163	NSAI	group	Drug_2

10004483|t|A fatal poisoning case involving etizolam, phenobarbital, promethazine and chlorpromazine is presented.
10004483	33	41	etizolam	drug	Drug_0
10004483	43	56	phenobarbital	drug	Drug_1
10004483	58	70	promethazine	drug	Drug_2
10004483	75	89	chlorpromazine	drug	Drug_3

10004484|t|Quantitative toxicological analysis showed that the concentrations of etizolam, phenobarbital, promethazine and chlorpromazine in the femoral blood were 86 ng/ml, 5082 microg/ml, 0.107 microg/ml and 0.144 microg/ml, respectively, and large amounts of drugs were also detected in the stomach contents.
10004484	70	78	etizolam	drug	Drug_0
10004484	80	93	phenobarbital	drug	Drug_1
10004484	95	107	promethazine	drug	Drug_2
10004484	112	126	chlorpromazine	drug	Drug_3

10004485|t|Standard antibiotic such as Gentamicin (10 microg), Cephalothin (30 microg), Ceftriaxone (10 microg), Nystatin (10 U) discs were used for comparison with the antimicrobial activities of essential oils of these plants.
10004485	9	19	antibiotic	group	Drug_0
10004485	28	38	Gentamicin	drug	Drug_1
10004485	52	63	Cephalothin	drug	Drug_2
10004485	77	88	Ceftriaxone	drug	Drug_3
10004485	102	110	Nystatin	drug	Drug_4

10004486|t|Evaluation of hepatic clearance and drug-drug interactions of luteolin and apigenin by using primary cultured rat hepatocytes.
10004486	62	70	luteolin	drug_n	Drug_0
10004486	75	83	apigenin	drug_n	Drug_1

10004487|t|The hepatic clearance and drug-drug interactions of luteolin and apigenin were studied by using primary cultured rat hepatocytes.
10004487	52	60	luteolin	drug_n	Drug_0
10004487	65	73	apigenin	drug_n	Drug_1

10004488|t|Luteolin and apigenin experienced extensive first-pass metabolism.
10004488	0	8	Luteolin	drug_n	Drug_0
10004488	13	21	apigenin	drug_n	Drug_1

10004489|t|The elimination percent of luteolin and apigenin was found to be 91.9% and 86.7% after 120 min of incubation.
10004489	27	35	luteolin	drug_n	Drug_0
10004489	40	48	apigenin	drug_n	Drug_1

10004490|t|The predicted % liver blood flow was 82.3% and 85.4% for luteolin and apigenin, respectively.
10004490	57	65	luteolin	drug_n	Drug_0
10004490	70	78	apigenin	drug_n	Drug_1

10004491|t|Compared with the elimination of pure luteolin and apigenin, the elimination of luteolin and apigenin was much lower in hydrolyzed Flos Chrysanthemi extract (FCE) containing comparable amounts of luteolin and apigenin.
10004491	196	204	luteolin	drug_n	Drug_0
10004491	209	217	apigenin	drug_n	Drug_1

10004492|t|The effect of a series of flavonoids, including flavonols, flavones, isoflavone, flavanone, flavanonols and catechins, on the elimination of luteolin and apigenin was studied.
10004492	26	36	flavonoids	drug_n	Drug_0
10004492	48	57	flavonols	drug_n	Drug_1
10004492	59	67	flavones	drug_n	Drug_2
10004492	69	79	isoflavone	drug_n	Drug_3
10004492	81	90	flavanone	drug_n	Drug_4
10004492	92	103	flavanonols	drug_n	Drug_5
10004492	108	117	catechins	drug_n	Drug_6
10004492	141	149	luteolin	drug_n	Drug_7
10004492	154	162	apigenin	drug_n	Drug_8

10004493|t|Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.
10004493	46	54	curcumin	drug_n	Drug_0
10004493	80	90	fluoxetine	drug	Drug_1
10004493	95	105	imipramine	drug	Drug_2

10004494|t|In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.
10004494	58	66	curcumin	drug_n	Drug_0
10004494	92	102	fluoxetine	drug	Drug_1
10004494	107	117	imipramine	drug	Drug_2

10004495|t|All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
10004495	334	342	curcumin	drug_n	Drug_0
10004495	300	310	fluoxetine	drug	Drug_1
10004495	358	368	imipramine	drug	Drug_2

10004496|t|The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).
10004496	14	22	curcumin	drug_n	Drug_0
10004496	115	125	fluoxetine	drug	Drug_1
10004496	130	140	imipramine	drug	Drug_2

10004497|t|Curcumin can be a useful antidepressant especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.
10004497	0	8	Curcumin	drug_n	Drug_0
10004497	25	39	antidepressant	group	Drug_1

10004498|t|PXR-ligands include a wide variety of pharmaceutical agents, such as antiepileptic drugs, taxol, rifampicin, and human immunodeficiency virus protease inhibitors such as ritonavir and saquinavir.
10004498	69	88	antiepileptic drugs	group	Drug_0
10004498	90	95	taxol	brand	Drug_1
10004498	97	107	rifampicin	drug	Drug_2
10004498	113	161	human immunodeficiency virus protease inhibitors	group	Drug_3
10004498	170	179	ritonavir	drug	Drug_4
10004498	184	194	saquinavir	drug	Drug_5

10004499|t|Beside this, the medication oriented supplementation of vitamin D can also ameliorate the pharmacologic action of many drugs, such as bisphosphonates, statins and cytostatic drugs.
10004499	56	65	vitamin D	group	Drug_0
10004499	134	149	bisphosphonates	group	Drug_1
10004499	151	158	statins	group	Drug_2
10004499	163	179	cytostatic drugs	group	Drug_3

10004500|t|A rapid, sensitive and reliable high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was developed and validated for the determination of propiverine hydrochloride (CAS 54556-98-8) in human plasma using cetirizine di-hydrochloride as internal standard (IS, CAS 8388-51-0).
10004500	169	194	propiverine hydrochloride	drug	Drug_0
10004500	234	261	cetirizine di-hydrochloride	drug	Drug_1

10004501|t|Following liquid-liquid extraction with ethyl acetate, the separation was performed on a reverse phase C18 column with a mobile phase consisted of methanol-ammonium acetate (pH 4.0; 10 mM) (70:30, v/v).
10004501	40	53	ethyl acetate	drug_n	Drug_0
10004501	147	172	methanol-ammonium acetate	drug_n	Drug_1

